Derivatives having 2, 3-dihydro-1h-indene or 2, 3-dihydrobenzofuran moiety or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing same

Through the development of 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran partial derivatives, the poor efficacy and high cost of existing GCS inhibitors in the treatment of lysosomal storage diseases are solved. , effectively reduces glycolipid accumulation and nervous system distribution, reducing the risk of antibody response.

CN118955495APending Publication Date: 2024-11-15YUHAN CORPORATION +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410840972.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-11-15
Filing Date
2020-11-12
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing glucose ceramide synthase (GCS) inhibitors have problems such as poor efficacy, high cost and difficulty in distributing to the nervous system in the treatment of lysosomal storage disorders, and may trigger autoantibodies.

Method used

Developed with 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moieties or pharmaceutically acceptable salts thereof with excellent GCS inhibitory activity to prevent or treat GCS-related diseases .

Benefits of technology

Effectively inhibit the production of glucose ceramide, reduce glycolipid accumulation, improve the clinical manifestations of lysosomal storage diseases, reduce treatment costs, and reduce the risk of antibody response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004914372630000061
    Figure BDA0004914372630000061
  • Figure BDA0004914372630000381
    Figure BDA0004914372630000381
  • Figure BDA0004914372630000401
    Figure BDA0004914372630000401
Patent Text Reader

Abstract

The present invention provides novel compounds having a 2, 3-dihydro-1H-indene or 2, 3-dihydrobenzofuran moiety, or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions comprising the same, and uses thereof. A compound having a 2, 3-dihydro-1H-indene or a 2, 3-dihydrobenzofuran moiety or a pharmaceutically acceptable salt thereof has inhibitory activity against glucosylceramide synthase (GCS), and thus can be effectively used for the prevention or treatment of various diseases associated with GCS, such as Gaucher disease, Fabry disease, Talaxophone disease, Parkinson's disease, and the like.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese Patent Application No. 202080075084.9, filed on November 12, 2020, entitled "Derivatives having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof", and claims priority to Korean Application No. 10-2019-0146679. Technical Field

[0002] This invention relates to a compound having inhibitory activity against glucose ceramide synthase (GCS), namely a derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or a pharmaceutically acceptable salt thereof, a method for its preparation, pharmaceutical compositions comprising the same, and uses thereof. Background Technology

[0003] Lysosomal storage disorders (LSDs) are metabolic disorders caused by the hereditary deficiency or defect of certain enzymes in lysosomes. With the accumulation of non-metabolized or non-degraded substrates, LSDs manifest as various pathological symptoms throughout the body. Currently, approximately 50 types of LSDs are known. Based on the substances accumulated, these LSDs are mainly classified into diseases such as mucopolysaccharidose storage disorders, oligosaccharidosis, and sphingolipidose storage disorders.

[0004] Among these diseases, sphingolipid storage disorders are a class of glycolipid storage disorders related to sphingolipid metabolism, manifesting as symptoms caused by the accumulation of various membrane glycosphingolipids (GSLs) such as glucosylceramide and trihexocylceramide. For example, when enzymes related to sphingolipid metabolism, such as β-glucosidase and α-galactosidase, lack normal activity, their substrates (such as glucosylceramide and trihexocylceramide) accumulate, resulting in various symptoms, such as Gaucher disease and Fabry disease.

[0005] There are two known types of LSD therapy. The first approach involves replacing or supplementing deficient or defective metabolic enzymes. While this enzyme replacement therapy (ERT) is safe and effective, it still requires regular intravenous administration of the relevant enzyme and dose adjustment based on enzyme response, resulting in higher costs. In particular, ERT has not shown satisfactory efficacy in treating neurologically related symptoms due to difficulties in distributing the enzyme to the nervous system. Furthermore, there is a frequent problem of developing autoantibodies against the administered enzyme.

[0006] The second approach is substrate reduction therapy (SRT), which inhibits the synthesis of accumulated substrates. Glucoceramide synthase (GCS) (also known as UDP-glucose:ceramide glycosyltransferase, UDP-glucose:N-acylsphingosine D-glucosyltransferase, or EC 2.4.1.80) is an enzyme involved in sphingolipid metabolism, participating in the reaction of ceramide with glucose to produce glucoceramide. The resulting glucoceramide is then converted into various GSLs. Glucoceramide synthase (GCS) inhibitors suppress GCS activity, thereby reducing the production of glucoceramide in the body and preventing the abnormal accumulation of glycolipids such as trihexycycloceramide, GM1, and GM2 in cells or organs.

[0007] Therefore, GCS inhibitors suppress GCS activity to prevent the accumulation of glycolipids, and can thus be used to treat lysosomal storage disorders, especially glycolipid storage disorders, such as GM1 gangliosidosis, Tay-Sachs disease, Sandhoff disease, Gaucher disease, Fabry disease, Niemann-Pick disease (types A and B), metachromatic leukodystrophy, Krabbe disease, etc. GCS inhibitors can also be used to treat secondary diseases associated with glucose and lipid storage, such as Niemann-Pick disease (type C), mucopolysaccharidosis, and mucolipidosis type IV (see Chen CS, et al., Abnormal transport along the lysosomal pathway in mucolipidosis, type IV disease Proc Natl Acad Sci US A. 1998 May 26; 95(11):6373-8; and Goodman LA, et al., Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in α-mannosidosis, Proc Natl Acad Sci US A. 1991 Dec 15; 88(24):11330-4).In addition, GCS inhibitors have been reported to be used to treat diseases associated with glucose and lipid accumulation, such as renal hypertrophy (e.g., diabetic nephropathy); hyperglycemia or hyperinsulinemia; cancers with abnormal glucose and lipid synthesis; infectious diseases caused by organisms that use cell surface glucose and lipids as receptors; infectious diseases where glucose ceramide synthesis is essential or important; diseases with excessive glucose and lipid synthesis (e.g., atherosclerosis, polycystic kidney disease, and renal hypertrophy); neurological disorders and / or nerve damage associated with macrophage supplementation and activity (e.g., Alzheimer's disease, epilepsy, stroke, spinal cord diseases, Parkinson's disease, etc.); inflammatory diseases or disorders (e.g., rheumatoid arthritis, Crohn's disease, asthma, sepsis); and diabetes and obesity (see WO2006 / 053043). Furthermore, GCS overexpression interferes with ceramide-induced apoptosis (see Liu YY, et al., Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance, J Biol Chem. 2000 Mar 10; 275(10):7138-43). Therefore, GCS inhibitors could be used to treat proliferative diseases, such as cancer, by inducing apoptosis in diseased cells.

[0008] Various studies have been conducted to develop GCS inhibitors. For example, various compounds with inhibitory activity against GCS have been disclosed in WO 2005 / 068426, WO 2006 / 053043, WO 2008 / 150486, WO 2009 / 117150, WO 2010 / 014554, WO 2014 / 043068, etc. Summary of the Invention

[0009] Technical issues

[0010] The inventors have discovered that derivatives having a 5,6-fused bicyclic moiety, namely 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety, or pharmaceutically acceptable salts thereof, possess excellent inhibitory activity against glucose-ceramide synthase (GCS). Therefore, derivatives having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety, or pharmaceutically acceptable salts thereof, can be effectively used for the prevention or treatment of various GCS-related diseases, such as Gaucher disease, Fabry disease, Ty-Sachs disease, Parkinson's disease, etc.

[0011] Therefore, the present invention provides the above-mentioned derivatives having the 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salts thereof, methods for their preparation, pharmaceutical compositions comprising them, and uses thereof.

[0012] Technical solution

[0013] According to one aspect of the invention, derivatives having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salts thereof are provided.

[0014] According to another aspect of the invention, a method is provided for preparing the derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or a pharmaceutically acceptable salt thereof.

[0015] According to another aspect of the invention, a pharmaceutical composition is provided comprising the derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or a pharmaceutically acceptable salt thereof as an active ingredient.

[0016] According to another aspect of the invention, a treatment method is provided comprising administering the derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or a pharmaceutically acceptable salt thereof.

[0017] According to another aspect of the invention, the use of the derivative having the 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or a pharmaceutically acceptable salt thereof in the preparation of a medicament for inhibiting glucose-ceramide synthase is provided.

[0018] Beneficial effects of the invention

[0019] This invention has discovered that derivatives having a 5,6-fused bicyclic moiety, namely 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety, or pharmaceutically acceptable salts thereof, possess excellent inhibitory activity against glucose-ceramide synthase (GCS). Therefore, compounds according to the invention or pharmaceutically acceptable salts thereof can be effectively used for the prevention or treatment of various GCS-related diseases, such as Gaucher disease, Fabry disease, Ty-Sachs disease, Parkinson's disease, etc. Detailed Implementation

[0020] As used herein, the term "alkyl" refers to a straight-chain or branched aliphatic hydrocarbon radical. For example, C1 to C6 alkyl refers to straight-chain or branched aliphatic hydrocarbons having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, neopentyl, and isopentyl.

[0021] The term "hydroxyl" refers to the "-OH" group. The term "alkoxy" refers to a group formed by replacing a hydrogen atom in a hydroxyl group with an alkyl group. For example, C1 to C6 alkoxy groups include methoxy, ethoxy, propoxy, n-butoxy, n-pentoxy, isopropoxy, sec-butoxy, tert-butoxy, neopentoxy, and isopentyloxy.

[0022] The term "halogen" refers to a fluorine, bromine, chlorine, or iodine group.

[0023] Unless otherwise defined, the term "cycloalkyl" refers to a saturated aliphatic 3-membered to 10-membered ring, preferably a 3-membered to 7-membered ring. Typical cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

[0024] The term "aryl" refers to an organic group derived by removing a hydrogen atom from an aromatic hydrocarbon, including mono- or poly-fused ring systems, such as 5- to 14-substituted or unsubstituted rings, and including forms in which multiple aryl groups are linked by single bonds. "Aryl" includes, for example, phenyl, naphthyl, biphenyl, terphenyl, anthracene, indenyl, fluorenyl, phenanthryl, triphenylene, pyrenyl, and perylenyl. Examples of phenyl groups include chrysenyl, naphthacenyl, and fluoranthenyl, but they are not limited to these.

[0025] The term "heteroaryl" refers to a 5- to 12-membered aromatic group having 1 to 3 heteroatoms selected from nitrogen (N), oxygen (O), and sulfur (S) atoms, including 5- or 6-membered monocyclic heteroaryls and bicyclic heteroaryls formed by fusion of a 5- or 6-membered monocyclic heteroaryl with a benzene or pyridine ring. Furthermore, the term "heterocycle" refers to a 3- to 12-membered monocyclic or polycyclic ring having one or more, preferably 1 to 4, identical or different heteroatoms selected from oxygen (O), nitrogen (N), and sulfur (S) atoms, but without an aromatic ring. Non-limiting examples of heteroaryl or heterocyclic compounds include oxetane, pyrrolidine, pyrrole, tetrahydrofuran, furan, tetrahydrothiophene, thiophene, imidazolidine, imidazolidine, pyrazolidine, pyrazole, pyrrolizine, oxazolidine, oxazole, isoxazolidine, isoxazole, thiazolidine, thiazole, isothiazolidine, isothiazolidine, dioxolane, dithiolane, oxadiazole, thiazolazole, tetrazole, oxatetrazole, thiatetrazole, piperidine, pyridine, pyrimidine, tetrahydropyran, pyran, thiazide. e) Thianone, piperazine, diazine, morpholine, oxazine, dioxane, indole, dihydroindole, benzodioxane, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzoisoxazole, benzothiazole, benzothiadiazole, benzotriazole, quinoline, isoquinoline, purine, furopyridine, mono- or diazabicyclic compounds (e.g., quinine ring, diazabicycloheptane, monoazabicyclooctane, diazaspiroundecane, etc.), hexahydropyrrolopyrrole, pyrrolopyrrole, pyrrolopyridine, imidazopyridazine, dihydrobenzodioxin, dihydrobenzofuran, etc., but not limited to these.

[0026] The term "amino" refers to the "-NH2" group. The term "alkylamino" refers to an amino group that is substituted with a single alkyl or dialkyl group. For example, C1-C6 alkylamino groups include amino groups substituted with one or two C1-C6 alkyl groups.

[0027] The term "alkylthio" refers to the "-SR" group, where R is an alkyl group. The term "cyano" refers to the "-CN" group.

[0028] This invention provides derivatives having a 5,6-fused bicyclic moiety, namely 2,3-dihydro-1H-indene or a 2,3-dihydrobenzofuran moiety, or pharmaceutically acceptable salts thereof, namely compounds of formula 1 or pharmaceutically acceptable salts thereof:

[0029] <Formula 1>

[0030]

[0031] in,

[0032] L is -O-, -CO-, -CR1R2-, or -NR3-.

[0033] Y and Z are independent of each other and are -CR1R2-; -NR3-; -O-; or -S-.

[0034] R1 and R2 are independently hydrogen; halogen; C1-C6 alkyl; C1-C6 alkyl having nitrogen, oxygen, or sulfur atoms; C3-C 10 Cycloalkyl; 3- to 12-membered heterocycles; or C1 to C6 alkoxy groups; or R1 and R2 together with the carbon atoms to which they are attached to form C3 to C6 alkoxy groups. 10 cycloalkyl,

[0035] R3 is hydrogen; C1-C6 alkyl; C1-C6 alkyl with nitrogen, oxygen, or sulfur atoms; C3-C 10 Cycloalkyl; 3- to 12-membered heterocyclic; or C1 to C6 alkoxy.

[0036] X is hydrogen; halogen; C1-C6 alkyl; C1-C6 alkyl substituted with 1 to 3 halogen atoms; C1-C6 alkyl having a nitrogen atom, an oxygen atom, or a sulfur atom; C1-C6 alkoxy; or C1-C6 alkoxy substituted with 1-3 halogen atoms.

[0037] W is a bond, -CH2-, -O-, -NH-, -CH2CH2-, -CH=CH-, or -C≡C-.

[0038] A ring is 6- to 12-aryl; 5- to 12-heteroaryl; C3 to C4 10 Cycloalkyl; or 3- to 12-membered heterocycles, and

[0039] X1, X2, X3, and X4 are independently hydrogen; cyano; halogen; C1–C6 alkyl; C1–C6 alkoxy-C1–C6 alkyl; C1–C6 alkyl substituted with 1 to 3 halogen atoms; C3–C 10Cycloalkyl; 3- to 12-membered heterocycles; C1 to C6 alkoxy; C1 to C6 alkoxy substituted with 1 to 3 halogen atoms; C1 to C6 alkoxy-C1 to C6 alkoxy; morpholinyl-C1 to C6 alkoxy; mono- or bis-C1 to C6 alkylamino-C1 to C6 alkoxy; C3 to C 10 Cycloalkyl-C1 to C6 alkoxy; C1 to C6 alkylthio; amino; mono- or bis-C1 to C6 alkylamino; C1 to C6 alkylcarbonyl; hydroxyl; or nitro.

[0040] In compounds of Formula 1 according to the invention or pharmaceutically acceptable salts thereof, L may be -O-.

[0041] In the compounds of Formula 1 according to the invention or their pharmaceutically acceptable salts, Y and Z can be independently -O- or -CR1R2-.

[0042] In the compounds of Formula 1 according to the invention or their pharmaceutically acceptable salts, R1 and R2 may be hydrogen or C1-C6 alkyl groups independently of each other; or R1 and R2 may form C3-C6 alkyl groups together with the carbon atoms to which they are attached. 10 Cycloalkyl. In one embodiment, Y can be -O-; and Z can be -CR1R2-.

[0043] In the compound of Formula 1 according to the invention or its pharmaceutically acceptable salt, X may be hydrogen, halogen or C1-C6 alkoxy.

[0044] In the compound of Formula 1 according to the invention or its pharmaceutically acceptable salt, W can be a bond (i.e., the A ring is directly bonded to the 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety) or -CH=CH-.

[0045] In the compounds of Formula 1 according to the invention, or pharmaceutically acceptable salts thereof, ring A may be a 6- to 12-membered aryl; a 5- to 12-membered heteroaryl; or a 3- to 12-membered heterocyclic ring. In one embodiment, the 6- to 12-membered aryl may be phenyl, naphthyl, or biphenyl. In another embodiment, the 5- to 12-membered heteroaryl may be benzodioxanepentenyl, pyridyl, thienyl, quinolinyl, isoquinolinyl, benzofuranyl, benzo[b]thienyl, quinoxalinyl, or furanyl. In yet another embodiment, the 3- to 12-membered heterocycle may be 2,3-dihydrobenzodioxinyl, 2,3-dihydrobenzofuranyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, benzodihydropyranyl (chromanyl) or 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl.

[0046] In the compounds of Formula 1 according to the invention or their pharmaceutically acceptable salts, X1, X2, X3, and X4 may be hydrogen, cyano, halogen, C1-C6 alkyl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkyl substituted with 1 to 3 halogen atoms, C3-C6 alkyl, C4-C6 alkyl, C5-C6 alkyl, C6-C6 alkyl, C1-C6 alkyl, C3-C6 alkyl, C4 ... 10 Cycloalkyl; morpholinyl; C1–C6 alkoxy; C1–C6 alkoxy substituted with 1 to 3 halogen atoms; C1–C6 alkoxy-C1–C6 alkoxy; morpholinyl-C1–C6 alkoxy; mono- or bis-C1–C6 alkylamino-C1–C6 alkoxy; C3–C 10 Cycloalkyl-C1 to C6 alkoxy; C1 to C6 alkylthio; mono- or bis-C1 to C6 alkylamino; or C1 to C6 alkylcarbonyl.

[0047] In a preferred embodiment of the present invention

[0048] L is -O-,

[0049] Y and Z are independently -O- or -CR1R2-.

[0050] R1 and R2 are independently hydrogen or C1–C6 alkyl groups; or R1 and R2 together with the carbon atoms they are attached to form C3–C6 alkyl groups. 10 cycloalkyl,

[0051] X is hydrogen, halogen, or C1–C6 alkoxy group.

[0052] W is a key or -CH = CH-.

[0053] Ring A is a 6- to 12-membered aryl, 5- to 12-membered heteroaryl, or 3- to 12-membered heterocycle, and

[0054] X1, X2, X3, and X4 are independently hydrogen; cyano; halogen; C1–C6 alkyl; C1–C6 alkoxy-C1–C6 alkyl; C1–C6 alkyl substituted with 1 to 3 halogen atoms; C3–C 10 Cycloalkyl; morpholinyl; C1–C6 alkoxy; C1–C6 alkoxy substituted with 1 to 3 halogen atoms; C1–C6 alkoxy-C1–C6 alkoxy; morpholinyl-C1–C6 alkoxy; mono- or bis-C1–C6 alkylamino-C1–C6 alkoxy; C3–C 10 Cycloalkyl-C1 to C6 alkoxy; C1 to C6 alkylthio; mono- or bis-C1 to C6 alkylamino; or C1 to C6 alkylcarbonyl.

[0055] In the embodiment described, Y can be -O-; and Z is -CR1R2-.

[0056] In the described embodiment, ring A may be phenyl, naphthyl, or biphenyl.

[0057] In the embodiments described, ring A may be benzodioxanepentenyl, pyridinyl, thiophene, quinolinyl, isoquinolinyl, benzofuranyl, benzo[b]thiophene, quinoxalinyl, or furanyl.

[0058] In the embodiments described, ring A may be 2,3-dihydrobenzodioxinyl, 2,3-dihydrobenzofuranyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, benzodihydropyranyl, or 3,4-dihydro-2H-benzo[b][1,4]dioxadiazineyl.

[0059] Among the compounds of Formula 1 or pharmaceutically acceptable salts, preferred compounds include those selected from the group consisting of pharmaceutically acceptable salts thereof:

[0060] (S)-quininecyclo-3-yl(5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0061] (S)-quininecyclo-3-yl(5-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0062] (S)-quininecyclo-3-yl(5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0063] (S)-quininecyclo-3-yl(5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0064] (S)-quininecyclo-3-yl(5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0065] (S)-quininecyclo-3-yl(5-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0066] (S)-quininecyclo-3-yl(5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0067] (S)-quininecyclo-3-yl(5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0068] (S)-quininecyclo-3-yl(5-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0069] (S)-quininecyclo-3-yl(5-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0070] (S)-quininecyclo-3-yl(5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0071] (S)-quininecyclo-3-yl(5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0072] (S)-quininecyclo-3-yl(5-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0073] (S)-quininecyclo-3-yl(5-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0074] (S)-quininecyclo-3-yl(5-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0075] (S)-quininecyclo-3-yl(5-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0076] (S)-quininecyclo-3-yl(5-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0077] (S)-quininecyclo-3-yl(5-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0078] (S)-quininecyclo-3-yl(5-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0079] (S)-quininecyclo-3-yl(5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0080] (S)-quininecyclo-3-yl(5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0081] (S)-quininecyclo-3-yl(5-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0082] (S)-quininecyclo-3-yl(5-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0083] (S)-quininecyclo-3-yl(5-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0084] (S)-quininecyclo-3-yl(6-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0085] (S)-quininecyclo-3-yl(6-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0086] (S)-quininecyclo-3-yl(6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0087] (S)-quininecyclo-3-yl(6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0088] (S)-quininecyclo-3-yl(6-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0089] (S)-quininecyclo-3-yl(6-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0090] (S)-quininecyclo-3-yl(6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0091] (S)-quininecyclo-3-yl(6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0092] (S)-quininecyclo-3-yl(6-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0093] (S)-quininecyclo-3-yl(6-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0094] (S)-quininecyclo-3-yl(6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0095] (S)-quininecyclo-3-yl(6-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0096] (S)-quininecyclo-3-yl(6-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0097] (S)-quininecyclo-3-yl(6-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0098] (S)-quininecyclo-3-yl(6-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0099] (S)-quininecyclo-3-yl(6-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0100] (S)-quininecyclo-3-yl(6-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0101] (S)-quininecyclo-3-yl(6-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0102] (S)-quininecyclo-3-yl(6-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0103] (S)-quininecyclo-3-yl(6-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0104] (S)-quininecyclo-3-yl(6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0105] (S)-quininecyclo-3-yl(6-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0106] (S)-quininecyclo-3-yl(6-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0107] (S)-quininecyclo-3-yl(6-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0108] (S)-quininecyclo-3-yl(6-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0109] (S)-quininecyclo-3-yl(6-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0110] (S)-Quininecyclo-3-yl(2,2-dimethyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0111] (S)-Quininecyclo-3-yl(2,2-dimethyl-6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0112] (S)-quininecyclo-3-yl(6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0113] (S)-quininecyclo-3-yl(6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0114] (S)-quininecyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0115] (S)-Quinylcyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0116] (S)-quininecyclo-3-yl(6-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0117] (S)-quininecyclo-3-yl(6-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0118] (S)-quininecyclo-3-yl(2,2-dimethyl-6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0119] (S)-quininecyclo-3-yl(2,2-dimethyl-6-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0120] (S)-quininecyclo-3-yl(6-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0121] (S)-quininecyclo-3-yl(6-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0122] (S)-quininecyclo-3-yl(6-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0123] (S)-quininecyclo-3-yl(6-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0124] (S)-quininecyclo-3-yl(6-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0125] (S)-quininecyclo-3-yl(6-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0126] (S)-quininecyclo-3-yl(2,2-dimethyl-6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0127] (S)-quininecyclo-3-yl(2,2-dimethyl-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0128] (S)-quininecyclo-3-yl(6-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0129] (S)-quininecyclo-3-yl(6-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0130] (S)-quininecyclo-3-yl(6-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0131] (S)-quininecyclo-3-yl(6-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0132] (S)-quininecyclo-3-yl(5-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0133] (S)-quininecyclo-3-yl(5-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0134] (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0135] (S)-Quinylcyclo-3-yl(2,2-dimethyl-5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0136] (S)-quininecyclo-3-yl(5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0137] (S)-quininecyclo-3-yl(5-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0138] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0139] (S)-Quinylcyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0140] (S)-quininecyclo-3-yl(5-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0141] (S)-quininecyclo-3-yl(5-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0142] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0143] (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0144] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0145] (S)-quininecyclo-3-yl(5-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0146] (S)-quininecyclo-3-yl(5-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0147] (S)-quininecyclo-3-yl(5-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0148] (S)-quininecyclo-3-yl(5-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0149] (S)-quininecyclo-3-yl(5-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0150] (S)-quininecyclo-3-yl(5-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0151] (S)-quininecyclo-3-yl(5-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0152] (S)-quininecyclo-3-yl(5-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0153] (S)-quininecyclo-3-yl(5-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0154] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0155] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0156] (S)-quininecyclo-3-yl(5-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0157] (S)-quininecyclo-3-yl(5-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0158] (S)-quininecyclo-3-yl(5-(2-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0159] (S)-quininecyclo-3-yl(5-(4-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0160] (S)-quininecyclo-3-yl(5-(3-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0161] (S)-quininecyclo-3-yl(5-(2-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0162] (S)-quininecyclo-3-yl(5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0163] (S)-quininecyclo-3-yl(5-(3-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0164] (S)-quininecyclo-3-yl(5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0165] (S)-quininecyclo-3-yl(5-(3-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0166] (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(3-(methylthio)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0167] (S)-quininecyclo-3-yl(5-(3-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0168] (S)-quininecyclo-3-yl(5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0169] (S)-quininecyclo-3-yl(5-(3-(tert-butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0170] (S)-quininylcyclo-3-yl(5-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0171] (S)-quininecyclo-3-yl(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0172] (S)-quininecyclo-3-yl(5-(2,3-dihydrobenzofuran-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0173] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(3-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0174] (S)-quininecyclo-3-yl(5-(4-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0175] (S)-Quinylcyclo-3-yl(2,2-dimethyl-5-(4-(2,2,2-trifluoroethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0176] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0177] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(2-(trifluoromethyl)pyridin-4-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0178] (S)-quininecyclo-3-yl(5-(2,5-dichloropyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0179] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0180] (S)-quininecyclo-3-yl(5-(2-chloro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0181] (S)-quininecyclo-3-yl(5-(3-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0182] (S)-quininecyclo-3-yl(5-(2-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0183] (S)-quininecyclo-3-yl(5-(2-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0184] (S)-quininecyclo-3-yl(5-(4-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0185] (S)-quininecyclo-3-yl(5-(2,3-dichloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0186] (S)-quininecyclo-3-yl(5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0187] (S)-quininecyclo-3-yl(5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0188] (S)-quininecyclo-3-yl(5-(3-(dimethylamino)-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0189] (S)-quininecyclo-3-yl(5-(benzodihydropyran-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0190] (S)-quininecyclo-3-yl(5-(4-cyclopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0191] (S)-quininecyclo-3-yl(5-(4-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0192] (S)-quininecyclo-3-yl(5-(4-ethoxy-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0193] (S)-quininecyclo-3-yl(5-(4-methoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0194] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0195] (S)-quininecyclo-3-yl(5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0196] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(thiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0197] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-methylthiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0198] (S)-quininecyclo-3-yl(5-(3-(2-(dimethylamino)ethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0199] (S)-quininecyclo-3-yl(5-(isoquinolin-8-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0200] (S)-quininecyclo-3-yl(5-(isoquinolin-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0201] (S)-quininecyclo-3-yl(5-(isoquinolin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0202] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0203] (S)-quininecyclo-3-yl(5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0204] (S)-quininecyclo-3-yl(5-(2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0205] (S)-quininecyclo-3-yl(5-(4-(tert-butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0206] (S)-quininecyclo-3-yl(5-(4-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0207] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0208] (S)-quininecyclo-3-yl(5-(4-(methoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0209] (S)-quininecyclo-3-yl(5-(4-(2,2-difluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0210] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(3-methyl-4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0211] (S)-quininecyclo-3-yl(5-(3-fluoro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0212] (S)-quininecyclo-3-yl(5-(3-chloro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0213] (S)-quininecyclo-3-yl(5-(3,4-dihydro-2H-benzo[b][1,4]dioxane-heptane-7-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0214] (S)-quininecyclo-3-yl(5-(3-(difluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0215] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(quinolin-8-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0216] (S)-quininecyclo-3-yl(5-(benzofuran-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0217] (S)-quininecyclo-3-yl(5-(benzofuran-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0218] (S)-quininecyclo-3-yl(5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0219] (S)-quininecyclo-3-yl(5-(4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0220] (S)-quininecyclo-3-yl(5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0221] (S)-quininecyclo-3-yl(5-(2,4-dichloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0222] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0223] (S)-quininecyclo-3-yl(5-(4-butylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0224] (S)-quininecyclo-3-yl(5-(2,3-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0225] (S)-quininecyclo-3-yl(5-(2,4-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0226] (S)-quininecyclo-3-yl(5-(2,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0227] (S)-quininecyclo-3-yl(5-(2,6-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0228] (S)-quininecyclo-3-yl(5-(3,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0229] (S)-quininecyclo-3-yl(5-(4-ethoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0230] (S)-quininecyclo-3-yl(5-(2,5-difluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0231] (S)-quininecyclo-3-yl(5-(2-fluoro-5-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0232] (S)-quininecyclo-3-yl(5-(3,5-dimethyl-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0233] (S)-quininecyclo-3-yl(5-(4-ethoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0234] (S)-quininecyclo-3-yl(5-(2-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0235] (S)-quininecyclo-3-yl(5-(2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0236] (S)-quininecyclo-3-yl(5-(2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0237] (S)-quininecyclo-3-yl(5-(2-chloro-5-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0238] (S)-quininecyclo-3-yl(5-(4-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0239] (S)-quininecyclo-3-yl(5-(4-methoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0240] (S)-quininecyclo-3-yl(5-(4-(tert-butoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0241] (S)-quininecyclo-3-yl(5-(2-chloro-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0242] (S)-quininecyclo-3-yl(5-(2-chloro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0243] (S)-quininecyclo-3-yl(5-(2,6-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0244] (S)-quininecyclo-3-yl(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0245] (S)-quininecyclo-3-yl(5-(benzo[b]thiophen-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0246] (S)-quininecyclo-3-yl(5-(2-(tert-butoxy)pyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0247] (S)-quininecyclo-3-yl(5-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0248] (S)-quininecyclo-3-yl(5-(6-methoxynaphthyl-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0249] (S)-quininecyclo-3-yl(5-([1,1'-biphenyl]-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0250] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(quinoxolin-6-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0251] (S)-quininecyclo-3-yl(5-(3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0252] (S)-quininecyclo-3-yl(5-(furan-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0253] (S)-quininecyclo-3-yl(5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0254] (S)-quininecyclo-3-yl(5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0255] (S)-quininecyclo-3-yl(5-(6-isopropoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0256] (S)-quininecyclo-3-yl(5-(3-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0257] (S)-quininecyclo-3-yl(5-(2-ethoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0258] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0259] (S)-quininecyclo-3-yl(5-(2-methoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0260] (S)-quininecyclo-3-yl(5-(2-butoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0261] (S)-quininecyclo-3-yl(5-(4-butoxy-3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0262] (S)-quininecyclo-3-yl(5-(2,4-dipropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0263] (S)-quininecyclo-3-yl(5-(3-chloro-4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0264] (S)-quininecyclo-3-yl(5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0265] (S)-quininecyclo-3-yl(5-(4-ethoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0266] (S)-quininecyclo-3-yl(5-(3-chloro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0267] (S)-quininecyclo-3-yl(5-(5-fluoro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0268] (S)-quininecyclo-3-yl(5-(3-fluoro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0269] (S)-quininecyclo-3-yl(5-(5-chloro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0270] (S)-quininecyclo-3-yl(5-(2-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0271] (S)-quininecyclo-3-yl(5-(5-chloro-2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0272] (S)-quininecyclo-3-yl(5-(5-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0273] (S)-quininecyclo-3-yl(5-(2-fluoro-6-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0274] (S)-quininecyclo-3-yl(5-(3-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0275] (S)-quininecyclo-3-yl(5-(3-fluoro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0276] (S)-quininecyclo-3-yl(5-(5-chloro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0277] (S)-quininecyclo-3-yl(5-(3-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0278] (S)-quininecyclo-3-yl(5-(3-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0279] (S)-quininecyclo-3-yl(5-(5-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0280] (S)-quininecyclo-3-yl(5-(2-chloro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0281] (S)-quininecyclo-3-yl(5-(3-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0282] (S)-quininecyclo-3-yl(5-(2-chloro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0283] (S)-quininecyclo-3-yl(5-(3-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0284] (S)-quininecyclo-3-yl(5-(2-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0285] (S)-quininecyclo-3-yl(5-(4-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0286] (S)-quininecyclo-3-yl(5-(3,4-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0287] (S)-quininecyclo-3-yl(5-(4-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0288] (S)-quininecyclo-3-yl(5-(2-fluoro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0289] (S)-quininecyclo-3-yl(5-(2-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0290] (S)-quininecyclo-3-yl(5-(2-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0291] (S)-Quininecyclo-3-yl(5-(5-isopropyl-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0292] (S)-quininecyclo-3-yl(5-(2-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0293] (S)-quininecyclo-3-yl(5-(5-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0294] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(5-methylfuran-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0295] (S)-quininecyclo-3-yl(5-(3-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0296] (S)-quininecyclo-3-yl(5-(2-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0297] (S)-quininecyclo-3-yl(5-(benzo[b]thiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0298] (S)-quininecyclo-3-yl(5-(4-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0299] (S)-quininecyclo-3-yl(5-(3-(tert-butyl)-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0300] (S)-quininecyclo-3-yl(5-(2-chloro-5-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0301] (S)-quininecyclo-3-yl(5-(4-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0302] (S)-quininecyclo-3-yl(5-(2-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0303] (S)-quininecyclo-3-yl(5-(5-cyano-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0304] (S)-quininecyclo-3-yl(5-(3-ethoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0305] (S)-quininecyclo-3-yl(5-(3-fluoro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0306] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(3-methyl-4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0307] (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(3-(methylthio)-5-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0308] (S)-quininecyclo-3-yl(5-(3-fluoro-4-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0309] (S)-quininecyclo-3-yl(5-(2-ethoxy-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0310] (S)-quininecyclo-3-yl(5-(2-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0311] (S)-quininecyclo-3-yl(5-(2,4-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0312] (S)-quininecyclo-3-yl(5-(3-chloro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0313] (S)-quininecyclo-3-yl(5-(3-methoxy-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0314] (S)-quininecyclo-3-yl(5-(4-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0315] (S)-quininecyclo-3-yl(5-(2-ethoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0316] (S)-quininecyclo-3-yl(5-(3-fluoro-5-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0317] (S)-Quininecyclo-3-yl(5-(3,5-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0318] (S)-quininecyclo-3-yl(5-(3-chloro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0319] (S)-quininecyclo-3-yl(5-(2,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0320] (S)-quininecyclo-3-yl(5-(3-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0321] (S)-quininecyclo-3-yl(5-(6-ethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0322] (S)-quininecyclo-3-yl(5-(2-ethoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0323] (S)-quininecyclo-3-yl(5-(2-isopropoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0324] (S)-quininecyclo-3-yl(2,2-dimethyl-5-(6-propoxypyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0325] (S)-quininecyclo-3-yl(5-(6-butoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0326] (S)-quininecyclo-3-yl(5-(6-(2-methoxyethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0327] (S)-quininecyclo-3-yl(5-(6-isobutoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0328] (S)-quininecyclo-3-yl(5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0329] (S)-quininecyclo-3-yl(5-(4-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0330] (S)-quininecyclo-3-yl(5-(2,4-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0331] (S)-quininecyclo-3-yl(5-(2-acetylthiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0332] (S)-quininecyclo-3-yl(5-((E)-3-fluorostyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0333] (S)-quininecyclo-3-yl(5-((E)-4-ethylstyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0334] (S)-quininecyclo-3-yl(5-((E)-2-cyclohexylvinyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0335] (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0336] (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0337] (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0338] (S)-quininecyclo-3-yl(5-(4-(tert-butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0339] (S)-quininecyclo-3-yl(5-(4-butylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0340] (S)-quininecyclo-3-yl(5-(4-cyclopropylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0341] (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0342] (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0343] (S)-quininecyclo-3-yl(5-(4-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0344] (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0345] (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0346] (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-isobutylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0347] (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0348] (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0349] (S)-quininecyclo-3-yl(5-(3-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0350] (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0351] (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0352] (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0353] (S)-quininecyclo-3-yl(5-(3-(tert-butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0354] (S)-quininecyclo-3-yl(5-(2,3-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0355] (S)-quininecyclo-3-yl(5-(2,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0356] (S)-quininecyclo-3-yl(5-(2,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0357] (S)-quininecyclo-3-yl(5-(3,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0358] (S)-quininecyclo-3-yl(5-(3,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0359] (S)-quininecyclo-3-yl(5-(2,6-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0360] (S)-quininecyclo-3-yl(5-(3-(difluoromethyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0361] (S)-quininecyclo-3-yl(5-(3-(dimethylamino)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0362] (S)-Quinylcyclo-3-yl(5-(4-ethoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0363] (S)-quininecyclo-3-yl(5-(3,5-dimethyl-4-propoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0364] (S)-quininecyclo-3-yl(5-(4-butoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0365] (S)-quininecyclo-3-yl(2,2-diethyl-5-(thiophen-3-yl)-2,3-dihydro1H-inden-1-yl)carbamate;

[0366] (S)-quininecyclo-3-yl(2,2-diethyl-5-(furan-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0367] (S)-quininecyclo-3-yl(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0368] (S)-quininecyclo-3-yl(5-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0369] (S)-quininecyclo-3-yl(2,2-diethyl-5-(2-fluoro-4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0370] (S)-quininecyclo-3-yl(5-(3-chloro-4-isopropoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0371] (S)-quininecyclo-3-yl(5-(4-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0372] (S)-quininecyclo-3-yl(6-methoxy-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0373] (S)-quininecyclo-3-yl(5-(4-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0374] (S)-quininecyclo-3-yl(5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0375] (S)-quininecyclo-3-yl(5-(4-(tert-butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0376] (S)-quininecyclo-3-yl(5-(4-cyclopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0377] (S)-quininecyclo-3-yl(5-(4-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0378] (S)-quininecyclo-3-yl(6-methoxy-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0379] (S)-quininecyclo-3-yl(5-(4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0380] (S)-quininecyclo-3-yl(5-(3,5-dimethyl-4-propoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0381] (S)-quininecyclo-3-yl(5-(3-chloro-4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0382] (S)-quininecyclo-3-yl(5-(2-fluoro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0383] (S)-quininecyclo-3-yl(5-(4-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0384] (S)-quininecyclo-3-yl(5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0385] (S)-quininecyclo-3-yl(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0386] (S)-quininecyclo-3-yl(5-(5-chloro-2-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0387] (S)-quininecyclo-3-yl(5-(4-butylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0388] (S)-quininecyclo-3-yl(6-methoxy-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0389] (S)-quininecyclo-3-yl(5-(4-ethoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0390] (S)-quininecyclo-3-yl(5-(4-butoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0391] (S)-quininecyclo-3-yl(6-methoxy-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0392] (S)-quininecyclo-3-yl(5-(3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0393] (S)-quininecyclo-3-yl(5-(3-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0394] (S)-quininecyclo-3-yl(5-(3-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0395] (S)-quininecyclo-3-yl(5-(3-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0396] (S)-quininecyclo-3-yl(5-(3-(tert-butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0397] (S)-quininecyclo-3-yl(6-methoxy-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0398] (S)-quininecyclo-3-yl(5-(3-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0399] (S)-quininecyclo-3-yl(6-methoxy-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0400] (S)-quininecyclo-3-yl(5-(3-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0401] (S)-quininecyclo-3-yl(5-(3-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0402] (S)-quininecyclo-3-yl(5-(3-isobutoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0403] (S)-quininecyclo-3-yl(5-(2,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0404] (S)-quininecyclo-3-yl(5-(3,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0405] (S)-quininecyclo-3-yl(5-(2-chloro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0406] (S)-quininecyclo-3-yl(5-(4-ethoxy-3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0407] (S)-quininecyclo-3-yl(5-(4-isopropoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0408] (S)-quininecyclo-3-yl(5-(4-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0409] (S)-quininecyclo-3-yl(6-fluoro-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0410] (S)-quininecyclo-3-yl(6-fluoro-5-(4-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0411] (S)-quininecyclo-3-yl(6-fluoro-5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0412] (S)-quininecyclo-3-yl(5-(4-(tert-butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0413] (S)-quininecyclo-3-yl(5-(4-cyclopropylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0414] (S)-quininecyclo-3-yl(6-fluoro-5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0415] (S)-quininecyclo-3-yl(5-(4-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0416] (S)-quininecyclo-3-yl(6-fluoro-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0417] (S)-Quininecyclo-3-yl(6-fluoro-5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0418] (S)-quininecyclo-3-yl(5-(3-chloro-4-isopropoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0419] (S)-Quininecyclo-3-yl(6-fluoro-5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0420] (S)-quininecyclo-3-yl(5-(4-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0421] (S)-Quininecyclo-3-yl(6-fluoro-5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0422] (S)-quininecyclo-3-yl(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0423] (S)-quininecyclo-3-yl(5-(5-chloro-2-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0424] (S)-quininecyclo-3-yl(5-(4-butylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0425] (S)-quininecyclo-3-yl(6-fluoro-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0426] (S)-quininecyclo-3-yl(5-(4-ethoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0427] (S)-quininecyclo-3-yl(5-(4-butoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0428] (S)-Quininecyclo-3-yl(6-fluoro-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0429] (S)-quininecyclo-3-yl(6-fluoro-5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0430] (S)-quininecyclo-3-yl(5-(3-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0431] (S)-Quininecyclo-3-yl(6-fluoro-5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0432] (S)-Quininecyclo-3-yl(6-fluoro-5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0433] (S)-quininecyclo-3-yl(5-(3-(tert-butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0434] (S)-quininecyclo-3-yl(6-fluoro-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0435] (S)-quininecyclo-3-yl(5-(3-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0436] (S)-quininecyclo-3-yl(6-fluoro-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0437] (S)-quininecyclo-3-yl(6-fluoro-5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0438] (S)-quininecyclo-3-yl(5-(3-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0439] (S)-quininecyclo-3-yl(6-fluoro-5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0440] (S)-quininecyclo-3-yl(5-(2,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0441] (S)-quininecyclo-3-yl(5-(2,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0442] (S)-quininecyclo-3-yl(5-(2,6-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0443] (S)-quininecyclo-3-yl(5-(3,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0444] (S)-quininecyclo-3-yl(5-(3,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0445] (S)-quininecyclo-3-yl(5-(2-chloro-4-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0446] (S)-quininecyclo-3-yl(5-(4-ethoxy-3-fluorophenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0447] (S)-quininecyclo-3-yl(6-fluoro-5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0448] (S)-quininecyclo-3-yl(5'-(4-fluorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0449] (S)-quininecyclo-3-yl(5'-(4-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0450] (S)-quininecyclo-3-yl(5'-(4-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0451] (S)-quininecyclo-3-yl(5'-(4-(trifluoromethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0452] (S)-quininecyclo-3-yl(5'-(3-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0453] (S)-quininecyclo-3-yl(5'-(3-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0454] (S)-quininecyclo-3-yl(5'-(4-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0455] (S)-quininecyclo-3-yl(5'-(3-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0456] (S)-quininecyclo-3-yl(5'-(4-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0457] (S)-quininecyclo-3-yl(5'-(3-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate;

[0458] (S)-quininecyclo-3-yl(5-(3-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0459] (S)-quininecyclo-3-yl(5-(2-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

[0460] (S)-quininecyclo-3-yl(3,3-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0461] (S)-Quininecyclo-3-yl(3,3-dimethyl-5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0462] (S)-Quininecyclo-3-yl(3,3-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

[0463] (S)-quininecyclo-3-yl(6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;

[0464] (S)-quininecyclo-3-yl(6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;

[0465] (S)-quininecyclo-3-yl(5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate;

[0466] (S)-quininecyclo-3-yl(6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate;

[0467] (S)-quininecyclo-3-yl(6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate;

[0468] (S)-quininecyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;

[0469] (S)-quininylcyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate; and

[0470] (S)-quininecyclo-3-yl(6-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate.

[0471] Compounds of Formula 1 or pharmaceutically acceptable salts thereof may be in the form of cis-geometric isomers or trans-geometric isomers. Unless otherwise stated, compounds of Formula 1 or pharmaceutically acceptable salts thereof include cis-geometric isomers and trans-geometric isomers. Compounds of Formula 1 or pharmaceutically acceptable salts thereof may also have substituents containing asymmetric atoms, and thus be in the form of racemic mixtures (RS) or optical isomers, such as (R) isomers or (S) isomers. Unless otherwise stated, compounds of Formula 1 or pharmaceutically acceptable salts thereof include racemic mixtures (RS) and optical isomers such as (R) isomers or (S) isomers. Furthermore, compounds of Formula 1 or pharmaceutically acceptable salts thereof may have two or more chiral centers, and thus be in the form of one or more diastereomers or mixtures thereof. Unless otherwise stated, compounds of Formula 1 or pharmaceutically acceptable salts thereof comprise diastereomers and mixtures thereof.

[0472] The compounds of Formula 1 of the present invention can be in pharmaceutically acceptable salt form. This salt can be in the form of a conventional acid addition salt, including salts derived from inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, or hydrobromic acid; and salts derived from organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, benzoic acid, citric acid, maleic acid, malonic acid, malic acid, tartaric acid, gluconic acid, lactic acid, gentisic acid, fumaric acid, lactobionic acid, salicylic acid, phthalic acid, embonic acid, aspartic acid, glutamic acid, or acetylsalicylic acid. Furthermore, the salt also includes salts derived from amino acids such as glycine, alanine, valine, isoleucine, serine, cysteine, cystine, aspartic acid, glutamine, lysine, arginine, tyrosine, or proline. Additionally, the salt includes salts derived from sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, or toluenesulfonic acid.

[0473] The compounds of Formula 1 according to the present invention, or their pharmaceutically acceptable salts, can be prepared by various methods.

[0474] For example, a compound of formula 1a or a pharmaceutically acceptable salt thereof according to the invention may be prepared by a method comprising: reacting a compound of formula 2 or a salt thereof with ethyl chloroformate to give a compound of formula 3; coupling a compound of formula 3 with a compound of formula 4 to give a compound of formula 5; reacting a compound of formula 5 with an AW-boric acid substituted with X1, X2, X3 or X4 to give a compound of formula 1a; and optionally converting a compound of formula 1a into a pharmaceutically acceptable salt thereof, as shown in reaction scheme 1 below.

[0475] <Reaction Scheme 1>

[0476]

[0477] In reaction scheme 1, X, Y, Z, W, ring A, X1, X2, X3, and X4 are the same as those defined above.

[0478] The compound of Formula 2 is a commercially available or known compound that can be synthesized according to literature. The reaction between the compound of Formula 2 or its salt and ethyl chloroformate can be carried out in the presence of an organic base such as triethylamine, N,N-diisopropylethylamine, or an inorganic base such as potassium carbonate. Based on 1 equivalent of the compound of Formula 2, a base can be used in an amount ranging from 1 to 1.5 equivalents, or a salt (e.g., hydrochloride) based on 1 equivalent of the compound of Formula 2 can be used in an amount ranging from 3 to 5 equivalents. The reaction can be carried out in a solvent such as dichloromethane or tetrahydrofuran, preferably at 0°C to room temperature.

[0479] The coupling between the compound of Formula 3 and the compound of Formula 4 (i.e., quinine cycloalcohol) can be carried out by a condensation reaction involving the removal of ethanol. This reaction is preferably carried out in the presence of a base, such as sodium hydride. Alternatively, the reaction can be carried out at 120°C to 140°C in a nonpolar organic solvent, such as toluene.

[0480] The reaction between the compound of Formula 5 and AW-boronic acid substituted with X1, X2, X3, and X4 can be carried out according to the Suzuki reaction. The Suzuki reaction can be carried out using palladium catalysts, such as tetrakis(triphenylphosphine)palladium (O)(Pd(PPh3)4), palladium(II) acetate (Pd(OAc)2), and [1,1'-bis(diphenylphosphine)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2). Furthermore, the Suzuki reaction can be carried out in the presence of inorganic bases such as cesium carbonate (Cs2CO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3), and potassium phosphate (K3PO4). The Suzuki reaction can be carried out in a nonpolar organic solvent such as toluene or a polar organic solvent such as 1,4-dioxane, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, or N,N-dimethylformamide at a temperature of 50°C to 150°C, preferably 80°C to 120°C. Other reaction conditions, including reaction time, can be determined according to known Suzuki reaction methods.

[0481] The conversion of a compound of Formula 1a into its pharmaceutically acceptable salt can be carried out using conventional methods. For example, a pharmaceutically acceptable salt of a compound of Formula 1a can be prepared by dissolving the compound of Formula 1a in a water-miscible solvent such as methanol, ethanol, acetone, or 1,4-dioxane, and then adding a free acid or a free base for crystallization.

[0482] Furthermore, the compound of formula 1a according to the invention, or a pharmaceutically acceptable salt thereof, can be prepared by a method comprising: reacting the compound of formula 4 with bis(4-nitrophenyl) carbonate to give the compound of formula 7; reacting the compound of formula 7 with the compound of formula 2 to give the compound of formula 5; reacting the compound of formula 5 with AW-boronic acid substituted with X1, X2, X3 or X4 to give the compound of formula 1a; and optionally converting the compound of formula 1a into its pharmaceutically acceptable salt, as shown in reaction scheme 2 below.

[0483] <Reaction Scheme 2>

[0484]

[0485] In reaction scheme 2, X, Y, Z, W, ring A, X1, X2, X3, and X4 are the same as those defined above.

[0486] The reaction between the compound of Formula 4 (i.e., quininecyclool) and bis(4-nitrophenyl) carbonate can be carried out, preferably at 0°C to 25°C, in a polar solvent such as N,N-dimethylformamide. The compound of Formula 7 can also be prepared by reacting the compound of Formula 4 with 4-nitrophenyl chloroformate in the presence of a base such as triethylamine in a solvent such as dichloromethane or acetonitrile.

[0487] The reaction between the compound of Formula 7 and the compound of Formula 2 can be carried out at 0°C to 25°C in a solvent such as N,N-dimethylformamide, tetrahydrofuran or acetonitrile, in the presence of a base such as N,N-diisopropylethylamine or triethylamine.

[0488] The reaction between the compound of Formula 5 and AW-boronic acid substituted with X1, X2, X3, or X4 can be carried out according to the Suzuki reaction as described above. Furthermore, the conversion of the compound of Formula 1a to its pharmaceutically acceptable salt can be carried out according to the conventional methods described above.

[0489] The compounds of the present invention having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety, i.e., compounds of Formula 1 or pharmaceutically acceptable salts thereof, have excellent inhibitory activity against glucose-ceramide synthase (GCS) and are therefore effective for the prevention or treatment of various diseases associated with GCS.

[0490] Therefore, the present invention includes, within its scope, a pharmaceutical composition for inhibiting glucose-ceramide synthase (GCS), the pharmaceutical composition comprising a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof as the active ingredient. In one embodiment, the present invention provides a pharmaceutical composition for the prevention or treatment of GCS-related diseases, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc., the pharmaceutical composition comprising a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof as the active ingredient.

[0491] The pharmaceutical compositions of the present invention may contain pharmaceutically acceptable carriers, such as diluents, disintegrants, sweeteners, lubricants, or flavoring agents. The pharmaceutical compositions may be formulated into oral dosage forms, such as tablets, capsules, powders, granules, suspensions, emulsions, or syrups; or parenteral dosage forms, such as topical solutions, topical suspensions, topical emulsions, gels (e.g., ointments), inhalers, nebulizers, or injections. The dosage form may be various, such as single-dose or multiple-dose dosage forms.

[0492] The pharmaceutical compositions of the present invention may contain, for example, diluents (e.g., lactose, corn starch, etc.); lubricants (e.g., magnesium stearate); emulsifying agents; suspending agents; stabilizers; and / or isotonic agents. If desired, the composition may further contain sweeteners and / or flavoring agents.

[0493] The compositions of the present invention can be administered orally or parenterally, including via inhalation, intravenous, intraperitoneal, subcutaneous, rectal, and topical routes of administration. Therefore, the compositions of the present invention can be formulated into various dosage forms, such as tablets, capsules, aqueous solutions, or suspensions. In the case of tablets for oral administration, carriers such as lactose, corn starch, and lubricants such as magnesium stearate are typically used. In the case of capsules for oral administration, lactose and / or dried corn starch can be used as diluents. When an aqueous suspension is required for oral administration, the active ingredient can be combined with an emulsifier and / or a suspending agent. Certain sweeteners and / or flavoring agents may be used if desired. For intramuscular, intraperitoneal, subcutaneous, and intravenous administration, a sterile solution of the active ingredient is typically prepared, and the pH of the buffered solution is appropriately adjusted and buffered. For intravenous administration, the total concentration of the solute should be controlled to make the formulation isotonic. The compositions of the present invention can be in the form of an aqueous solution containing a pharmaceutically acceptable carrier, such as saline solution with a pH of 7.4. The solution can be introduced into the patient's intramuscular bloodstream via local bolus injection.

[0494] The compound of Formula 1 or a pharmaceutically acceptable salt thereof may be administered to the study patients at a therapeutically effective dose of about 0.0001 mg / kg to about 100 mg / kg per day. Of course, the dose may be varied depending on the patient's age, weight, sensitivity, symptoms, or the activity of the compound.

[0495] This invention, within its scope, includes a method for inhibiting glucose-ceramide synthase (GCS) in mammals, the method comprising administering to a mammal in need a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof. In one embodiment, the invention provides a method for treating GCS-related diseases, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc., the method comprising administering to a mammal in need a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof.

[0496] The present invention also provides the use of compounds of Formula 1 or pharmaceutically acceptable salts thereof in the preparation of medicaments for inhibiting glucose-ceramide synthase (GCS) in mammals. In one embodiment, the present invention provides the use of compounds of Formula 1 or pharmaceutically acceptable salts thereof in the preparation of medicaments for the prevention or treatment of GCS-related diseases such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

[0497] The following embodiments and experimental examples are provided for illustrative purposes only and are not intended to limit the scope of the invention.

[0498] In the following examples, brine refers to a saturated aqueous solution of sodium chloride. Unless otherwise stated, all temperatures are in degrees Celsius (°C). Unless otherwise stated, all reactions are carried out at room temperature.

[0499] The compounds prepared in the following preparation examples and embodiments were analyzed as follows: Nuclear magnetic resonance (NMR) spectroscopy was performed using a Bruker 400MHz spectrometer, with chemical shifts analyzed in ppm. Column chromatography was performed on silica gel (Merck, 70-230 mesh). Each starting material was a known compound synthesized according to literature or purchased commercially. All reactions and chromatographic fractions were analyzed by thin-layer chromatography (TLC) on 250nm silica gel plates and visualized by ultraviolet light or iodine (I2) staining.

[0500] Preparation Example 1. (S)-quininecyclo-3-yl(5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate

[0501] Step 1. Ethyl (5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate

[0502] 5-Bromo-2,3-dihydro-1H-indene-1-amine (2 g, 9.4 mmol) was dissolved in dichloromethane (50 mL), and then triethylamine (1.45 mL, 10.4 mmol) and ethyl chloroformate (1 mL, 10.4 mmol) were slowly added to the mixture. The reaction mixture was stirred at room temperature for 4 hours. Water was added to the reaction mixture, and the mixture was then extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The resulting residue (2.6 g) in the form of a pale yellow oil was used for subsequent reactions without further purification.

[0503] Step 2. (S)-quininecyclo-3-yl(5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate

[0504] (S)-(+)-3-quininecyclool (3.5 g, 27.5 mmol) was dissolved in toluene (80 mL), and sodium hydride (219.6 mg, 9.2 mmol) was added to it at 0 °C. The reaction mixture was stirred for 15 min, and then ethyl (5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate (2.6 g, 9.2 mmol) prepared in step 1 was added. The reaction mixture was refluxed at 140 °C for 21 h, and then cooled to room temperature. Brine was added to the reaction mixture, and then it was extracted with ethyl acetate. The organic layer was washed twice with brine, dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The residue was purified by column chromatography (ethyl acetate / (methanol / ammonia = 1 / 1) = 9 / 1, v / v) to give the title compound as a white solid. (1.3 g, yield: 46%)

[0505] 1 H-NMR (400MHz, CDCl3) δ7.34 (s, 1H), 7.30 (m, 1H), 7.15 (m, 1H), 5.50 (br, 1H), 5.13 (m, 1H), 4.75 (m, 2 H), 3.18(m, 2H), 2.82~2.68(m, 7H), 1.96(m, 1H), 1.80(m, 1H), 1.66(m, 1H), 1.55(m, 1H), 1.37(m, 1H)

[0506] Preparation Example 2. (S)-quininecyclo-3-yl(6-bromo-2,3-dihydro-1H-inden-1-yl)carbamate

[0507] The title compound was prepared using 6-bromo-2,3-dihydro-1H-indene-1-amine as a starting material, following the same steps as in Preparation Example 1.

[0508] 1 H-NMR (400MHz, CDCl3) δ7.40 (s, 1H), 7.30 (m, 1H), 7.08 (d, 1H), 5.51 (br, 1H), 5.19 (m, 1H), 4.75 (m, 2 H), 3.20 (m, 2H), 2.82~2.69 (m, 7H), 1.97 (m, 1H), 1.80 (m, 1H), 1.67 (m, 1H), 1.55 (m, 1H), 1.38 (m, 1H)

[0509] Preparation Example 3. (S)-quininecyclo-3-yl(6-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0510] The title compound was prepared using 6-bromo-2,2-dimethyl-2,3-dihydro-1H-indene-1-amine as a starting material, following the same steps as in Preparation Example 1.

[0511] 1 H-NMR (400MHz, CDCl3) δ7.28 (m, 2H), 7.00 (d, 1H), 4.89 (m, 1H), 4.73 (m, 2H), 3.15 (m, 1H), 2.81~ 2.70 (m, 7H), 1.95 (m, 1H), 1.80 (br, 1H), 1.64 (br, 1H), 1.53 (br, 1H), 1.39 (br, 1H), 0.85 (d, 6H)

[0512] Preparation Example 4. (S)-quininecyclo-3-yl(5-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0513] Step 1. 5-Bromo-2,2-dimethyl-2,3-dihydro-1H-indene-1-carbamate

[0514] 100 g (418.2 mmol) of 5-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-one was dissolved in methanol (500 mL) and isopropanol (500 mL), and then ammonium acetate (515.8 g, 6691.5 mmol) and sodium cyanoborohydride (157.7 g, 2509.3 mmol) were slowly added to the mixture at room temperature. The reaction mixture was stirred at room temperature for 4 hours, and then refluxed at 80 °C for 22 hours. The reaction mixture was cooled to room temperature, alkalized with 1 N sodium hydroxide solution to pH > 12, and then extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. Ethyl acetate was added to the residue, followed by a solution of 1,4-dioxane in hydrochloric acid (4 M). The mixture was stirred at room temperature for 1 hour. The solid obtained by filtration under reduced pressure was washed with ethyl acetate and dried to give the title compound as a white solid. (100g, yield: 86.5%)

[0515] 1 H-NMR (400MHz, CDCl3) δ7.50 (m, 2H), 7.39 (d, 1H), 4.28 (s, 1H), 3.02~2.82 (m, 2H), 1.24 (s, 3H), 1.20 (s, 3H)

[0516] Step 2. (S)-quininecyclo-3-yl(5-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0517] A solution of (S)-(+)-3-quininecyclool (38.6 g, 303.7 mmol) and bis(4-nitrophenyl) carbonate (92.4 g, 303.7 mmol) in N,N-dimethylformamide (700 mL) was stirred at room temperature for 8 hours. The solution of 5-bromo-2,2-dimethyl-2,3-dihydro-1H-indene-1-amine hydrochloride (70 g, 253.1 mmol) and diisopropylethylamine (132.3 mL, 759.2 mmol) prepared in step 1 was added to the solution, and the mixture was stirred overnight at room temperature. The reaction mixture was diluted with water (500 mL), acidified to pH 1-2 with 1N hydrochloric acid aqueous solution, and then extracted with diisopropyl ether (300 mL × 2). The aqueous layer was alkalized to pH 12 with ammonia and then extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The resulting residue was dissolved in isopropyl acetate, and then heptane was added. The mixture was stirred overnight at room temperature. The resulting solid was filtered under reduced pressure, washed with heptane, and dried to give the title compound as a white solid (56 g, yield: 56.3%).

[0518] 1 H-NMR (400MHz, CDCl3) δ7.32 (m, 2H), 7.09 (m, 1H), 4.89 (m, 1H), 4.86 (m, 1H), 4.77 (m, 1H), 3.25 (m, 1H), 2.87~2.75 (m, 2 H), 2.74~2.69(m, 5H), 2.07(m, 1H), 1.83(br, 1H), 1.69(br, 1H), 1.57(br, 1H), 1.41(br, 1H), 1.27(s, 3H), 0.92(s, 3H)

[0519] Preparation Example 5. (S)-quininecyclo-3-yl(5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0520] Step 1. 5-Bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-one

[0521] 5-Bromo-1-indanone (20 g, 94.8 mmol) was dissolved in tetrahydrofuran (100 mL), and then 60% sodium hydride (19 g, 473.8 mmol) was added to it at 0 °C. The reaction mixture was stirred for 15 min, and then iodoethane (19.1 mL, 236.9 mmol) was slowly added to it at the same temperature. The reaction mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and then it was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The residue was purified by column chromatography (n-hexane / ethyl acetate = 10 / 1, v / v) to give the title compound as a white solid. (17 g, yield: 67%)

[0522] 1 H-NMR (400MHz, CDCl3) δ7.61 (s, 1H), 7.58 (m, 1H), 7.51 (m, 1H), 2.97 (s, 2H), 1.65 (m, 2H), 1.62 (m, 2H), 0.77 (t, 6H)

[0523] Step 2. 5-Bromo-2,2-diethyl-2,3-dihydro-1H-indene-1-amine hydrochloride

[0524] The title compound was prepared using the 5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-one obtained in step 1, following the same procedure as in step 1 of Preparation Example 4.

[0525] 1 H-NMR (400MHz, MeOD) δ7.49 (s, 1H), 7.45 (m, 2H), 4.38 (s, 1H), 3.07 (m, 1H), 2.83 (m, 1H), 1.70 (m, 2H), 1.40 (m, 2H), 1.09 (t, 3H), 0.88 (t, 3H)

[0526] Step 3. (S)-Quininecyclo-3-yl(5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0527] The title compound was prepared using the 5-bromo-2,2-diethyl-2,3-dihydro-1H-indene-1-amine hydrochloride obtained in step 2, following the same steps as in step 2 of Preparation Example 4.

[0528] 1H-NMR (400MHz, CDCl3) δ7.32 (m, 2H), 7.09 (m, 1H), 5.01 (m, 1H), 4.85 (m, 1H), 4.76 (m, 1H), 3.25 (m, 1H), 2.89~2.70 ( m, 7H), 2.10 (br, 1H), 1.80 (br, 1H), 1.69 (br, 1H), 1.55 (m, 3H), 1.49 (m, 2H), 1.40 (br, 1H), 0.95 (m, 3H), 0.81 (m, 3H)

[0529] Preparation Example 6. (S)-quininecyclo-3-yl(5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0530] Step 1. 5-Bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one

[0531] 5-Bromo-6-methoxy-2,3-dihydro-1H-inden-1-one (10 g, 43.7 mmol) was dissolved in tetrahydrofuran (50 mL), and then 60% sodium hydride (8.7 g, 218.3 mmol) was added to it at 0 °C. The reaction mixture was stirred for 15 min, and then iodomethane (10.9 mL, 174.6 mmol) was slowly added to it at the same temperature. The reaction mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and then it was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The residue was purified by column chromatography (n-hexane / ethyl acetate = 10 / 1, v / v) to give the title compound as a white solid. (10 g, yield: 89%)

[0532] 1 H-NMR (400MHz, CDCl3) δ7.66 (s, 1H), 7.21 (s, 1H), 3.94 (s, 3H), 2.93 (s, 2H), 1.24 (s, 6H)

[0533] Step 2. 5-Bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-indene-1-amine hydrochloride

[0534] The title compound was prepared using the 5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one obtained in step 1, following the same steps as in step 1 of Preparation Example 4.

[0535] 1H-NMR (400MHz, MeOD) δ7.47 (s, 1H), 7.23 (s, 1H), 4.29 (s, 1H), 4.11 (s, 3H), 2.95 ~ 2.92 (m, 1H), 2.78 ~ 2.74 (m, 1H), 1.29 (m, 3H), 0.98 (m, 3H)

[0536] Step 3. (S)-quininecyclo-3-yl(5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0537] The title compound was prepared using the 5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-indene-1-amine hydrochloride obtained in step 2, following the same steps as in step 2 of Preparation Example 4.

[0538] 1 H-NMR (400MHz, CDCl3) δ7.34 (s, 1H), 6.77 (m, 1H), 4.87 (s, 2H), 4.78 (m, 1H), 3.85 (m, 3H), 3.25 (m, 1H), 2.78~ 2.61(m,7H),2.10(br,1H),1.85(br,1H),1.69(br,1H),1.57(br,1H),1.44(br,1H),1.21(m,3H),0.95(m,3H)

[0539] Preparation Example 7. (S)-quininecyclo-3-yl(5-bromo-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0540] The title compound was prepared using 5-bromo-6-fluoro-2,3-dihydro-1H-inden-1-one as a starting material, following the same steps as in Preparation Example 6.

[0541] 1 H-NMR (400MHz, CDCl3) δ7.34 (d, 1H), 7.01 (d, 1H), 4.91 (m, 1H), 4.84 (m, 1H), 4.69 (m, 1H), 3.25 (m, 1H), 2.93~ 2.72(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.40(br,1H),1.27(m,3H),0.92(m,3H)

[0542] Preparation Example 8. (S)-quininecyclo-3-yl(5'-bromo-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[0543] Step 1. 5'-Bromospiro[cyclopropane-1,2'-indene]-1'(3'H)-one

[0544] 5-Bromo-1-indanone (5 g, 23.7 mmol) was dissolved in N,N-dimethylformamide (100 mL), and then 60% sodium hydride (2.7 g, 35.5 mmol) was added to it at 0 °C. The reaction mixture was stirred for 15 minutes, and then 1,2-dibromomethane (5.1 mL, 35.5 mmol) was slowly added to it at the same temperature. The reaction mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and then it was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The residue was purified by column chromatography (n-hexane / ethyl acetate = 10 / 1, v / v) to give the title compound as a white solid. (3.5 g, yield: 62%)

[0545] 1 H-NMR (400MHz, CDCl3) δ7.69 (s, 1H), 7.65 (m, 1H), 7.55 (d, 1H), 3.15 (s, 2H), 1.47 (d, 2H), 1.19 (d, 2H)

[0546] Step 2. 5'-Bromo-1',3'-Dihydrospiro[cyclopropane-1,2'-indene]-1'-amine hydrochloride

[0547] The title compound was prepared using the 5'-bromospiro[cyclopropane-1,2'-indene]-1'(3'H)-one obtained in step 1, following the same method as in step 1 of Preparation Example 4.

[0548] 1 H-NMR (400MHz, MeOD) δ7.56 (s, 1H), 7.52 (m, 1H), 7.45 (m, 1H), 4.25 (s, 1H), 3.45 (m, 1H), 2.71 (m, 1H), 1.15 (m, 1H), 0.92 (m, 2H), 0.82 (m, 1H)

[0549] Step 3. (S)-quininecyclo-3-yl(5'-bromo-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[0550] The title compound was prepared using the 5'-bromo-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-amine hydrochloride obtained in step 2, following the same steps as in Preparation Example 1.

[0551] 1H-NMR (400MHz, CDCl3) δ7.36 (m, 2H), 7.24 (m, 1H), 4.92 (m, 1H), 4.91 (m, 1H), 4.74 (m, 1H), 3.25 (m, 1H), 3.00 (m, 2H), 2.87 ~2.68 (m, 5H), 1.97 (br, 1H), 1.79 (m, 1H), 1.67 (br, 1H), 1.56 (m, 1H), 1.41 (br, 1H), 0.91 (m, 2H), 0.81 (m, 1H), 0.59 (m, 1H)

[0552] Preparation Example 9. (S)-quininecyclo-3-yl(5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0553] Step 1. 6-Bromo-1,1-dimethyl-2,3-dihydro-1H-indene

[0554] A solution of titanium(IV) chloride in dichloromethane (28.4 mL, 1.0 M) was slowly added to dichloromethane (20 mL) at -30 °C under a nitrogen atmosphere. At the same temperature, a solution of dimethylzinc in toluene (16.6 mL, 2.0 M) was slowly added to the mixture, and the mixture was stirred for 30 min. A solution of 6-bromo-2,3-dihydro-1H-inden-1-one (2 g, 9.5 mmol) in dichloromethane (10 mL) was slowly added to the reaction mixture, and the mixture was stirred at -10 °C for 4 h. The reaction was quenched by adding ice water to the reaction mixture, and the reaction mixture was then extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The residue was purified by silica gel column chromatography (n-hexane / ethyl acetate = 5 / 1, v / v) to give the title compound as a white solid (2.1 g, yield: 99%).

[0555] 1 H-NMR (400MHz, CDCl3) δ7.28 (s, 1H), 7.20 (d, 1H), 7.07 (d, 1H), 2.85 (t, 2H), 1.94 (t, 2H), 1.26 (s, 6H)

[0556] Step 2. 5-Bromo-3,3-dimethyl-2,3-dihydro-1H-indanone

[0557] The 6-bromo-1,1-dimethyl-2,3-dihydro-1H-indene (1.9 g, 8.4 mmol) obtained in step 1 was dissolved in acetone (20 mL), and then a solution of anhydrous magnesium sulfate (2.5 g, 21.1 mmol) in water (10 mL) was slowly added. Potassium permanganate (4 g, 25.3 mmol) was slowly added to the reaction mixture, and the mixture was refluxed under stirring for 5 hours. The reaction mixture was cooled to room temperature, filtered under reduced pressure, and concentrated. The residue was diluted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The residue was purified by silica gel column chromatography (n-hexane / ethyl acetate = 5 / 1, v / v) to give the title compound as a white solid. (1.85 g, yield: 92%)

[0558] 1 H-NMR (400MHz, CDCl3) δ7.65 (s, 1H), 7.58~7.47 (m, 2H), 2.58 (s, 2H), 1.42 (s, 6H)

[0559] Step 3. 5-Bromo-3,3-dimethyl-2,3-dihydro-1H-indene-1-amine hydrochloride

[0560] The title compound was prepared using the 5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-one obtained in step 2, following the same procedure as in step 1 of Preparation Example 4. The product was ready for use in subsequent reactions without further purification.

[0561] Step 4. Ethyl(5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0562] The title compound was prepared using the 5-bromo-3,3-dimethyl-2,3-dihydro-1H-indene-1-amine hydrochloride obtained in step 3, following the same steps as in step 1 of Preparation Example 1.

[0563] 1 H-NMR (400MHz, CDCl3) δ7.35 (d, 1H), 7.30 (s, 1H), 7.16 (d, 1H), 5.24 (q, 1H), 4.81 (brd, 1H), 4.17(q, 2H), 2.46(m, 1H), 1.73~1.68(m, 1H), 1.37(s, 3H), 1.28(t, 3H), 1.22(s, 3H)

[0564] Step 5. (S)-Quininecyclo-3-yl(5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0565] The title compound was prepared using the ethyl (5-bromo-3,3-dimethyl-2,3-dihydro-1H-indene-1-yl) carbamate obtained in step 4, following the same steps as in step 2 of Preparation Example 1.

[0566] 1 H-NMR (400MHz, MeOD) δ7.38~7.33 (m, 2H), 7.14 (dd, 1H), 5.14 (t, 1H), 4.80~4.75 (m, 1H), 3.30~3.21 (m, 1H), 2.90~2.69 (m, 5H), 2.39~ 2.32(m, 1H), 2.11~2.04(m, 1H), 1.99~1.90(m, 1H), 1.84~1.74(m, 2H), 1.70~1.61(m, 1H), 1.55~1.45(m, 1H), 1.39(s, 3H), 1.22(s, 3H)

[0567] Preparation Example 10. (S)-quininecyclo-3-yl(6-bromo-2,3-dihydrobenzofuran-3-yl)carbamate

[0568] The title compound was prepared using 6-bromo-2,3-dihydrobenzofuran-3-amine as a starting material, following the same steps as in Preparation Example 1.

[0569] 1 H-NMR (400MHz, CDCl3) δ7.21 (t, 1H), 7.08~7.06 (m, 1H), 7.02 (s, 1H), 5.35~5.31 (m, 2H), 4.73~4.68 (m, 2H), 4.41~4.37 ( m, 1H), 3.24 ~ 3.19 (m, 1H), 2.82 ~ 2.66 (m, 5H), 2.05 ~ 1.98 (m, 1H), 1.75 ~ 1.66 (m, 2H), 1.56 ~ 1.55 (m, 1H), 1.40 ~ 1.38 (m, 1H)

[0570] Preparation Example 11. (S)-quininecyclo-3-yl(5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[0571] Step 1. 5-Bromo-2,2-dimethylbenzofuran-3(2H)-one

[0572] 5-Bromobenzofuran-3-one (2.75 g, 12.9 mmol) was dissolved in tetrahydrofuran (43 mL), and then 60% sodium hydride (2.07 g, 51.6 mmol) was added to it at 0 °C. The reaction mixture was stirred for 15 minutes, and then iodomethane (9.15 g, 64.5 mmol) was slowly added to it at the same temperature. The reaction mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and then it was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The residue was purified by column chromatography (n-hexane / ethyl acetate = 10 / 1, v / v) to give the title compound as a white solid. (2.5 g, yield: 80%)

[0573] 1 H-NMR (400MHz, CDCl3) δ7.81 (s, 1H), 7.79 (d, 1H), 6.98 (d, 1H), 1.47 (s, 6H)

[0574] Step 2. 5-Bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-amine

[0575] The title compound was prepared using the 5-bromo-2,2-dimethylbenzofuran-3(2H)-one obtained in step 1, following the same steps as in step 1 of Preparation Example 4.

[0576] 1 H-NMR (400MHz, CDCl3) δ7.40 (s, 1H), 7.27 (d, 1H), 6.63 (d, 1H), 4.12 (s, 1H), 1.41 (d, 6H)

[0577] Step 3. (S)-Quininecyclo-3-yl(5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[0578] The title compound was prepared using the 5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-amine obtained in step 2, following the same steps as in Preparation Example 1.

[0579] 1H-NMR (400MHz, CDCl3) δ7.40(d, 1H), 7.31(d, 1H), 6.65(d, 1H), 5.36(t, 1H), 5.00(d, 1H), 4.78~4.69(m, 1H), 3.25~3.15(m, 1H) , 2.89~2.59(m, 5H), 2.06~2.00(m, 1H), 1.83~1.74(m, 1H), 1.72~1.63(m, 1H), 1.60~1.51(m, 1H), 1.48(s, 3H), 1.41~1.36(m, 4H)

[0580] Preparation Example 12. (S)-quininecyclo-3-yl(6-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[0581] Step 1. 6-Bromo-2,2-dimethylbenzofuran-3(2H)-one

[0582] The title compound was prepared using 6-bromobenzofuran-3(2H)-one as a starting material, following the same steps as in step 1 of Preparation Example 11.

[0583] 1 H-NMR (400MHz, CDCl3) δ7.53 (d, 1H), 7.30~7.27 (m, 1H), 7.21 (dd, 1H), 1.47 (s, 6H)

[0584] Step 2. (S)-Quininecyclo-3-yl(6-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[0585] The title compound was prepared using the 6-bromo-2,2-dimethylbenzofuran-3(2H)-one obtained in step 1, following the same steps as in Preparation Example 4.

[0586] 1 H-NMR (400MHz, CDCl3) δ7.14 (dd, 1H), 7.05~6.99 (m, 1H), 6.91 (s, 1H), 5.59~5.46 (m, 1H), 4.94 (d, 1H), 4.77~4.66 (m, 1H), 3. 27~3.14(m,1H), 2.91~2.61(m,5H), 2.12~2.01(m,1H), 1.86~1.64(m,2H), 1.61~1.52(m,1H), 1.45(s,3H), 1.43~1.32(m,4H)

[0587] Example 1. (S)-quininecyclo-3-yl(5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0588] To a mixture of (S)-quininecyclo-3-yl(5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate (30 mg, 0.082 mmol), 4-fluorophenylboronic acid (17.2 mg, 0.12 mmol), potassium phosphate (52.3 mg, 0.25 mmol), and tetrakis(triphenylphosphine)palladium(0) (9.4 mg, 10 mol%), 1,4-dioxane (1 mL) and water were slowly added. The reaction mixture was stirred and refluxed overnight at 120 °C, and then cooled to room temperature. Water was added to the reaction mixture, and the reaction mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate / (methanol / ammonia = 1 / 1) = 9 / 1, v / v) to give the title compound as a white solid (19 mg, yield: 64%).

[0589] 1 H-NMR (400MHz, CDCl3) δ7.55 (m, 2H), 7.42 (m, 3H), 7.13 (m, 2H), 5.29 (m, 1H), 5.00 (m, 1H), 4.81 (br, 1H), 3.28 (m, 1H), 3.0 5(m, 1H), 2.94(m, 3H), 2.82(m, 3H), 2.65(m, 1H), 2.06(m, 1H), 1.93~1.88(m, 2H), 1.71(m, 1H), 1.60(br, 1H), 1.42(br, 1H)

[0590] Examples 2 to 24

[0591] The title compounds of Examples 2 to 24 were prepared using the (S)-quininecyclo-3-yl(5-bromo-2,3-dihydro-1H-inden-1-yl) carbamate and the corresponding substituted phenylboronic acid obtained in Preparation Example 1, respectively, following the same steps as in Example 1.

[0592] Example 2. (S)-quininecyclo-3-yl(5-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0593] 1H-NMR (400MHz, CDCl3) δ7.52 (m, 2H), 7.42 (m, 5H), 5.29 (m, 1H), 5.01 (m, 1H), 4.80 (br, 1H), 3.28 (m, 1H), 3.03 (m, 1H) , 2.85 (m, 3H), 2.78~2.67 (m, 4H), 2.09 (m, 1H), 1.98 (m, 1H), 1.87 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0594] Example 3. (S)-quininecyclo-3-yl(5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0595] 1 H-NMR (400MHz, CDCl3) δ7.69 (s, 4H), 7.47 (m, 3H), 5.31 (m, 1H), 5.01 (m, 1H), 4.81 (br, 1H), 3.31 (m, 1H), 3 .04(m,1H),2.94(m,3H),2.78(m,4H),2.03(m,2H),1,91(m,1H),1.71(br,1H),1.60(br,1H),1.41(br,1H)

[0596] Example 4. (S)-quininecyclo-3-yl(5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0597] 1 H-NMR (400MHz, CDCl3) δ7.58 (d, 2H), 7.43 (m, 3H), 7.29 (d, 2H), 5.29 (m, 1H), 4.99 (m, 1H), 4.80 (br, 1H), 3.31 (m, 1H), 3.05 (m, 1H), 2.95~2.75 (m, 7H), 2.07 (m, 1H), 1.84 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0598] Example 5. (S)-quininecyclo-3-yl(5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0599] 1H-NMR (400MHz, CDCl3) δ7.70 (m, 1H), 7.45 (m, 5H), 7.05 (m, 1H), 5.28 (m, 1H), 4.98 (m, 1H), 4.80 (br, 1H), 3.31 (m, 1H), 2.94 (m, 1H), 2.82~2.75 (m, 7H), 2.09 (m, 1H), 1.82 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H)

[0600] Example 6. (S)-quininecyclo-3-yl(5-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0601] 1 H-NMR (400MHz, CDCl3) δ7.57 (s, 1H), 7.45 (m, 4H), 7.34 (m, 2H), 5.29 (m, 1H), 4.98 (m, 1H), 4.81 (m, 1H), 3.30 (m, 1H), 3.04 (m, 1H), 2.95~2.66 (m, 7H), 2.09 (m, 1H), 1.82 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H)

[0602] Example 7. (S)-quininecyclo-3-yl(5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0603] 1 H-NMR (400MHz, CDCl3) δ7.82 (s, 1H), 7.76 (d, 1H), 7.58 (m, 2H), 7.47 (m, 3H), 5.30 (m, 1H), 4.98 (m, 1H), 4.81 (m, 1H), 3.30 ( m, 1H), 3.05 (m, 1H), 3.05~2.68 (m, 7H), 2.09 (m, 1H), 1.91 (br, 1H), 1.79 (m, 1H), 1.72 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H)

[0604] Example 8. (S)-quininecyclo-3-yl(5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0605] 1H-NMR (400MHz, CDCl3) δ7.52~7.42(m, 6H), 7.21(m, 1H), 5.29(m, 1H), 5.01(m, 1H), 4.81(m, 1H), 3.31(m, 1H), 3. 04(m,1H),2.95~2.75(m,7H),2.09(m,1H),1.92(m,1H),1.84(br,1H),1.71(br,1H),1.60(br,1H),1.41(br,1H)

[0606] Example 9. (S)-quininecyclo-3-yl(5-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0607] 1 H-NMR (400MHz, CDCl3) δ7.42 (m, 3H), 7.28~7.16 (m, 4H), 5.29 (m, 1H), 4.98 (m, 1H), 4.81 (m, 1H), 3.29 (m, 1H), 2.95(m, 1H), 2.89~2.66(m, 7H), 2.06(m, 1H), 1.83(m, 1H), 1.74(m, 2H), 1.60(br, 1H), 1.41(br, 1H)

[0608] Example 10. (S)-quininecyclo-3-yl(5-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate 1 H-NMR (400MHz, CDCl3) δ7.49 (d, 1H), 7.41 (d, 1H), 7.32 (m, 5H), 5.32 (m, 1H), 4.99 (m, 1H), 4.81 (br, 1H), 3.30 (m, 1H) , 3.03 (m, 1H), 2.95~2.67 (m, 7H), 2.06 (m, 1H), 1.91 (br, 1H), 1.83 (br, 1H), 1.73 (m, 1H), 1.61 (br, 1H), 1.41 (br, 1H)

[0609] Example 11. (S)-quininecyclo-3-yl(5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0610] 1H-NMR (400MHz, CDCl3) δ7.75 (d, 1H), 7.54 (m, 1H), 7.49 (m, 1H), 7.36 (m, 4H), 5.31 (m, 1H), 5.12 (m, 1H), 4.81 (br, 1H), 3.29 ( m, 1H), 3.01 (m, 1H), 2.93~2.66 (m, 7H), 2.09 (br, 1H), 1.95 (m, 1H), 1.88 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0611] Example 12. (S)-quininecyclo-3-yl(5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0612] 1 H-NMR (400MHz, CDCl3) δ7.41 (m, 6H), 7.26 (m, 1H), 5.29 (m, 1H), 5.04 (m, 1H), 4.81 (m, 1H), 3.31 (m, 1H) , 3.02 (m, 1H), 2.94~2.76 (m, 7H), 2.06 (m, 1H), 1.84 (m, 2H), 1.71 (br, 1H), 1.61 (br, 1H), 1.42 (br, 1H)

[0613] Example 13. (S)-quininecyclo-3-yl(5-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0614] 1 H-NMR (400MHz, CDCl3) δ7.46 (m, 5H), 7.25 (m, 2H), 5.29 (m, 1H), 4.98 (m, 1H), 4.80 (m, 1H), 3.30 (m, 1H), 3.04 (m, 1H), 2.96 ~ 2.67 (m, 7H), 2.40 (s, 3H), 2.09 (m, 1H), 1.85 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H)

[0615] Example 14. (S)-quininecyclo-3-yl(5-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0616] 1H-NMR (400MHz, CDCl3) δ7.58 (m, 2H), 7.41 (m, 3H), 7.20 (d, 2H), 6.75~6.38 (t, 1H), 5.29 (m, 1H), 4.98 (m, 1H), 4. 80 (m, 1H), 3.30 (m, 1H), 2.95~2.66 (m, 7H), 2.08 (m, 1H), 1.85 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H)

[0617] Example 15. (S)-quininecyclo-3-yl(5-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0618] 1 H-NMR (400MHz, CDCl3) δ7.40 (m, 4H), 7.23 (m, 2H), 5.28 (m, 1H), 5.00 (m, 1H), 4.80 (m, 1H), 3.30 (m, 1H) , 3.03 (m, 1H), 2.94~2.66 (m, 7H), 2.06 (m, 1H), 1.87 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0619] Example 16. (S)-quininecyclo-3-yl(5-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0620] 1 H-NMR (400MHz, CDCl3) δ7.40 (m, 4H), 6.96 (m, 2H), 5.30 (m, 1H), 5.00 (m, 1H), 4.80 (m, 1H), 3.28 (m, 1H) , 3.03 (m, 1H), 2.95~2.66 (m, 7H), 2.06 (m, 1H), 1.82 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0621] Example 17. (S)-quininecyclo-3-yl(5-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0622] 1H-NMR (400MHz, CDCl3) δ7.42 (m, 3H), 7.16 (m, 3H), 5.31 (m, 1H), 5.00 (m, 1H), 4.81 (m, 1H), 3.27 (m, 1H) , 3.04(m, 1H), 2.95~2.67(m, 7H), 2.09(m, 1H), 1.86(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[0623] Example 18. (S)-quininecyclo-3-yl(5-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0624] 1 H-NMR (400MHz, CDCl3) δ7.41 (m, 3H), 7.12 (m, 2H), 7.01 (m, 1H), 5.30 (m, 1H), 5.02 (m, 1H), 4.81 (m, 1H), 3.30 (m, 1H), 3.03 (m, 1H), 2.95~2.66 (m, 7H), 2.09 (m, 1H), 1.89 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0625] Example 19. (S)-quininecyclo-3-yl(5-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0626] 1 H-NMR (400MHz, CDCl3) δ7.42 (m, 3H), 7.09 (d, 2H), 6.79 (t, 1H), 5.29 (m, 1H), 4.98 (m, 1H), 4.81 (m, 1H), 3.30 (m, 1H) , 3.04 (m, 1H), 2.97~2.67 (m, 7H), 2.09 (m, 1H), 1.90 (m, 1H), 1.82 (m, 1H), 1.71 (br, 1H), 1.61 (br, 1H), 1.42 (br, 1H)

[0627] Example 20. (S)-quininecyclo-3-yl(5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0628] 1H-NMR (400MHz, CDCl3) δ7.43 (m, 1H), 7.37 (m, 2H), 7.13 (m, 1H), 7.04 (m, 1H), 5.29 (m, 1H), 5.02 (m, 1H), 4.80 (m, 1H), 3.28 (m, 1H), 3.03 (m, 1H), 2.97~2.67 (m, 7H), 2.06 (m, 1H), 1.91 (m, 1H), 1.84 (m, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H)

[0629] Example 21. (S)-quininecyclo-3-yl(5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0630] 1 H-NMR (400MHz, CDCl3) δ7.45 (d, 1H), 7.36 (s, 2H), 7.21 (m, 1H), 7.02 (m, 1H), 5.30 (m, 1H), 5.01 (m, 1H), 4.81 (m, 1H) , 3.28 (m, 1H), 3.04 (m, 1H), 2.95 ~ 2.67 (m, 7H), 2.09 (m, 1H), 1.90 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0631] Example 22. (S)-quininecyclo-3-yl(5-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0632] 1 H-NMR (400MHz, CDCl3) δ7.57 (m, 1H), 7.49~7.42 (m, 5H), 5.29 (m, 1H), 5.00 (m, 1H), 4.81 (m, 1H), 3.28 (m, 1H), 3.05(m, 1H), 2.89~2.67(m, 7H), 2.06(m, 1H), 1.83(m, 2H), 1.71(br, 1H), 1.61(br, 1H), 1.42(br, 1H)

[0633] Example 23. (S)-quininecyclo-3-yl(5-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0634] 1H-NMR (400MHz, CDCl3) δ7.66 (s, 1H), 7.52 (m, 2H), 7.42 (m, 4H), 5.30 (m, 1H), 4.98 (m, 1H), 4.81 (m, 1H), 3.29 (m, 1H) , 3.05 (m, 1H), 2.97~2.67 (m, 7H), 2.06 (m, 1H), 1.93 (m, 1H), 1.80 (m, 1H), 1.72 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)

[0635] Example 24. (S)-quininecyclo-3-yl(5-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0636] 1 H-NMR (400MHz, CDCl3) δ7.42 (m, 1H), 7.32 (m, 2H), 7.28 (m, 3H), 5.31 (m, 1H), 5.07 (m, 1H), 4.80 (m, 1H), 3.28 (m, 1H) , 3.03 (m, 1H), 2.94~2.66 (m, 7H), 2.06 (m, 1H), 1.94 (m, 1H), 1.87 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0637] Examples 25 to 48

[0638] The title compounds of Examples 25 to 48 were prepared using the (S)-quininecyclo-3-yl (6-bromo-2,3-dihydro-1H-inden-1-yl) carbamate and the corresponding substituted phenylboronic acid obtained in Preparation Example 2, respectively, following the same steps as in Example 1.

[0639] Example 25. (S)-quininecyclo-3-yl(6-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate 1 H-NMR (400MHz, CDCl3) δ7.54 (m, 3H), 7.42 (m, 1H), 7.33 (m, 1H), 7.13 (t, 2H), 5.31 (m, 1H), 5.00 (m, 1H), 4.80 (m, 1H) , 3.28 (m, 1H), 3.02 (m, 1H), 3.00~2.72 (m, 7H), 2.06 (m, 2H), 1.93 (m, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0640] Example 26. (S)-quininecyclo-3-yl(6-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate 1 H-NMR (400MHz, CDCl3) δ7.52 (m, 3H), 7.40 (m, 3H), 7.33 (m, 1H), 5.31 (m, 1H), 5.03 (m, 1H), 4.80 (br, 1H), 3.28 (m, 1H), 3.00 (m, 1H), 2.93~2.66 (m, 7H), 1.91 (m, 2H), 1.85 (m, 1H), 1.72 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)

[0641] Example 27. (S)-quininecyclo-3-yl(6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0642] 1 H-NMR (400MHz, CDCl3) δ7.69 (s, 4H), 7.55 (s, 1H), 7.49 (d, 1H), 7.36 (d, 1H), 5.33 (m, 1H), 5.04 (m, 1H), 4.81 (br, 1H ), 3.28(m, 1H), 3.02(m, 1H), 2.94~2.67(m, 7H), 1.93(m, 2H), 1.83(m, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[0643] Example 28. (S)-quininecyclo-3-yl(6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0644] 1 H-NMR (400MHz, CDCl3) δ7.60 (d, 2H), 7.58 (s, 1H), 7.46 (d, 1H), 7.34 (d, 1H), 7.28 (d, 2H), 5.32 (m, 1H), 5.04 (m, 1H), 4.80 (br, 1H), 3.28 (m, 1H), 3.09 (m, 1H), 2.93~2.86 (m, 3H), 2.76 (m, 4H), 1.97 (m, 1H), 1.90 (m, 1H), 1.83 (m, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.39 (br, 1H)

[0645] Example 29. (S)-quininecyclo-3-yl(6-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate 1H-NMR (400MHz, CDCl3) δ7.52 (s, 1H), 7.46 (d, 1H), 7.37 (m, 3H), 7.28 (m, 1H), 7.04 (m, 1H), 5.31 (m, 1H), 5.02 (m, 1H), 4.81 (br, 1H), 3 .31 (m, 1H), 3.04 (m, 1H), 2.88 (m, 3H), 2.77 (m, 4H), 2.06 (m, 1H), 1.93 (m, 1H), 1.84 (m, 1H), 1.68 (m, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0646] Example 30. (S)-quininecyclo-3-yl(6-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate 1 H-NMR (400MHz, CDCl3) δ7.56~7.45(m, 4H), 7.37~7.28(m, 3H), 5.32(m, 1H), 5.02(m, 1H), 4.81(br, 1H), 3.27(m, 1H), 3. 03(m,1H),2.93(m,3H),2.77(m,4H),1.92(m,1H),1.86(m,1H),1.85(m,1H),1.71(br,1H),1.60(br,1H),1.41(br,1H)

[0647] Example 31. (S)-quininecyclo-3-yl(6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0648] 1 H-NMR (400MHz, CDCl3) δ7.81 (s, 1H), 7.77 (m, 1H), 7.60 ~ 7.54 (m, 3H), 7.50 (m, 1H), 7.36 (m, 1H), 5.33 (m, 1H), 5.04 (m, 1H), 4.80 (br, 1H) , 3.27 (m, 1H), 3.03 (m, 1H), 2.94 (m, 3H), 2.76 (m, 4H), 2.09 (m, 1H), 1.96 (m, 1H), 1.83 (m, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)

[0649] Example 32. (S)-quininecyclo-3-yl(6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0650] 1H-NMR (400MHz, CDCl3) δ7.51 (d, 2H), 7.46 (m, 2H), 7.42 (s, 1H), 7.35 (d, 1H), 7.21 (d, 1H), 5.30 (m, 1H), 5.05 (m, 1H), 4.80 (br, 1H), 3 .30(m,1H),3.02(m,1H),2.87(m,3H),2.70(m,4H),2.08(m,1H),2.00(m,1H),1.90(m,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H)

[0651] Example 33. (S)-quininecyclo-3-yl(6-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate 1 H-NMR (400MHz, CDCl3) δ7.49 (s, 1H), 7.43 (s, 2H), 7.33 (m, 2H), 7.22 (m, 1H), 7.18 (m, 1H), 5.31 (m, 1H), 5.05 (m, 1H), 4,78 (br, 1H), 3.27(m, 1H), 3.03(m, 1H), 2,91(m, 3H), 2.75(m, 4H), 1.95(m, 2H), 1.88(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.39(br, 1H)

[0652] Example 34. (S)-quininecyclo-3-yl(6-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate 1 H-NMR (400MHz, CDCl3) δ7.48 (d, 1H), 7.39 (s, 1H), 7.32 (m, 5H), 5.31 (m, 1H), 5.07 (m, 1H), 4.77 (br, 1H), 3.24 (m, 1H) , 3.04 (m, 1H), 2.94~2.71 (m, 7H), 1.99 (m, 1H), 1.90 (m, 1H), 1.81 (br, 1H), 1.68 (br, 1H), 1.57 (br, 1H), 1.38 (br, 1H)

[0653] Example 35. (S)-quininecyclo-3-yl(6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0654] 1H-NMR (400MHz, CDCl3) δ7.76 (d, 1H), 7.56 (m, 1H), 7.49 (m, 1H), 7.34 (m, 1H), 7.27 (m, 2H), 7.22 (m, 1H), 5.31 (m, 1H), 5.06 (m, 1H), 4.76 (br, 1H ), 3.25(m, 1H), 2.94(m, 1H), 2.84(m, 2H), 2.75~2.71(m, 5H), 1.93(m, 1H), 1.91(m, 1H), 1.81(m, 1H), 1.67(m, 1H), 1.56(br, 1H), 1.37(br, 1H)

[0655] Example 36. (S)-quininecyclo-3-yl(6-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0656] 1 H-NMR (400MHz, CDCl3) δ7.42 (s, 2H), 7.36 (m, 4H), 7.28 (s, 1H), 5.32 (m, 1H), 5.00 (m, 1H), 4.78 (br, 1H), 3.27 (m, 1H), 3.04(m, 1H), 2.94(m, 3H), 2.72(m, 4H), 1.92(m, 2H), 1.82(m, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.39(br, 1H)

[0657] Example 37. (S)-quininecyclo-3-yl(6-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0658] 1 H-NMR (400MHz, CDCl3) δ7.58 (d, 2H), 7.50 (s, 1H), 7.45 (d, 1H), 7.33 (d, 1H), 7.21 (d, 2H), 6.75~6.38 (t, 1H), 5.31 (m, 1H), 5.02 (m, 1H), 4.79 ( br, 1H), 3.28 (m, 1H), 3.01 (m, 1H), 2.90 (m, 3H), 2.72 (m, 4H), 2.06 (m, 1H), 1.93 (br, 1H), 1.83 (m, 1H), 1.70 (m, 1H), 1.58 (m, 1H), 1.40 (br, 1H)

[0659] Example 38. (S)-quininecyclo-3-yl(6-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0660] 1 H-NMR (400MHz, CDCl3) δ7.53 (s, 1H), 7.48 (m, 3H), 7.32 (d, 1H), 7.25 (m, 2H), 5.31 (m, 1H), 5.01 (m, 1H), 4.80 (br, 1H), 3.28 (m, 1H) ), 3.00(m, 1H), 2.76(m, 3H), 2.68(m, 4H), 2.41(s, 3H), 2.06(m, 1H), 1.92~1.82(m, 2H), 1.69(m, 1H), 1.59(br, 1H), 1.40(br, 1H)

[0661] Example 39. (S)-quininecyclo-3-yl(6-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0662] 1 H-NMR (400MHz, CDCl3) δ7.47 (s, 1H), 7.42 (m, 2H), 7.37 (m, 2H), 7.21 (m, 1H), 5.31 (m, 1H), 5.01 (m, 1H), 4.80 (br, 1H), 3.27 (m, 1H), 3.02(m, 1H), 2.93(m, 3H), 2.76(m, 4H), 2.08(m, 1H), 1.93(m, 1H), 1.89(m, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[0663] Example 40. (S)-quininecyclo-3-yl(6-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0664] 1 H-NMR (400MHz, CDCl3) δ7.50 (s, 1H), 7.44 (d, 1H), 7.32 (d, 1H), 7.10 (d, 2H), 6.79 (m, 1H), 5.31 (m, 1H), 5.03 (m, 1H), 4.80 (br, 1H ), 3.28(m, 1H), 3.03(m, 1H), 2.93~2.67(m, 7H), 2.09(m, 1H), 1.92(m, 1H), 1.84(m, 1H), 1.70(m, 1H), 1.61(br, 1H), 1.40(br, 1H)

[0665] Example 41. (S)-quininecyclo-3-yl(6-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0666] 1H-NMR (400MHz, CDCl3) δ7.47 (s, 1H), 7.42 (d, 1H), 7.34 (m, 1H), 7.10 (m, 2H), 7.01 (m, 1H), 5.30 (m, 1H), 5.04 (m, 1H), 4.79 (m, 1H) , 3.26 (m, 1H), 3.04 (m, 1H), 2.87~2.75 (m, 7H), 2.06 (s, 1H), 1.93 (m, 1H), 1.88 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.40 (br, 1H)

[0667] Example 42. (S)-quininecyclo-3-yl(6-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0668] 1 H-NMR (400MHz, CDCl3) δ7.48 (s, 1H), 7.43 (m, 1H), 7.34 (d, 1H), 7.15 (m, 3H), 5.31 (m, 1H), 5.04 (m, 1H), 4.79 (m, 1H), 3.26 ( m, 1H), 3.04 (m, 1H), 2.94~2.67 (m, 7H), 2.09 (m, 1H), 1.93 (m, 1H), 1.83 (br, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.39 (br, 1H)

[0669] Example 43. (S)-quininecyclo-3-yl(6-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0670] 1 H-NMR (400MHz, CDCl3) δ7.44 (s, 1H), 7.40 (m, 2H), 7.32 (m, 1H), 6.94 (m, 2H), 5.31 (m, 1H), 5.02 (m, 1H), 4.78 (m, 1H), 3.27 ( m, 1H), 3.03 (m, 1H), 2.93~2.66 (m, 7H), 2.06 (m, 1H), 1.89 (m, 1H), 1.83 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.40 (br, 1H)

[0671] Example 44. (S)-quininecyclo-3-yl(6-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0672] 1H-NMR (400MHz, CDCl3) δ7.43 (s, 1H), 7.36 (m, 2H), 7.23 (m, 1H), 7.04 (m, 1H), 5.31 (m, 1H), 5.02 (m, 1H), 4.79 (m, 1H), 3.26 ( m, 1H), 3.02 (m, 1H), 2.93~2.72 (m, 7H), 2.06 (m, 1H), 1.88 (m, 1H), 1.83 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.41 (br, 1H)

[0673] Example 45. (S)-quininecyclo-3-yl(6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0674] 1 H-NMR (400MHz, CDCl3) δ7.44 (s, 1H), 7.33 (m, 2H), 7.13 (m, 1H), 7.04 (m, 1H), 5.31 (m, 1H), 5.01 (, 1H), 4.79 (m, 1H), 3.29 ( m, 1H), 3.05 (m, 1H), 2.96~2.67 (m, 7H), 2.06 (m, 1H), 1.88 (m, 1H), 1.84 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.40 (br, 1H)

[0675] Example 46. (S)-quininecyclo-3-yl(6-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0676] 1 H-NMR (400MHz, CDCl3) δ7.49 (m, 2H), 7.32 (m, 3H), 7.25 (m, 1H), 5.32 (m, 1H), 5.01 (m, 1H), 4.79 (m, 1H), 3.27 (m, 1H) , 3.04 (m, 1H), 2.97~2.68 (m, 7H), 2.06 (m, 1H), 1.93 (br, 1H), 1.88 (m, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.39 (br, 1H)

[0677] Example 47. (S)-quininecyclo-3-yl(6-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0678] 1H-NMR (400MHz, CDCl3) δ7.66 (s, 1H), 7.52 (m, 2H), 7.44 (m, 2H), 7.34 (m, 1H), 5.31 (m, 1H), 4.99 (m, 1H), 4.81 (br, 1H), 3.28 (m , 1H), 3.01(m, 1H), 2.88(m, 3H), 2.77(m, 4H), 2.08(m, 1H), 1.89(m, 1H), 1.81(m, 1H), 1.71(m, 1H), 1.61(m, 1H), 1.42(br, 1H)

[0679] Example 48. (S)-quininecyclo-3-yl(6-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0680] 1 H-NMR (400MHz, CDCl3) δ7.48 (m, 2H), 7.45 (m, 2H), 7.34 (m, 2H), 5.31 (m, 1H), 5.00 (m, 1H), 4.81 (m, 1H), 3.30 (m, 1H ), 3.03(m, 1H), 2.95~2.68(m, 7H), 2.10(m, 1H), 1.91(m, 1H), 1.82(m, 1H), 1.70(m, 1H), 1.59(br, 1H), 1.41(br, 1H)

[0681] Examples 49 to 72

[0682] The title compounds of Examples 49 to 72 were prepared using (S)-quininecyclo-3-yl(6-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate and the corresponding substituted phenylboronic acid, respectively, following the same steps as in Example 1.

[0683] Example 49. (S)-quininecyclo-3-yl(6-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0684] 1H-NMR (400MHz, CDCl3) δ7.54 (m, 2H), 7.40 (m, 2H), 7.24 (t, 1H), 7.14 (t, 2H), 5.01 (m, 1H), 4.88 (m, 1H), 4.81 (m, 1H), 3.31 (m, 1 H), 2.81(m, 2H), 2.77(m, 5H), 2.10(m, 1H), 1.80(br, 1H), 1.75(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[0685] Example 50. (S)-quininecyclo-3-yl(6-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0686] 1 H-NMR (400MHz, CDCl3) δ7.50 (m, 2H), 7.42 (m, 3H), 7.26 (m, 2H), 5.02 (m, 1H), 4.89 (m, 1H), 4.81 (m, 1H), 3.30 (m, 1H), 2. 89 (m, 2H), 2.77 (m, 5H), 2.14 (m, 1H), 1.86 (br, 1H), 1.73 (br, 1H), 1.62 (br, 1H), 1.43 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0687] Example 51. (S)-quininecyclo-3-yl(2,2-dimethyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0688] 1 H-NMR (400MHz, CDCl3) δ7.69 (s, 4H), 7.45 (m, 2H), 7.29 (d, 1H), 5.04 (m, 1H), 4.94 (m, 1H), 4.80 (m, 1H), 3.30 (m, 1H), 2.91~ 2.66(m, 6H), 2.09(s, 1H), 2.00(br, 1H), 1.84(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(d, 3H), 0.99(d, 3H)

[0689] Example 52. (S)-Quininecyclo-3-yl(2,2-dimethyl-6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0690] 1H-NMR (400MHz, CDCl3) δ7.60 (m, 2H), 7.41 (m, 2H), 7.29 (m, 3H), 5.03 (m, 1H), 4.95 (m, 1H), 4.80 (m, 1H), 3.29 (m, 1H), 2.88~ 2.66(m, 6H), 2.09(s, 1H), 2.00(br, 1H), 1.85(br, 1H), 1.71(br, 1H), 1.59(br, 1H), 1.42(br, 1H), 1.34(d, 3H), 0.99(d, 3H)

[0691] Example 53. (S)-quininecyclo-3-yl(6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0692] 1 H-NMR (400MHz, CDCl3) δ7.43 (s, 2H), 7.39 (m, 2H), 7.25 (m, 2H), 7.04 (t, 1H), 5.03 (m, 1H), 4.89 (m, 1H), 4.82 (m, 1H), 3.30 (m, 1 H), 2.90 (m, 2H), 2.78 (m, 5H), 2.14 (m, 1H), 1.85 (br, 1H), 1.76 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0693] Example 54. (S)-quininecyclo-3-yl(6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0694] 1 H-NMR (400MHz, CDCl3) δ7.57 (s, 1H), 7.43 (m, 2H), 7.38 (m, 1H), 7.33 (t, 1H), 7.25 (m, 2H), 5.03 (m, 1H), 4.90 (m, 1H), 4.83 (m, 1H), 3. 31(m,1H),2.83(m,2H),2.78(m,5H),2.14(m,1H),1.88(br,1H),1.75(br,1H),1.60(br,1H),1.44(br,1H),1.32(d,3H),0.99(d,3H)

[0695] Example 55. (S)-Quininecyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0696] 1 H-NMR (400MHz, CDCl3) δ7.82 (s, 1H), 7.76 (m, 1H), 7.58 (m, 2H), 7.45 (m, 2H), 7.30 (m, 1H), 5.04 (m, 1H), 4.91 (m, 1H), 4.81 (m, 1H), 3. 29(m,1H),2.87(m,2H),2.79(m,5H),2.14(m,1H),1.85(br,1H),1.76(br,1H),1.61(br,1H),1.42(br,1H),1.32(d,3H),1.00(d,3H)

[0697] Example 56. (S)-quininecyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0698] 1 H-NMR (400MHz, CDCl3) δ7.48 (m, 5H), 7.21 (m, 2H), 5.04 (m, 1H), 4.90 (m, 1H), 4.82 (m, 1H), 3.30 (m, 1H), 2.89 (m, 2 H), 2.78(m, 5H), 2.11(m, 1H), 1.86(br, 1H), 1.75(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[0699] Example 57. (S)-quininecyclo-3-yl(6-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0700] 1 H-NMR (400MHz, CDCl3) δ7.43 (m, 2H), 7.31~7.16 (m, 5H), 5.03 (m, 1H), 4.91 (m, 1H), 4.80 (m, 1H), 3.30 (m, 1H), 2.89 (m , 2H), 2.78(m, 5H), 2.09(br, 1H), 1.85(br, 1H), 1.74(br, 1H), 1.59(br, 1H), 1.42(br, 1H), 1.31(d, 3H), 1.00(d, 3H)

[0701] Example 58. (S)-quininecyclo-3-yl(6-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0702] 1H-NMR (400MHz, CDCl3) δ7.48 (m, 1H), 7.30 (m, 6H), 5.04 (m, 1H), 4.91 (m, 1H), 4.79 (br, 1H), 3.30 (m, 1H), 2.87~ 2.75(m,7H),2.08(br,1H),1.79(br,1H),1.69(br,1H),1.58(br,1H),1.42(br,1H),1.32(d,3H),0.99(d,3H)

[0703] Example 59. (S)-Quininecyclo-3-yl(2,2-dimethyl-6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0704] 1 H-NMR (400MHz, CDCl3) δ7.76 (d, 1H), 7.56 (m, 1H), 7.49 (m, 1H), 7.34 (m, 1H), 7.20 (m, 3H), 5.03 (m, 1H), 4.89 (m, 1H), 4.79 (m, 1H) , 3.26 (m, 1H), 2.88~2.71 (m, 7H), 2.09 (m, 1H), 1.81 (br, 1H), 1.71 (br, 1H), 1.58 (br, 1H), 1.41 (br, 1H), 1.33 (d, 3H), 0.99 (d, 3H)

[0705] Example 60. (S)-quininecyclo-3-yl(2,2-dimethyl-6-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0706] 1 H-NMR (400MHz, CDCl3) δ7.44(m, 4H), 7.26(m, 3H), 5.02(m, 1H), 4.88(m, 1H), 4.82(m, 1H), 3.29(m, 1H), 2.89~2.77(m , 7H), 2.41(s, 3H), 2.08(br, 1H), 1.85(br, 1H), 1.75(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.31(d, 3H), 0.99(d, 3H)

[0707] Example 61. (S)-quininecyclo-3-yl(6-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0708] 1H-NMR (400MHz, CDCl3) δ7.58 (m, 2H), 7.50 (m, 2H), 7.25 (m, 1H), 7.20 (m, 2H), 6.75~6.38 (t, 1H), 5.03 (m, 1H), 4.89 (m, 1H), 4.81 (m, 1H) , 3.31 (m, 1H), 2.90 (m, 2H), 2.78 (m, 5H), 2.11 (m, 1H), 1.87 (m, 1H), 1.71 (br, 1H), 1.61 (br, 1H), 1.43 (br, 1H), 1.31 (d, 3H), 1.00 (d, 3H)

[0709] Example 62. (S)-quininecyclo-3-yl(6-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0710] 1 H-NMR (400MHz, CDCl3) δ7.69 (m, 1H), 7.50 (m, 1H), 7.38 (m, 3H), 7.21 (m, 1H), 5.02 (m, 1H), 4.89 (m, 1H), 4.83 (m, 1H), 3.30 (m, 1 H), 2.86 (m, 2H), 2.78 (m, 5H), 2.14 (m, 1H), 1.87 (br, 1H), 1.73 (br, 1H), 1.61 (br, 1H), 1.43 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0711] Example 63. (S)-quininecyclo-3-yl(6-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0712] 1 H-NMR (400MHz, CDCl3) δ7.48 (m, 3H), 7.28 (m, 1H), 6.94 (m, 2H), 5.03 (m, 1H), 4.90 (m, 1H), 4.81 (m, 1H), 3.28 (m, 1H), 2. 88(m,3H),2.78(m,4H),2.14(m,1H),1.87(br,1H),1.75(br,1H),1.60(br,1H),1.42(br,1H),1.32(d,3H),0.99(d,3H)

[0713] Example 64. (S)-quininecyclo-3-yl(6-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0714] 1 H-NMR (400MHz, CDCl3) δ7.49 (m, 1H), 7.39 (m, 2H), 7.16 (m, 3H), 5.04 (m, 1H), 4.91 (m, 1H), 4.88 (m, 1H), 3.29 (m, 1H), 2. 86 (m, 2H), 2.79 (m, 5H), 2.10 (m, 1H), 1.85 (br, 1H), 1.73 (br, 1H), 1.59 (br, 1H), 1.43 (br, 1H), 1.35 (d, 3H), 0.99 (d, 3H)

[0715] Example 65. (S)-quininecyclo-3-yl(6-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0716] 1 H-NMR (400MHz, CDCl3) δ7.60 (m, 1H), 7.39 (m, 2H), 7.13 (m, 2H), 7.02 (m, 1H), 5.03 (m, 1H), 4.91 (m, 1H), 4.81 (m, 1H), 3.31 (m, 1 H), 2.86 (m, 2H), 2.78 (m, 5H), 2.14 (m, 1H), 1.87 (br, 1H), 1.75 (br, 1H), 1.60 (br, 1H), 1.43 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0717] Example 66. (S)-quininecyclo-3-yl(6-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0718] 1 H-NMR (400MHz, CDCl3) δ7.69~7.49 (m, 1H), 7.42 (m, 2H), 7.09 (m, 2H), 6.79 (m, 1H), 5.03 (m, 1H), 4.90 (m, 1H), 4.82 (m, 1H), 3.31 ( m, 1H), 2.95 (m, 2H), 2.78 (m, 5H), 2.14 (m, 1H), 1.86 (br, 1H), 1.73 (br, 1H), 1.61 (br, 1H), 1.44 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0719] Example 67. (S)-Quininecyclo-3-yl(2,2-dimethyl-6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0720] 1 H-NMR (400MHz, CDCl3) δ7.34 (m, 1H), 7.28 (m, 2H), 7.13 (m, 1H), 7.07 (m, 1H), 5.03 (m, 1H), 4.91 (m, 1H), 4.80 (m, 1H), 3.29 (m, 1H), 2.88(m, 2H), 2.79(m, 5H), 2.10(m, 1H), 1.85(br, 1H), 1.70(m, 1H), 1.61(br, 1H), 1.42(br, 1H), 1.31(d, 3H), 1.00(d, 3H)

[0721] Example 68. (S)-quininecyclo-3-yl(2,2-dimethyl-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0722] 1 H-NMR (400MHz, CDCl3) δ7.34 (m, 2H), 7.28 (m, 2H), 7.04 (m, 1H), 5.03 (m, 1H), 4.90 (m, 1H), 4.80 (m, 1H), 3.28 (m, 1H), 2. 98(m,2H),2.78(m,5H),2.10(m,1H),1.85(br,1H),1.73(br,1H),1.60(br,1H),1.43(br,1H),1.32(d,3H),0.98(d,3H)

[0723] Example 69. (S)-quininecyclo-3-yl(6-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0724] 1 H-NMR (400MHz, CDCl3) δ7.71 (m, 1H), 7.66 (m, 1H), 7.50 (m, 1H), 7.45 (m, 1H), 7.40 (m, 1H), 7.33 (m, 1H), 5.03 (m, 1H), 4.89 (m, 1H), 4.82 ( m, 1H), 3.30 (m, 1H), 2.91~2.74 (m, 7H), 2.14 (m, 1H), 1.88 (br, 1H), 1.72 (br, 1H), 1.67 (br, 1H), 1.44 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0725] Example 70. (S)-quininecyclo-3-yl(6-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0726] 1 H-NMR (400MHz, CDCl3) δ7.69 (m, 2H), 7.50 (m, 2H), 7.39 (m, 2H), 5.02 (m, 1H), 4.89 (m, 1H), 4.82 (m, 1H), 3.31 (m, 1H), 2. 90(m,2H),2.78(m,5H),2.14(m,1H),1.87(br,1H),1.74(br,1H),1.62(br,1H),1.44(br,1H),1.32(d,3H),0.99(d,3H)

[0727] Example 71. (S)-quininecyclo-3-yl(6-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0728] 1 H-NMR (400MHz, CDCl3) δ7.41 (m, 1H), 7.39 (m, 1H), 7.28 (m, 4H), 5.01 (m, 1H), 4.92 (m, 1H), 4.80 (m, 1H), 3.27 (m, 1 H), 2.78(m, 7H), 2.09(m, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.41(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[0729] Example 72. (S)-quininecyclo-3-yl(6-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0730] 1 H-NMR (400MHz, CDCl3) δ7.51 (m, 2H), 7.40 (m, 2H), 7.21 (d, 1H), 6.99 (m, 2H), 4.98 (m, 1H), 4.84 (m, 1H), 4.80 (br, 1H), 4.17 (m, 2H), 3.78 (m, 2H) , 3.47 (s, 3H), 3.25 (m, 1H), 2.88 ~ 2.71 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0731] Examples 73 to 275

[0732] The title compounds of Examples 73 to 275 were prepared using the (S)-quininecyclo-3-yl(5-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate and the corresponding substituted phenylboronic acid obtained in Preparation Example 4, respectively, following the same steps as in Example 1.

[0733] Example 73. (S)-quininecyclo-3-yl(5-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0734] 1 H-NMR (400MHz, CDCl3) δ7.53 (m, 2H), 7.40 (m, 2H), 7.30 (m, 1H), 7.13 (t, 2H), 5.00 (m, 1H), 4.88 (m, 1H), 4.83 (m, 1H), 3.29 (m, 1H), 2. 91 ~ 2.86 (m, 2H), 2.82 ~ 2.75 (m, 5H), 2.12 (br, 1H), 1.82 (br, 1H), 1.72 (br, 1H), 1.61 (br, 1H), 1.44 (br, 1H), 1.31 (d, 3H), 0.99 (d, 3H)

[0735] Example 74. (S)-quininecyclo-3-yl(5-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0736] 1 H-NMR (400MHz, CDCl3) δ7.51 (d, 2H), 7.41 (d, 2H), 7.36 (m, 2H), 7.31 (m, 1H), 5.00 (m, 1H), 4.90 (m, 1H), 4.81 (br, 1H), 3.31 (m, 1H), 2. 91~2.87(m,2H),2.82~2.75(m,5H),2.12(br,1H),1.86(br,1H),1.72(br,1H),1.61(br,1H),1.44(br,1H),1.31(d,3H),0.99(d,3H)

[0737] Example 75. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0738] 1H-NMR (400MHz, CDCl3) δ7.67 (s, 4H), 7.46 ~ 7.44 (m, 1H), 7.42 (s, 1H), 7.35 ~ 7.27 (m, 1H), 5.02 (m, 1H), 4.89 (m, 1H), 4.82 (m, 1H), 3.29 (m, 1 H), 2.90~2.85(m, 2H), 2.81~2.77(m, 5H), 2.13(br, 1H), 1.83(br, 1H), 1.72(br, 1H), 1.62(br, 1H), 1.46(br, 1H), 1.33(d, 3H), 1.01(d, 3H)

[0739] Example 76. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0740] 1 H-NMR (400MHz, CDCl3) δ7.58 (d, 2H), 7.42~7.37 (m, 2H), 7.29 (m, 3H), 5.01 (m, 1H), 4.89 (m, 1H), 4.82 (m, 1H), 3.29 (m, 1H), 2.90~ 2.87(m,2H),2.83~2.77(m,5H),2.12(br,1H),1.83(br,1H),1.73(br,1H),1.61(br,1H),1.44(br,1H),1.32(d,3H),1.00(d,3H)

[0741] Example 77. (S)-quininecyclo-3-yl(5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0742] H-NMR (400MHz, CDCl3) δ7.44~7.37 (m, 3H), 7.34 (m, 1H), 7.31 (m, 2H), 7.04 (t, 1H), 5.01 (m, 1H), 4.90 (m, 1H), 4.81 (m, 1H), 3.29 (m, 1H), 2.89~2.87(m,2H), 2.83~2.75(m,5H), 2.11(br,1H), 1.86(br,1H), 1.71(br,1H), 1.61(br,1H), 1.43(br,1H), 1.32(d,3H), 1.00(d,3H)

[0743] Example 78. (S)-quininecyclo-3-yl(5-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0744] 1 H-NMR (400MHz, CDCl3) δ7.56 (s, 1H), 7.45 (m, 2H), 7.40 (m, 2H), 7.34 (m, 1H), 7.30 (m, 1H), 5.01 (m, 1H), 4.96 (m, 1H), 4.81 (m, 1H), 3.28 (m, 1 H), 2.89~2.86(m, 2H), 2.82~2.75(m, 5H), 2.11(br, 1H), 1.86(br, 1H), 1,72(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[0745] Example 79. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0746] 1 H-NMR (400MHz, CDCl3) δ7.82 (s, 1H), 7.75 (d, 1H), 7.60 ~ 7.56 (m, 2H), 7.43 (m, 2H), 7.35 (m, 1H), 5.03 (m, 1H), 4.92 (m, 1H), 4.81 (br, 1H), 3.29 ( m, 1H), 2.89 ~ 2.84 (m, 2H), 2.81 ~ 2.77 (m, 5H), 2.12 (br, 1H), 1.84 (br, 1H), 1.72 (br, 1H), 1.61 (br, 1H), 1.44 (br, 1H), 1.33 (d, 3H), 1.00 (d, 3H)

[0747] Example 80. (S)-quininecyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0748] 1 H-NMR (400MHz, CDCl3) δ7.52~7.45 (m, 1H), 7.41 (m, 4H), 7.32 (m, 1H), 7.20 (d, 1H), 5.02 (m, 1H), 4.89 (m, 1H), 4.82 (m, 1H), 3.28 (m, 1H), 2.90~2.84(m,2H), 2.79~2.76(m,5H), 2.12(br,1H), 1.82(br,1H), 1.70(br,1H), 1.61(br,1H), 1.44(br,1H), 1.32(d,3H), 1.00(d,3H)

[0749] Example 81. (S)-quininecyclo-3-yl(5-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0750] 1 H-NMR (400MHz, CDCl3) δ7.43~7.37(m,3H), 7.33~7.28(m,2H), 7.23(m,1H), 7.18(m,1H), 5.01(m,1H), 4.91(m,1H), 4.81(br,1H), 3.30(m,1 H), 2.89~2.87(m, 2H), 2.83~2.76(m, 5H), 2.12(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[0751] Example 82. (S)-quininecyclo-3-yl(5-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0752] 1 H-NMR (400MHz, CDCl3) δ7.47 (d, 1H), 7.33~7.25 (m, 6H), 5.02 (m, 1H), 4.94 (m, 1H), 4.82 (br, 1H), 3.28 (m, 1H), 2.89~2.87 ( m, 2H), 2.83~2.75 (m, 5H), 2.13 (br, 1H), 1.85 (br, 1H), 1.72 (br, 1H), 1.61 (br, 1H), 1.43 (br, 1H), 1.34 (d, 3H), 1.00 (d, 3H)

[0753] Example 83. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0754] 1H-NMR (400MHz, CDCl3) δ7.74 (d, 1H), 7.55 (m, 1H), 7.48 (m, 1H), 7.33 (d, 1H), 7.27 (m, 1H), 7.17 (m, 1H), 7.14 (s, 1H), 5.03 (m, 2H), 4.82 (br, 1H), 3. 31(m, 1H), 2.89~2.85(m, 2H), 2.82~2.73(m, 5H), 2.11(br, 1H), 1.85(br, 1H), 1.71(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[0755] Example 84. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0756] 1 H-NMR (400MHz, CDCl3) δ7.42 (m, 1H), 7.36 (m, 3H), 7.27 (m, 3H), 5.03 (m, 1H), 4.94 (m, 1H), 4.82 (m, 1H), 3.28 (m, 1H), 2.90~2. 87(m2H), 2.83~2.75(m, 5H), 2.12(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.62(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[0757] Example 85. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0758] 1 H-NMR (400MHz, CDCl3) δ7.49 (d, 2H), 7.42 (m, 2H), 7.26 (m, 3H), 5.00 (m, 1H), 4.89 (m, 1H), 4.80 (m, 1H), 3.29 (m, 1H), 2.89~2.85 (m, 2 H), 2.82~2.75(m, 5H), 2.41(s, 3H), 2.11(br, 1H), 1.82(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.44(br, 1H), 1.31(d, 3H), 1.00(d, 3H)

[0759] Example 86. (S)-quininecyclo-3-yl(5-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0760] 1 H-NMR (400MHz, CDCl3) δ7.56 (d, 2H), 7.37 (m, 2H), 7.32 (m, 1H), 7.19 (d, 2H), 6.75~6.38 (t, 1H), 4.99 (m, 1H), 2.90 (m, 1H), 4.82 (br, 1H), 3.29 ( m, 1H), 2.90 ~ 2.87 (m, 2H), 2.83 ~ 2.79 (m, 5H), 2.11 (br, 1H), 1.82 (br, 1H), 1.72 (br, 1H), 1.60 (br, 1H), 1.44 (br, 1H), 1.32 (s, 3H), 0.99 (d, 3H)

[0761] Example 87. (S)-quininecyclo-3-yl(5-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0762] 1 H-NMR (400MHz, CDCl3) δ7.37 (m, 3H), 7.29 (m, 2H), 7.23 (m, 1H), 5.01 (m, 1H), 4.90 (m, 1H), 4.82 (m, 1H), 3.32 (m, 1H), 2.89~2. 86 (m, 2H), 2.82~2.75 (m, 5H), 2.11 (m, 1H), 1.90 (br, 1H), 1.72 (br, 1H), 1.60 (br, 1H), 1.43 (br, 1H), 1.34 (d, 3H), 0.99 (d, 3H)

[0763] Example 88. (S)-quininecyclo-3-yl(5-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0764] 1H-NMR (400MHz, CDCl3) δ7.36 (m, 3H), 7.12 (m, 2H), 6.99 (m, 1H), 5.02 (m, 1H), 4.90 (m, 1H), 4.80 (m, 1H), 3.29 (m, 1H), 2.89~2. 87(m, 2H), 2.83~2.75(m, 5H), 2.11(m, 1H), 1.86(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[0765] Example 89. (S)-quininecyclo-3-yl(5-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0766] 1 H-NMR (400MHz, CDCl3) δ7.40 (m, 1H), 7.35 (m, 3H), 6.95 (m, 2H), 5.01 (m, 1H), 4.91 (m, 1H), 4.80 (m, 1H), 3.29 (m, 1H), 2.89~2. 86 (m, 2H), 2.83~2.75 (m, 5H), 2.11 (m, 1H), 1.85 (br, 1H), 1.75 (br, 1H), 1.60 (br, 1H), 1.43 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0767] Example 90. (S)-quininecyclo-3-yl(5-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0768] 1 H-NMR (400MHz, CDCl3) δ7.50(m, 3H), 7.10(m, 2H), 6.78((m, 1H), 5.02(m, 1H), 4.89(m, 1H), 4.81(m, 1H), 3.30(m, 1H), 2.90~2. 87 (m, 2H), 2.83~2.75 (m, 5H), 2.12 (m, 1H), 1.86 (br, 1H), 1.75 (br, 1H), 1.61 (br, 1H), 1.45 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0769] Example 91. (S)-quininecyclo-3-yl(5-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0770] 1H-NMR (400MHz, CDCl3) δ7.38~7.28 (m, 3H), 7.16 (m, 3H), 5.02 (m, 1H), 4.91 (m, 1H), 4.82 (m, 1H), 3.30 (m, 1H), 2.88 (m, 2 H), 2.83~2.76(m, 5H), 2.12(m, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[0771] Example 92. (S)-quininecyclo-3-yl(5-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0772] 1 H-NMR (400MHz, CDCl3) δ7.71 (m, 2H), 7.56 (m, 1H), 7.48 (m, 2H), 7.39 (m, 1H), 5.03 (m, 1H), 4.86 (m, 2H), 3.31 (m, 1 H), 2.91(m, 2H), 2.86~2.78(m, 5H), 2.13(m, 1H), 1.86(br, 1H), 1.75(br, 1H), 1.68(br, 1H), 1.46(br, 1H), 1.32(d 3H), 0.99(d, 3H)

[0773] Example 93. (S)-quininecyclo-3-yl(5-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0774] 1 H-NMR (400MHz, CDCl3) δ7.41 (d, 1H), 7.33~7.23 (m, 5H), 5.03 (m, 1H), 4.94 (m, 1H), 4.82 (m, 1H), 3.28 (m, 1H), 2.90~2.87 ( m, 2H), 2.83~2.75 (m, 5H), 2.11 (m, 1H), 1.85 (br, 1H), 1.71 (br, 1H), 1.61 (br, 1H), 1.44 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0775] Example 94. (S)-quininecyclo-3-yl(5-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0776] 1H-NMR (400MHz, CDCl3) δ7.50 (m, 1H), 7.45 (m, 1H), 7.39 (s, 2H), 7.35 (d, 2H), 5.02 (m, 1H), 4.87 (m, 2H), 3.30 (m, 1H), 2.90~2.8 2(m, 2H), 2.83~2.79(m, 5H), 2.13(br, 1H), 2.06(br, 1H), 1.88(br, 1H), 1.69(br, 1H), 1.48(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[0777] Example 95. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0778] 1 H-NMR (400MHz, CDCl3) δ7.31 (m, 3H), 7.13 (m, 1H), 7.06 (m, 1H), 5.02 (m, 1H), 4.90 (m, 1H), 4.83 (m, 1H), 3.30 (m, 1H), 2.94~2. 88(m, 2H), 2.83~2.76(m, 5H), 2.12(m, 1H), 1.87(br, 1H), 1.73(m, 1H), 1.61(br, 1H), 1.47(br, 1H), 1.31(d, 3H), 1.00(d, 3H)

[0779] Example 96. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0780] 1 H-NMR (400MHz, CDCl3) δ7.32 (m, 3H), 7.23 (m, 1H), 7.03 (m, 1H), 5.02 (m, 1H), 4.89 (m, 1H), 4.81 (m, 1H), 3.32 (m, 1H), 2.91~2. 87 (m, 2H), 2.83~2.75 (m, 5H), 2.11 (m, 1H), 1.85 (br, 1H), 1.72 (br, 1H), 1.61 (br, 1H), 1.44 (br, 1H), 1.32 (d, 3H), 0.99 (d, 3H)

[0781] Example 97. (S)-quininecyclo-3-yl(5-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0782] 1 H-NMR (400MHz, CDCl3) δ7.49 (d, 2H), 7.39 (m, 1H), 7.36 (s, 1H), 7.27 (m, 1H ), 7.00(d, 2H), 4.98(m, 1H), 4.84(m, 1H), 4.80(br, 1H), 4.18(m, 2H), 3.78( m, 2H), 3.48 (s, 3H), 3.25 (m, 1H), 2.90~2.75 (m, 7H), 2.10 (br, 1H), 1.86 (b r, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0783] Example 98. (S)-quininecyclo-3-yl(5-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0784] 1 H-NMR (400MHz, CDCl3) δ7.42 (m, 1H), 7.36 (s, 1H), 7.31~7.27 (m, 2H), 7.18 (m, 2H), 6.91 (d, 1H), 4.99 (m, 1H), 4.84~4.80 (m, 2H), 4.18 (m, 2H), 3.79 (m , 2H), 3.48(s, 3H), 3.25(m, 1H), 2.90~2.75(m, 7H), 2.10(br, 1H), 1.86(br ,1H),1.71(br,1H),1.60(br,1H),1.42(br,1H),1.30(m,3H),0.98(m,3H)

[0785] Example 99. (S)-quininecyclo-3-yl(5-(2-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0786] 1H-NMR (400MHz, CDCl3) δ7.40(m, 2H), 7.32~7.27(m, 3H), 7.04~7.98(m, 2H), 4.99(m, 1H), 4.84(m, 1H), 4.80(m, 1H), 4.10(m, 2H), 3.68(m, 2H), 3.38(s, 3H), 3.25(m, 1H), 2.90~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[0787] Example 100. (S)-quininecyclo-3-yl(5-(4-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0788] 1 H-NMR (400MHz, CDCl3) δ7.51 (d, 2H), 7.38 (m, 1H), 7.35 (s, 1H), 7.27 (m, 1H), 7.10 (d, 2H), 5.22 (s, 2H), 4.99 (m, 1H), 4.84 (m, 1H), 4.80 (m, 1H), 3.31 (s, 3H), 3.25 (m, 1H), 2.90 ~ 2.75 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0789] Example 101. (S)-quininecyclo-3-yl(5-(3-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0790] 1 H-NMR (400MHz, MeOD) δ7.41 (m, 2H), 7.28 (m, 1H), 7.26 (m, 1H), 7.05 (d, 1H), 7.00 (s, 1H), 6.75 (d, 1H), 5.07 (br, 1H), 4.87 (s, 2H), 3.72 (m, 1H) , 3.67 (s, 3H), 3.39 (m, 2H), 3.39~3.29 (m, 5H), 2.81 (s, 2H), 2.45 (m, 1H), 2.30 (br, 1H), 2.10 (br, 1H), 1.93 (br, 1H), 1.24 (d, 3H), 0.98 (d, 3H)

[0791] Example 102. (S)-quininecyclo-3-yl(5-(2-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0792] 1 H-NMR (400MHz, CDCl3) δ7.39 (m, 1H), 7.35 (m, 4H), 7.21 (m, 1H), 7.09 (m, 1H), 5.12 (s, 2H), 4.99 (m, 1H), 4.84 (m, 1H), 4.80 (m, 1H), 3.41 ( s, 3H), 3.25 (m, 1H), 2.90 ~ 2.75 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0793] Example 103. (S)-quininecyclo-3-yl(5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0794] 1 H-NMR (400MHz, CDCl3) δ7.44 (m, 1H), 7.39 (s, 1H), 7.31~7.27 (m, 2H), 7.15 (d, 1H), 7.10 (s, 1H), 6.89 (d, 1H), 4.98 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1 H), 3.87(s, 3H), 3.25(m, 1H), 2.90~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[0795] Example 104. (S)-quininecyclo-3-yl(5-(3-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0796] 1H-NMR (400MHz, CDCl3) δ7.44 (m, 1H), 7.39 (s, 1H), 7.31~7.27 (m, 2H), 7.15 (d, 1H), 7.10 (s, 1H), 6.89 (d, 1H), 4.98 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 4.11(m, 2H), 3.25(m, 1H), 2.90~2.74(m, 7H), 2.10(br, 1H), 1.86(br , 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.45 (t, 4H), 1.29 (m, 3H), 0.98 (m, 3H)

[0797] Example 105. (S)-quininecyclo-3-yl(5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0798] 1 H-NMR (400MHz, CDCl3) δ7.43 (m, 1H), 7.39 (s, 1H), 7.35~7.27 (m, 2H), 7.14 ( d, 1H), 7.10 (s, 1H), 6.88 (d, 1H), 5.00 (m, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 4. 62 (m, 1H), 3.25 (m, 1H), 2.90~2.74 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.38 (d, 6H), 1.29 (m, 3H), 0.98 (m, 3H)

[0799] Example 106. (S)-quininecyclo-3-yl(5-(3-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0800] 1 H-NMR (400MHz, CDCl3) δ7.44 (m, 1H), 7.40 (s, 1H), 7.32~7.27 (m, 2H), 6.91 (m, 2H), 6.74 (d, 1H), 4.99 (m, 1H), 4.86 (m, 1H), 4.80 (br, 1H), 3. 25(m,1H),3.01(s,6H),2.92~2.75(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.42(br,1H),1.30(m,3H),0.97(m,3H)

[0801] Example 107. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(3-(methylthio)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0802] 1 H-NMR (400MHz, CDCl3) δ7.45 (s, 1H), 7.41~7.23 (m, 6H), 4.99 (m, 1H), 4.87 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H), 2.92~2.7 5(m,7H),2.54(s,3H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.42(br,1H),1.31(m,3H),0.98(m,3H)

[0803] Example 108. (S)-quininecyclo-3-yl(5-(3-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0804] 1 H-NMR (400MHz, CDCl3) δ7.45 (d, 1H), 7.42 (s, 2H), 7.40~7.28 (m, 3H), 7.19 (d, 1H), 5.00 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H), 2. 92~2.75(m,7H),2.70(m,2H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.42(br,1H),1.31(t,3H),1.29(m,3H),0.98(m,3H)

[0805] Example 109. (S)-quininecyclo-3-yl(5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0806] 1H-NMR (400MHz, CDCl3) δ7.43~7.34 (m, 5H), 7.28 (m, 1H), 7.22 (d, 1H), 5.00 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H), 2. 98(m,1H),2.92~2.75(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.42(br,1H),1.30(m,9H),0.98(m,3H)

[0807] Example 110. (S)-quininecyclo-3-yl(5-(3-(tert-butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0808] 1 H-NMR (400MHz, CDCl3) δ7.58 (s, 1H), 7.44 (d, 1H), 7.38 (s, 4H), 7.28 (m, 1H), 5.00 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 3.25 (m, 1H) , 2.92~2.75(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.42(br,1H),1.38(s,9H),1.29(m,3H),0.98(m,3H)

[0809] Example 111. (S)-quininecyclo-3-yl(5-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0810] 1 H-NMR (400MHz, CDCl3) δ7.34~7.27 (m, 3H), 7.25 (m, 2H), 7.10 (d, 1H), 5.00 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 3.25 (m, 1 H), 2.92~2.75 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0811] Example 112. (S)-quininecyclo-3-yl(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0812] 1 H-NMR (400MHz, CDCl3) δ7.38 (m, 1H), 7.36 (s, 1H), 7.25 (m, 1H), 7.09 (s, 1H), 7.05 (d, 1H), 6.91 (d, 1H), 4.98 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H) , 4.29 (s, 4H), 3.25 (m, 1H), 2.92 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.29 (m, 3H), 0.97 (m, 3H)

[0813] Example 113. (S)-quininecyclo-3-yl(5-(2,3-dihydrobenzofuran-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0814] 1 H-NMR (400MHz, CDCl3) δ7.41 (s, 1H), 7.36~7.30 (m, 3H), 7.25 (m, 1H), 6.84 (d, 1H), 4.98 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 4.62 (t, 2 H), 3.25 (m, 3H), 2.92~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.29 (m, 3H), 0.97 (m, 3H)

[0815] Example 114. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(3-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0816] 1H-NMR (400MHz, CDCl3) δ7.43 (d, 1H), 7.39 (s, 1H), 7.38~7.30 (m, 2H), 7.17 (d, 1 H), 7.11(s, 1H), 6.89(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.19(t, 2 H), 3.75(m, 4H), 3.25(m, 3H), 2.92~2.73(m, 9H), 2.60(m, 4H), 2.10(br, 1H), 1. 86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0817] Example 115. (S)-quininecyclo-3-yl(5-(4-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0818] 1 H-NMR (400MHz, CDCl3) δ7.52 (d, 2H), 7.35 (m, 2H), 7.26 (m, 1H), 7.00 (d, 2H), 4.99 (m, 1H), 4.87 (m, 2H), 4.81 (m, 1H), 4.71 (br, 1H), 4.31~4. 22(m, 2H), 3.25(m, 3H), 2.90~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.59(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[0819] Example 116. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(4-(2,2,2-trifluoroethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0820] 1 H-NMR (400MHz, CDCl3) δ7.43~7.36(m, 3H), 7.31~7.25(m, 2H), 7.15(s, 1H), 6.91(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.42( q, 2H), 3.25 (m, 3H), 2.92~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0821] Example 117. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0822] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.39 (m, 2H), 7.24 (m, 1H), 6.97 (d, 2H), 4.98 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 4.16 (t, 2H), 3.76 (m, 4H) , 3.25 (m, 3H), 2.92~2.73 (m, 9H), 2.60 (m, 4H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0823] Example 118. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(2-(trifluoromethyl)pyridin-4-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0824] 1 H-NMR (400MHz, CDCl3) δ8.76 (d, 1H), 7.87 (s, 1H), 7.67 (d, 1H), 7.49 (m, 2H), 7.37 (m, 1H), 5.00 (m, 1H), 4.93 (m, 1H), 4.80 (br, 1H) , 3.25 (m, 1H), 2.92~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.31 (m, 3H), 0.98 (m, 3H)

[0825] Example 119. (S)-quininecyclo-3-yl(5-(2,5-dichloropyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0826] 1H-NMR (400MHz, CDCl3) δ8.44 (s, 1H), 7.30 (m, 1H), 7.19 (m, 3H), 4.96 (m, 1H), 4.86 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H) , 2.92~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.31 (m, 3H), 0.98 (m, 3H)

[0827] Example 120. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0828] 1 H-NMR (400MHz, CDCl3) δ7.39 (m, 1H), 7.33 (s, 1H), 7.25 (m, 1H), 7.07 (d, 1H), 7 .03(s, 1H), 6.72(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.33(m, 2H) , 3.29(m, 2H), 3.25(m, 1H), 2.92(s, 3H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.8 6(br,1H),1.71(br,1H),1.60(br,1H),1.42(br,1H),1.30(m,3H),0.98(m,3H)

[0829] Example 121. (S)-quininecyclo-3-yl(5-(2-chloro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0830] 1 H-NMR (400MHz, CDCl3) δ7.36 (d, 1H), 7.28 (m, 3H), 6.86 (m, 1H), 6.81 (m, 1H), 5.00 (m, 2H), 4.80 (br, 1H), 3.81 (s, 3H), 3.25 ( m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.31 (m, 3H), 0.99 (m, 3H)

[0831] Example 122. (S)-quininecyclo-3-yl(5-(3-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0832] 1 H-NMR (400MHz, CDCl3) δ7.59 (d, 1H), 7.44 (d, 1H), 7.37 (m, 1H), 7.25 (m, 1H), 6.98 (d, 1H), 4.98 (m, 2H), 4.80 (br, 1H), 3.94 (s, 3H) , 3.25 (m, 1H), 2.88~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.31 (m, 3H), 0.98 (m, 3H)

[0833] Example 123. (S)-quininecyclo-3-yl(5-(2-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0834] 1 H-NMR (400MHz, CDCl3) δ7.24 (m, 1H), 7.22 (m, 3H), 7.01 (s, 1H), 6.85 (d, 1H), 4.99 (s, 2H), 4.79 (br, 1H), 3.84 (s, 3H), 3.25 ( m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.31 (m, 3H), 0.97 (m, 3H)

[0835] Example 124. (S)-quininecyclo-3-yl(5-(2-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0836] 1 H-NMR (400MHz, CDCl3) δ7.31~7.22 (m, 4H), 6.94 (d, 2H), 4.99 (s, 2H), 4.79 (br, 1H), 3.95 (s, 3H), 3.25 (m, 1H), 2. 91~2.74(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.42(br,1H),1.31(m,3H),0.98(m,3H)

[0837] Example 125. (S)-quininecyclo-3-yl(5-(4-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0838] 1 H-NMR (400MHz, CDCl3) δ7.41~7.37 (m, 3H), 7.27 (m, 1H), 7.08 (m, 2H), 5.00 (m, 1H), 4.91 (m, 1H), 4.80 (br, 1H), 3.97 (s, 3H), 3. 25(m,1H),2.91~2.75(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.42(br,1H),1.30(m,3H),0.98(m,3H)

[0839] Example 126. (S)-quininecyclo-3-yl(5-(2,3-dichloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0840] 1 H-NMR (400MHz, CDCl3) δ7.27 (m, 1H), 7.21 (m, 1H), 7.19 (d, 2H), 6.90 (d, 1H), 5.00 (s, 2H), 4.80 (br, 1H), 3.95 (s, 3H), 3.25 ( m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0841] Example 127. (S)-quininecyclo-3-yl(5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0842] 1H-NMR (400MHz, CDCl3) δ7.59 (s, 1H), 7.39 (m, 2H), 7.33 (s, 1H), 7.26 (m, 1H), 7.00 (d, 1H), 4.96 (m, 2H), 4.79 (br, 1H), 4.60 (m, 1H), 3.25 ( m, 1H), 2.88~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.38 (d, 6H), 1.30 (m, 3H), 0.97 (m, 3H)

[0843] Example 128. (S)-quininecyclo-3-yl(5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0844] 1 H-NMR (400MHz, CDCl3) δ7.35~7.27 (m, 4H), 6.77 (d, 1H), 6.69 (d, 1H), 4.97 (m, 2H), 4.80 (br, 1H), 3.84 (s, 3H), 3.25 (m, 1H), 2. 89~2.73(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.40(br,1H),1.38(d,6H),1.30(m,3H),0.98(m,3H)

[0845] Example 129. (S)-quininecyclo-3-yl(5-(3-(dimethylamino)-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0846] 1 H-NMR (400MHz, CDCl3) δ7.39 (m, 1H), 7.30 (s, 1H), 7.25 (m, 1H), 7.09 (s, 1H), 7.04 (m, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H) , 2.90 (s, 6H), 2.89 ~ 2.74 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.38 (d, 6H), 1.30 (m, 3H), 0.98 (m, 3H)

[0847] Example 130. (S)-quininecyclo-3-yl(5-(benzodihydropyran-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0848] 1 H-NMR (400MHz, CDCl3) δ7.37 (m, 1H), 7.33 (s, 1H), 7.25 (m, 3H), 6.85 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 4.23 (m, 2H) , 3.25 (m, 1H), 2.89~2.74 (m, 9H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0849] Example 131. (S)-quininecyclo-3-yl(5-(4-cyclopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0850] 1 H-NMR (400MHz, CDCl3) δ7.47 (d, 2H), 7.42 (m, 1H), 7.38 (s, 1H), 7.25 (m, 1H), 7.13 (d, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H) , 2.89~2.74(m,7H),2.10(br,1H),1.91(m,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.98(m,6H),0.74(m,2H)

[0851] Example 132. (S)-quininecyclo-3-yl(5-(4-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0852] 1H-NMR (400MHz, CDCl3) δ7.48 (d, 2H), 7.39 (m, 1H), 7.36 (s, 1H), 7.21 (m, 2H), 6.80 (d, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 3.25 ( m, 1H), 3.00 (s, 6H), 2.89~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[0853] Example 133. (S)-quininecyclo-3-yl(5-(4-ethoxy-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0854] 1 H-NMR (400MHz, CDCl3) δ7.38~7.32 (m, 2H), 7.27 (m, 3H), 6.99 (t, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 4.15 (m, 2H), 3.25 (m, 1 H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.48(t, 3H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[0855] Example 134. (S)-quininecyclo-3-yl(5-(4-methoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0856] 1 H-NMR (400MHz, CDCl3) δ7.76 (s, 1H), 7.69 (d, 1H), 7.31 (m, 2H), 7.27 (m, 1H), 7.07 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 4.95 ( s, 3H), 3.25 (m, 1H), 2.89~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.31 (m, 3H), 0.98 (m, 3H)

[0857] Example 135. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0858] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.38 (m, 1H), 7.35 (s, 1H), 7.26 (m, 1H ), 6.96(d, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.96(q, 2H), 3.25( m, 1H), 2.89~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.84 (m, 2H), 1.71 ( br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.31 (m, 3H), 1.06 (t, 3H), 0.98 (m, 3H)

[0859] Example 136. (S)-quininecyclo-3-yl(5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0860] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.39 (m, 1H), 7.36 (s, 1H), 7.26 (m, 1H), 6.96 (d, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 3.77 (d, 2H) , 3.25 (m, 1H), 2.89~2.73 (m, 7H), 2.10 (m, 2H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.31 (m, 3H), 1.05 (d, 6H), 0.98 (m, 3H)

[0861] Example 137. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(thiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0862] 1H-NMR (400MHz, CDCl3) δ7.46~7.41 (m, 3H), 7.38 (m, 2H), 7.21 (m, 1H), 4.98 (m, 1H), 4.87 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1 H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[0863] Example 138. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-methylthiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0864] 1 H-NMR (400MHz, CDCl3) δ7.28~7.16 (m, 4H), 7.02 (s, 1H), 4.99 (m, 1H), 4.87 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H), 2.26 (s, 3 H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[0865] Example 139. (S)-quininecyclo-3-yl(5-(3-(2-(dimethylamino)ethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0866] 1 H-NMR (400MHz, CDCl3) δ7.28 (m, 1H), 7.24 (m, 4H), 6.94 (m, 2H), 4.99 (m, 1H), 4.87 (m, 1H), 4.80 (br, 1H), 4.07 (m, 2H), 3.25 (m, 1H) , 2.89~2.73(m,9H),2.35(s,6H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.40(br,1H),1.31(m,3H),0.98(m,3H)

[0867] Example 140. (S)-quininecyclo-3-yl(5-(isoquinolin-8-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0868] 1 H-NMR (400MHz, CDCl3) δ9.31 (s, 1H), 8.51 (d, 1H), 7.82 (d, 1H), 7.72 (m, 2H), 7.52 (d, 1H), 7.36 (m, 3H), 5.24 (m, 1H), 5.07 (m, 1H), 4.81 ( m, 1H), 3.25 (m, 1H), 2.89~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.35 (m, 3H), 0.98 (m, 3H)

[0869] Example 141. (S)-quininecyclo-3-yl(5-(isoquinolin-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0870] 1 H-NMR (400MHz, CDCl3) δ9.31 (s, 1H), 8.47 (d, 1H), 7.99 (d, 1H), 7.71 (d, 1H), 7.65 (m, 2H), 7.39~7.27 (m, 3H), 5.05 (m, 2H), 4.82 (m, 1 H), 3.25 (m, 1H), 2.89~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.34 (m, 3H), 0.98 (m, 3H)

[0871] Example 142. (S)-quininecyclo-3-yl(5-(isoquinolin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0872] 1 H-NMR (400MHz, CDCl3) δ9.25 (s, 1H), 8.44 (s, 1H), 8.04 (d, 1H), 7.91 (d, 1H), 7.65 (m, 2H), 7.38 (m, 3H), 5.09 (m, 2H), 4.82 (m, 1H), 3.25(m,1H),2.89~2.73(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.40(br,1H),1.35(m,3H),0.99(m,3H)

[0873] Example 143. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0874] 1 H-NMR (400MHz, CDCl3) δ9.16 (s, 1H), 8.30 (s, 1H), 8.14 (d, 1H), 7.88 (d, 1H), 7.72 (m, 1H), 7.61~7.53 (m, 3H), 7.39 (m, 1H), 5.05~4.94 (m, 2H), 4.82(m,1H),3.25(m,1H),2.91~2.77(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.40(br,1H),1.34(m,3H),1.00(m,3H)

[0875] Example 144. (S)-quininecyclo-3-yl(5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0876] 1 H-NMR (400MHz, CDCl3) δ7.48 (d, 1H), 7.37 (m, 1H), 7.35 (s, 1H), 7.25 (m, 1H), 6.95 (d, 2H), 4.98 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 4.61 (m, 1H) , 3.25 (m, 1H), 2.89~2.74 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.36 (d, 6H), 1.30 (m, 3H), 0.98 (m, 3H)

[0877] Example 145. (S)-quininecyclo-3-yl(5-(2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0878] 1H-NMR (400MHz, CDCl3) δ7.42 (m, 1H), 7.36 (s, 1H), 7.30~7.21 (m, 3H), 7.01 (m, 2H), 4.98 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 4.42 (m, 1H), 3. 25(m,1H),2.91~2.72(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.40(br,1H),1.29(m,3H),1.26(d,6H),0.98(m,3H)

[0879] Example 146. (S)-quininecyclo-3-yl(5-(4-(tert-butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0880] 1 H-NMR (400MHz, CDCl3) δ7.53 (m, 2H), 7.47 (m, 2H), 7.26 (m, 2H), 7.24 (m, 1H), 4.98 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H) , 2.91~2.72(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.40(br,1H),1.36(s,9H),1.29(m,3H),0.98(m,3H)

[0881] Example 147. (S)-quininecyclo-3-yl(5-(4-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0882] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.43 (m, 1H), 7.38 (s, 1H), 7.27 (m, 3H), 4.98 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H) , 2.91~2.72(m,7H),2.69(m,2H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,6H),0.98(m,3H)

[0883] Example 148. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0884] 1 H-NMR (400MHz, CDCl3) δ7.51 (d, 2H), 7.39 (m, 1H), 7.36 (s, 1H), 7.27 (m, 1H), 6.97 (d, 2H), 4.98 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 3.89 (m, 4H) , 3.25 (m, 1H), 3.21 (m, 4H), 2.91 ~ 2.72 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0885] Example 149. (S)-quininecyclo-3-yl(5-(4-(methoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0886] 1 H-NMR (400MHz, CDCl3) δ7.56 (d, 2H), 7.42 (m, 4H), 7.27 (m, 1H), 4.98 (m, 1H), 4.88 (m, 1H), 4.80 (br, 1H), 4.50 (s, 2H), 3.42 (s, 3H) , 3.25 (m, 1H), 2.89~2.74 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.29 (m, 3H), 0.98 (m, 3H)

[0887] Example 150. (S)-quininecyclo-3-yl(5-(4-(2,2-difluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0888] 1H-NMR (400MHz, CDCl3) δ7.53 (d, 2H), 7.39 (m, 2H), 7.27 (m, 1H), 6.99 (d, 2H), 6.25 ~ 5.98 (t, 1H), 4.98 (m, 2H), 4.79 (br, 1H), 4.21 (m, 2 H), 3.25 (m, 1H), 2.90~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.29 (m, 3H), 0.97 (m, 3H)

[0889] Example 151. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(3-methyl-4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0890] 1 H-NMR (400MHz, CDCl3) δ7.40~7.36 (m, 4H), 7.24 (m, 1H), 7.07 (d, 1H), 4.95 (m, 2H), 4.78 (br, 1H), 3.89 (m, 4H), 3.25 (m, 1H), 2.95 (m, 4 H), 2.91~2.73 (m, 7H), 2.38 (s, 3H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0891] Example 152. (S)-quininecyclo-3-yl(5-(3-fluoro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0892] 1 H-NMR (400MHz, CDCl3) δ7.34 (m, 2H), 7.26 (m, 2H), 7.23 (m, 1H), 6.98 (t, 1H), 4.96 (m, 1H), 4.91 (br, 1H), 4.78 (br, 1H), 3.90 (m, 4H), 3.25 (m, 1H), 3.14 (m, 4H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0893] Example 153. (S)-quininecyclo-3-yl(5-(3-chloro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0894] 1 H-NMR (400MHz, CDCl3) δ7.60 (s, 1H), 7.45 (d, 1H), 7.36 (m, 2H), 7.26 (m, 1H), 7.10 (d, 1H), 4.99 (m, 1H), 4.91 (br, 1H), 4.78 (br, 1H), 3.90 (m, 4H) , 3.25 (m, 1H), 3.09 (m, 4H), 2.91 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0895] Example 154. (S)-quininecyclo-3-yl(5-(3,4-dihydro-2H-benzo[b][1,4]dioxane-heptadiene-7-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0896] 1 H-NMR (400MHz, CDCl3) δ7.37 (m, 1H), 7.34 (s, 1H), 7.24 (m, 1H), 7.20 (s, 1H ), 7.15(d, 1H), 7.02(d, 1H), 4.99(m, 1H), 4.91(br, 1H), 4.78(br, 1H), 4.23 (m, 4H), 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.22 (m, 2H), 2.10 (br, 1H), 1.86 (b r, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.29 (m, 3H), 0.97 (m, 3H)

[0897] Example 155. (S)-quininecyclo-3-yl(5-(3-(difluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0898] 1H-NMR (400MHz, CDCl3) δ7.71 (m, 2H), 7.54 (m, 2H), 7.41 (m, 2H), 7.30 (m, 1H), 6.85~6.57 (t, 1H), 5.01 (m, 1H), 4.92 (br, 1H), 4.80 (br, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.97(m, 3H)

[0899] Example 156. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(quinolin-8-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0900] 1 H-NMR (400MHz, CDCl3) δ8.96 (m, 1H), 8.22 (d, 1H), 7.84 (d, 1H), 7.72 (m, 1H), 7 .62(d,1H),7.58(m,1H),7.50(s,1H),7.44(d,1H),7.35(d,1H),5.00(m,1H),4 .92 (br, 1H), 4.80 (br, 1H), 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.8 6(br,1H),1.71(br,1H),1.60(br,1H),1.40(br,1H),1.28(m,3H),0.95(m,3H)

[0901] Example 157. (S)-quininecyclo-3-yl(5-(benzofuran-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0902] 1 H-NMR (400MHz, CDCl3) δ7.84 (d, 1H), 7.78 (s, 1H), 7.55 (d, 1H), 7.49 (m, 1H), 7.45 (s, 1H), 7.34 (m, 3H), 5.02 (m, 1H), 4.92 (br, 1H), 4.80 ( br, 1H), 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.32 (m, 3H), 0.97 (m, 3H)

[0903] Example 158. (S)-quininecyclo-3-yl(5-(benzofuran-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0904] 1 H-NMR (400MHz, CDCl3) δ7.73 (d, 1H), 7.71 (s, 1H), 7.59 (d, 1H), 7.53 (d, 1H), 7.26 (m, 3H), 5.02 (m, 1H), 4.92 (br, 1H), 4.80 (br, 1H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.31 (m, 3H), 0.97 (m, 3H)

[0905] Example 159. (S)-quininecyclo-3-yl(5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0906] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.38 (m, 1H), 7.35 (s, 1H), 7.26 (m, 1H), 6.97 (d, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.85 (s, 3H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0907] Example 160. (S)-quininecyclo-3-yl(5-(4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0908] 1H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.38 (m, 1H), 7.35 (s, 1H), 7.26 (m, 1H), 6.95 (d, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 4.08 (m, 2H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (t, 3H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0909] Example 161. (S)-quininecyclo-3-yl(5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0910] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.44 (m, 1H), 7.39 (s, 1H), 7.26 (m, 1H ), 7.20(d, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91 ~2.74(m,7H),2.51(d,2H),2.10(br,1H),1.90(m,1H),1.87(br,1H),1.71( br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H), 0.93 (d, 6H)

[0911] Example 162. (S)-quininecyclo-3-yl(5-(2,4-dichloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0912] 1 H-NMR (400MHz, CDCl3) δ7.34 (d, 2H), 7.26 (m, 2H), 7.20 (s, 1H), 7.02 (d, 1H), 4.99 (m, 2H), 4.79 (br, 1H), 3.94 (s, 3H), 3.25 ( m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.87 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0913] Example 163. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0914] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.42 (m, 1H), 7.39 (s, 1H), 7.25 (m, 3H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.25 (m, 1H ), 2.91~2.74(m, 7H), 2.61(m, 2H), 2.10(br, 1H), 1.87(br, 1H), 1.67(m, 3H), 1.59(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 6H)

[0915] Example 164. (S)-quininecyclo-3-yl(5-(4-butylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0916] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.42 (m, 1H), 7.39 (s, 1H), 7.25 (m, 3H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.25 (m, 1H ), 2.91~2.74(m, 7H), 2.65(m, 2H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(m, 3H), 1.40(m, 3H), 1.30(m, 3H), 0.98(m, 6H)

[0917] Example 165. (S)-quininecyclo-3-yl(5-(2,3-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0918] 1H-NMR (400MHz, CDCl3) δ7.38 (m, 1H), 7.36 (s, 1H), 7.23 (m, 1H), 7.10 (m, 1H), 6.92 (d, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.91 (s, 3H) , 3.58 (s, 3H), 3.25 (m, 1H), 2.91 ~ 2.74 (m, 7H), 2.10 (br, 1H), 1.87 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0919] Example 166. (S)-quininecyclo-3-yl(5-(2,4-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0920] 1 H-NMR (400MHz, CDCl3) δ7.35 (m, 1H), 7.33 (s, 1H), 7.23 (m, 1H), 7.20 (d, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.25 (m, 1H), 2.91 ~ 2.74 (m, 7H), 2.10 (br, 1H), 1.87 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0921] Example 167. (S)-quininecyclo-3-yl(5-(2,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0922] 1 H-NMR (400MHz, CDCl3) δ7.39 (m, 1H), 7.33 (s, 1H), 7.26 (m, 1H), 6.87 (m, 3H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 3.25 (m, 1H), 2.91 ~ 2.74 (m, 7H), 2.10 (br, 1H), 1.87 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0923] Example 168. (S)-quininecyclo-3-yl(5-(2,6-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0924] 1 H-NMR (400MHz, CDCl3) δ7.26 (m, 2H), 7.19 (m, 1H), 7.15 (s, 1H), 6.65 (d, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.71 (s, 6H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.87 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0925] Example 169. (S)-quininecyclo-3-yl(5-(3,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0926] 1 H-NMR (400MHz, CDCl3) δ7.43 (m, 1H), 7.38 (s, 1H), 7.26 (m, 1H), 6.71 (s, 2H), 6.46 (s, 1H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.85 (s, 6H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.87 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0927] Example 170. (S)-quininecyclo-3-yl(5-(4-ethoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0928] 1H-NMR (400MHz, CDCl3) δ7.75 (s, 1H), 7.66 (d, 1H), 7.34 (m, 2H), 7.26 (m, 1H), 7.04 (d, 1H), 5.00 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 4.16 (m, 2H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.87 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.45 (t, 3H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0929] Example 171. (S)-quininecyclo-3-yl(5-(2,5-difluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0930] 1 H-NMR (400MHz, CDCl3) δ7.32 (m, 3H), 7.16 (m, 1H), 6.78 (m, 1H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.91 (s, 3H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.87 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0931] Example 172. (S)-quininecyclo-3-yl(5-(2-fluoro-5-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0932] 1 H-NMR (400MHz, CDCl3) δ7.37 (m, 2H), 7.26 (m, 1H), 7.04 (t, 1H), 6.91 (m, 1H), 6.80 (m, 1H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 4.51 (m, 1H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.87 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.33 (d, 6H), 1.30 (m, 3H), 0.98 (m, 3H)

[0933] Example 173. (S)-Quininecyclo-3-yl(5-(3,5-dimethyl-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0934] 1 H-NMR (400MHz, CDCl3) δ7.39 (m, 1H), 7.35 (s, 1H), 7.25 (m, 1H), 7.21 (s, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.78 (t, 2H), 3.25 (m, 1H ), 2.91~2.74(m,7H),2.34(s,6H),2.10(br,1H),1.85(m,3H),1.70(br,1H),1.64(br,1H),1.40(br,1H),1.30(m,3H),1.10(t,3H),0.98(m,3H)

[0935] Example 174. (S)-quininecyclo-3-yl(5-(4-ethoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0936] 1 H-NMR (400MHz, CDCl3) δ7.39 (m, 1H), 7.35 (s, 1H), 7.25 (m, 1H), 7.22 (s, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.91 (q, 2H), 3.25 (m, 1H) , 2.91~2.74(m,7H),2.34(s,6H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.64(br,1H),1.44(t,3H),1.40(br,1H),1.30(m,3H),0.98(m,3H)

[0937] Example 175. (S)-quininecyclo-3-yl(5-(2-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0938] 1H-NMR (400MHz, CDCl3) δ7.31 (d, 2H), 7.25 (m, 2H), 7.18 (m, 2H), 7.11 (s, 1H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 4.12 (q, 2H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 1.10 (t, 3H), 0.98 (m, 3H)

[0939] Example 176. (S)-quininecyclo-3-yl(5-(2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0940] 1 H-NMR (400MHz, CDCl3) δ7.39 (m, 1H), 7.37~7.25 (m, 4H), 7.04~6.78 (m, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.82 (s, 3H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0941] Example 177. (S)-quininecyclo-3-yl(5-(2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0942] 1 H-NMR (400MHz, CDCl3) δ7.43 (m, 1H), 7.35 (s, 1H), 7.32 ~ 7.23 (m, 3H), 7.03 ~ 6.96 (m, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 4.05 (q, 2H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.37 (t, 3H), 1.30 (m, 3H), 0.98 (m, 3H)

[0943] Example 178. (S)-quininecyclo-3-yl(5-(2-chloro-5-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0944] 1 H-NMR (400MHz, CDCl3) δ7.48 (d, 1H), 7.26 (m, 2H), 7.21 (d, 2H), 7.14 (d, 1H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0945] Example 179. (S)-quininecyclo-3-yl(5-(4-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0946] 1 H-NMR (400MHz, CDCl3) δ7.27 (m, 1H), 7.25 (m, 3H), 6.70 (m, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.80 (s, 3H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0947] Example 180. (S)-quininecyclo-3-yl(5-(4-methoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0948] 1 H-NMR (400MHz, CDCl3) δ7.26 (m, 1H), 7.15 (m, 3H), 6.77 (m, 2H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 3.84 (s, 3H), 3.25 (m, 1H) , 2.91~2.74(m,7H),2.26(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.64(br,1H),1.40(br,1H),1.30(m,3H),0.98(m,3H)

[0949] Example 181. (S)-quininecyclo-3-yl(5-(4-(tert-butoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0950] 1 H-NMR (400MHz, CDCl3) δ7.54 (d, 2H), 7.40 (m, 4H), 7.26 (m, 1H), 4.99 (m, 1H), 4.92 (br, 1H), 4.79 (br, 1H), 4.48 (s, 2H), 3.25 (m, 1H) , 2.91~2.74(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.64(br,1H),1.40(br,1H),1.32(s,9H),1.30(m,3H),0.99(m,3H)

[0951] Example 182. (S)-quininecyclo-3-yl(5-(2-chloro-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0952] 1 H-NMR (400MHz, CDCl3) δ7.72 (d, 1H), 7.49 (d, 1H), 7.40 (m, 1H), 7.32 (m, 1H), 7.22 (m, 2H), 5.00 (m, 2H), 4.79 (br, 1H), 3.25 ( m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0953] Example 183. (S)-quininecyclo-3-yl(5-(2-chloro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0954] 1H-NMR (400MHz, CDCl3) δ7.74 (s, 1H), 7.57 (d, 1H), 7.43 (d, 1H), 7.33~7.23 (m, 3H), 5.00 (m, 2H), 4.79 (br, 1H), 3.25 (m, 1 H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[0955] Example 184. (S)-quininecyclo-3-yl(5-(2,6-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0956] 1 H-NMR (400MHz, CDCl3) δ7.56 (d, 1H), 7.36 (m, 1H), 7.49 (m, 1H), 7.32 (s, 1H), 6.38 (d, 1H), 4.99 (m, 1H), 4.86 (br, 1H), 4.79 (br, 1H), 3.97 (s, 6H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0957] Example 185. (S)-quininecyclo-3-yl(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0958] 1 H-NMR (400MHz, CDCl3) δ8.32 (s, 1H), 7.78 (d, 1H), 7.33 (m, 3H), 6.83 (d, 1H), 4.99 (m, 1H), 4.86 (br, 1H), 4.79 (br, 1H), 4.15 (d, 2H), 3.25 (m, 1H) , 2.91~2.74(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.64(br,1H),1.40(br,1H),1.30(m,3H),0.98(m,3H),0.63(m,2H),0.37(m,2H)

[0959] Example 186. (S)-quininecyclo-3-yl(5-(benzo[b]thiophen-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0960] 1 H-NMR (400MHz, CDCl3) δ7.67 (m, 2H), 7.57 (m, 3H), 7.48 (m, 2H), 7.30 (m, 1H), 4.99 (m, 1H), 4.86 (br, 1H), 4.79 (br, 1H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0961] Example 187. (S)-quininecyclo-3-yl(5-(2-(tert-butoxy)pyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0962] 1 H-NMR (400MHz, CDCl3) δ8.16 (d, 1H), 7.45 (m, 2H), 7.28 (m, 1H), 7.03 (d, 1H), 6.85 (s, 1H), 5.00 (m, 1H), 4.86 (br, 1H), 4.79 (br, 1H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.61 (s, 9H), 1.40 (br, 1H), 1.30 (m, 3H), 0.98 (m, 3H)

[0963] Example 188. (S)-quininecyclo-3-yl(5-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0964] 1H-NMR (400MHz, CDCl3) δ8.50 (s, 1H), 8.03 (s, 1H), 7.33 (m, 3H), 5.00 (m, 1H), 4.86 (br, 1H), 4.79 (br, 1H), 4.09 (s, 3H), 3.25 (m, 1H) , 2.91~2.74(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.64(br,1H),1.61(s,9H),1.40(br,1H),1.30(m,3H),0.98(m,3H)

[0965] Example 189. (S)-Quininecyclo-3-yl(5-(6-methoxynaphthyl-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0966] 1 H-NMR (400MHz, CDCl3) δ7.96 (s, 1H), 7.81 (m, 2H), 7.70 (m, 1H), 7.54 (m, 2H), 7.32 (m, 1H), 7.18 (m, 2H), 5.02 (m, 1H), 4.86 (br, 1H), 4.79 (br, 1H) , 3.96 (s, 3H), 3.25 (m, 1H), 2.91 ~ 2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.32 (m, 3H), 1.00 (m, 3H)

[0967] Example 190. (S)-quininecyclo-3-yl(5-([1,1'-biphenyl]-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0968] 1 H-NMR (400MHz, CDCl3) δ7.78 (s, 1H), 7.66 (m, 2H), 7.56 (m, 1H), 7.50 (m, 5H), 7.39 (m, 2H), 7.33 (m, 1H), 5.05 (m, 1H), 4.92 (br, 1H), 4.82 ( br, 1H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.32 (m, 3H), 1.00 (m, 3H)

[0969] Example 191. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(quinoxalo-6-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0970] 1 H-NMR (400MHz, CDCl3) δ8.85 (d, 2H), 8.28 (s, 1H), 8.16 (m, 1H), 8.04 (m, 1H), 7.59 (m, 2H), 7.33 (m, 1H), 5.02 (m, 2H), 4.79 (br, 1H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.32 (m, 3H), 1.00 (m, 3H)

[0971] Example 192. (S)-quininecyclo-3-yl(5-(3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0972] 1 H-NMR (400MHz, CDCl3) δ7.41 (m, 2H), 7.26 (m, 1H), 7.19 (s, 2H), 6.99 (s, 1H), 4.99 (m, 1H), 4.81 (br, 1H), 4.79 (br, 1H), 3.25 (m, 1H) , 2.91~2.74(m,7H),2.38(s,6H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.64(br,1H),1.40(br,1H),1.31(m,3H),0.99(m,3H)

[0973] Example 193. (S)-quininecyclo-3-yl(5-(furan-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0974] 1H-NMR (400MHz, CDCl3) δ7.54 (m, 1H), 7.49 (s, 1H), 7.45 (s, 1H), 7.23 (m, 1H), 6.63 (m, 1H), 6.47 (m, 1H), 4.99 (m, 1H), 4.81 (br, 1H), 4.79 (br, 1H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.38 (s, 6H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.31 (m, 3H), 0.99 (m, 3H)

[0975] Example 194. (S)-quininecyclo-3-yl(5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0976] 1 H-NMR (400MHz, CDCl3) δ7.40 (m, 1H), 7.36 (s, 1H), 7.25 (m, 3H), 4.98 (m, 1H), 4.81 (br, 1H), 4.79 (br, 1H), 4.13 (m, 1H), 3.25 (m, 1H), 2.91 ~2.74(m,7H),2.33(s,6H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.64(br,1H),1.40(br,1H),1.33(d,6H),1.31(m,3H),0.99(m,3H)

[0977] Example 195. (S)-quininecyclo-3-yl(5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0978] 1 H-NMR (400MHz, CDCl3) δ7.39 (m, 1H), 7.35 (s, 1H), 7.27 (m, 3H), 4.99 (m, 1H), 4.81 (br, 1H), 4.79 (br, 1H), 3.76 (s, 3H), 3.25 (m, 1H), 2.91 ~2.74(m,7H),2.35(s,6H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.64(br,1H),1.40(br,1H),1.33(d,6H),1.31(m,3H),0.99(m,3H)

[0979] Example 196. (S)-quininecyclo-3-yl(5-(6-isopropoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0980] 1 H-NMR (400MHz, CDCl3) δ8.34 (s, 1H), 7.76 (d, 1H), 7.30 (m, 3H), 6.74 (d, 1H), 5.35 (m, 1H), 4.99 (m, 1H), 4.81 (br, 1H), 4.79 (br, 1H), 3.25 (m, 1H), 2.91 ~ 2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.64 (br, 1H), 1.40 (br, 1H), 1.38 (d, 6H), 1.31 (m, 3H), 0.99 (m, 3H)

[0981] Example 197. (S)-quininecyclo-3-yl(5-(3-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0982] 1 H-NMR (400MHz, CDCl3) δ7.42 (m, 1H), 7.34 (m, 1H), 7.27 (m, 1H), 7.19 (d, 1H ), 7.14(s, 1H), 6.91(d, 1H), 5.00(m, 1H), 4.96(m, 3H), 4.79(m, 1H), 4.33( m, 1H), 4.25 (m, 1H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (b r, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.31 (m, 3H), 1.00 (m, 3H)

[0983] Example 198. (S)-quininecyclo-3-yl(5-(2-ethoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0984] 1H-NMR (400MHz, CDCl3) δ7.41 (m, 1H), 7.34 (s, 1H), 7.22 (m, 1H), 7.09 (s, 1H), 7 .07(d,1H), 6.88(d,1H), 4.99(m,1H), 4.96(m,1H), 4.79(m,1H), 4.00(m,2H), 3.25(m,1H),2.91~2.73(m,7H),2.33(s,3H),2.10(br,1H),1.85(br,1H),1.7 0(br,1H),1.60(br,1H),1.40(br,1H),1.31(m,3H),1.29(m,3H),1.00(m,3H)

[0985] Example 199. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[0986] 1 H-NMR (400MHz, CDCl3) δ7.44(m, 1H), 7.35(s, 1H), 7.31(m, 2H), 7.15(m, 1H ), 7.11(s, 1H), 6.88(m, 1H), 5.00(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.01( t, 2H), 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (m, 3H), 1.70 (b r, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 1.06 (t, 3H), 0.99 (m, 3H)

[0987] Example 200. (S)-quininecyclo-3-yl(5-(2-methoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0988] 1 H-NMR (400MHz, CDCl3) δ7.36 (m, 1H), 7.31 (s, 1H), 7.27 (m, 1H), 7.10 (m, 2H), 6.98 (d, 1H), 4.98 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 3.79 (s, 3H), 3.25(m,1H),2.91~2.73(m,7H),2.33(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[0989] Example 201. (S)-quininecyclo-3-yl(5-(2-butoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0990] 1 H-NMR (400MHz, CDCl3) δ7.36 (m, 1H), 7.34 (s, 1H), 7.25 (m, 1H), 7.05 (m, 1 H), 6.95 (m, 1H), 6.89 (m, 1H), 4.98 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 3.90 (t, 2H), 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (m, 3H), 1.60 (br, 1H), 1.40 (m, 3H), 1.30 (m, 3H), 0.99 (m, 3H), 0.91 (t, 3H)

[0991] Example 202. (S)-quininecyclo-3-yl(5-(4-butoxy-3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0992] 1 H-NMR (400MHz, CDCl3) δ7.59 (s, 1H), 7.39 (m, 2H), 7.33 (s, 1H), 7.26 (m, 1H), 6.97 (d, 1H), 4.98 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 4.09 (t, 2H) , 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (m, 3H), 1.70 (br, 1H), 1.60 (m, 3H), 1.40 (br, 3H), 1.30 (m, 3H), 0.99 (m, 3H), 0.97 (t, 3H)

[0993] Example 203. (S)-quininecyclo-3-yl(5-(2,4-dipropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0994] 1H-NMR (400MHz, CDCl3) δ7.38 (m, 1H), 7.33 (s, 1H), 7.22 (m, 2H), 6.55 (s, 1 H), 6.54(m, 1H), 4.98(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.95(m, 2H), 3.91 (m, 2H), 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (m, 3H), 1.70 ( m, 3H), 1.60 (br, 1H), 1.40 (br, 3H), 1.30 (m, 3H), 1.05 (t, 3H), 0.99 (m, 6H)

[0995] Example 204. (S)-quininecyclo-3-yl(5-(3-chloro-4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0996] 1 H-NMR (400MHz, CDCl3) δ7.60 (s, 1H), 7.41 (m, 2H), 7.33 (s, 1H), 7.26 (m, 1H), 6.97 (d, 1H), 4.99 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 4.15 (m, 2H), 3.25(m,1H),2.91~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.50(t,3H),1.40(br,3H),1.30(m,3H),0.99(m,3H)

[0997] Example 205. (S)-quininecyclo-3-yl(5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[0998] 1 H-NMR (400MHz, CDCl3) δ7.44(m, 1H), 7.39(s, 1H), 7.31~7.26(m, 2H), 7.14( d, 1H), 7.11 (s, 1H), 6.87 (d, 1H), 4.99 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 3. 78(d, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(m, 2H), 1.85(br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 3H), 1.30 (m, 3H), 1.06 (d, 6H), 0.99 (m, 3H)

[0999] Example 206. (S)-quininecyclo-3-yl(5-(4-ethoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1000] 1 H-NMR (400MHz, CDCl3) δ7.25 (m, 1H), 7.14 (m, 3H), 6.81 (s, 1H), 6.76 (d, 1H), 4.99 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 4.06 (m, 2H), 3.25 ( m, 1H), 2.91 ~ 2.73 (m, 7H), 2.24 (s, 3H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.43 (m, 4H), 1.30 (m, 3H), 1.00 (m, 3H)

[1001] Example 207. (S)-quininecyclo-3-yl(5-(3-chloro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1002] 1 H-NMR (400MHz, CDCl3) δ7.59 (s, 1H), 7.38 (m, 3H), 7.25 (m, 1H), 6.97 (d, 1H), 4.99 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 4.05 (m, 2H), 3.25 ( m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (m, 3H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 1.11 (t, 3H), 0.99 (m, 3H)

[1003] Example 208. (S)-quininecyclo-3-yl(5-(5-fluoro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1004] 1H-NMR (400MHz, CDCl3) δ7.38 (m, 1H), 7.34 (s, 1H), 7.25 (m, 1H), 7.02 (d, 1H), 6.92 (m, 2H), 4.99 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 4.24 (m, 1H), 3.25(m,1H),2.91~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),1.20(d,6H),0.99(m,3H)

[1005] Example 209. (S)-quininecyclo-3-yl(5-(3-fluoro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1006] 1 H-NMR (400MHz, CDCl3) δ7.38 (m, 1H), 7.36 (s, 1H), 7.32~7.24 (m, 3H), 7.01 (t, 1H), 6.92 (m, 2H), 4.99 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 4.57 (m, 1 H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br , 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.38 (d, 6H), 1.30 (m, 3H), 0.99 (m, 3H)

[1007] Example 210. (S)-quininecyclo-3-yl(5-(5-chloro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1008] 1 H-NMR (400MHz, CDCl3) δ7.36 (m, 1H), 7.27 (m, 4H), 6.90 (d, 1H), 4.99 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 3.80 (s, 3H), 3.25 ( m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1009] Example 211. (S)-quininecyclo-3-yl(5-(2-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1010] 1 H-NMR (400MHz, CDCl3) δ7.37 (m, 2H), 7.29 (m, 1H), 7.20 (d, 1H), 7.07 (m, 1H), 7.00 (m, 1H), 4.99 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 3.25 ( m, 1H), 2.91~2.73 (m, 7H), 2.36 (s, 3H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1011] Example 212. (S)-quininecyclo-3-yl(5-(5-chloro-2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1012] 1 H-NMR (400MHz, CDCl3) δ7.38 (m, 1H), 7.31~7.25 (m, 3H), 7.21 (m, 1H), 6.88 (d, 1H), 4.99 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 4.00 (m, 1 H), 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 6H), 0.99 (m, 3H)

[1013] Example 213. (S)-quininecyclo-3-yl(5-(5-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1014] 1H-NMR (400MHz, CDCl3) δ7.37 (m, 1H), 7.34 (s, 1H), 7.25 (m, 1H), 7.03 (d, 1H), 6.93 (m, 1H), 6.88 (m, 1H), 5.00 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H) , 3.88 (m, 1H), 3.25 (m, 1H), 2.91 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (m, 3H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 6H)

[1015] Example 214. (S)-quininecyclo-3-yl(5-(2-fluoro-6-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1016] 1 H-NMR (400MHz, CDCl3) δ7.25 (m, 4H), 6.76 (m, 2H), 5.00 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 3.91 (m, 1H), 3.25 (m, 1H), 2.91~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (m, 3H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H), 0.91 (t, 3H)

[1017] Example 215. (S)-quininecyclo-3-yl(5-(3-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1018] 1 H-NMR (400MHz, CDCl3) δ7.40 (m, 1H), 7.36 (s, 1H), 7.25 (m, 4H), 5.00 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 3.25 (m, 1H), 2.91~ 2.73(m,7H),2.31(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1019] Example 216. (S)-quininecyclo-3-yl(5-(3-fluoro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1020] 1 H-NMR (400MHz, CDCl3) δ7.38 (m, 1H), 7.33 (s, 1H), 7.25 (m, 3H), 7.01 (t, 1H), 5.00 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 4.05 (t, 2H), 3.25 ( m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (m, 3H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 1.07 (t, 3H), 0.99 (m, 3H)

[1021] Example 217. (S)-quininecyclo-3-yl(5-(5-chloro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1022] 1 H-NMR (400MHz, CDCl3) δ7.38 (m, 1H), 7.31 (s, 1H), 7.28 (m, 1H), 7.20 (d, 2H), 6.89 (d, 1H), 5.00 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H), 4.36 (m, 1H), 3.25(m,1H),2.91~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),1.28(d,6H),0.99(m,3H)

[1023] Example 218. (S)-quininecyclo-3-yl(5-(3-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1024] 1 H-NMR (400MHz, CDCl3) δ7.44 (m, 1H), 7.34 (s, 1H), 7.32 (m, 2H), 7.15 (d, 1H), 7.10 (s, 1H), 6.87 (m, 1H), 5.00 (m, 1H), 4.96 (m, 1H), 4.79 (m, 1H) , 4.03 (t, 2H), 3.25 (m, 1H), 2.91 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (m, 3H), 1.70 (br, 1H), 1.60 (m, 3H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1025] Example 219. (S)-quininecyclo-3-yl(5-(3-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1026] 1 H-NMR (400MHz, CDCl3) δ7.41 (m, 1H), 7.36 (s, 1H), 7.27 (m, 1H), 7.16 (s, 1H), 7.05 (d, 1H), 6.85 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25(m,1H),2.91~2.73(m,7H),2.41(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1027] Example 220. (S)-quininecyclo-3-yl(5-(5-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1028] 1 H-NMR (400MHz, CDCl3) δ7.27 (m, 1H), 7.25 (m, 1H), 7.18 (m, 1H), 7.13 (s, 1H), 6.96 (m, 1H), 6.92 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25(m,1H),2.91~2.73(m,7H),2.21(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1029] Example 221. (S)-quininecyclo-3-yl(5-(2-chloro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1030] 1H-NMR (400MHz, CDCl3) δ7.65 (m, 2H), 7.51 (m, 1H), 7.26 (m, 3H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.91~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1031] Example 222. (S)-quininecyclo-3-yl(5-(3-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1032] 1 H-NMR (400MHz, CDCl3) δ7.41 (m, 1H), 7.36 (s, 1H), 7.26 (m, 1H), 6.89 (m, 2H), 6.58 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.86 ( s, 3H), 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1033] Example 223. (S)-quininecyclo-3-yl(5-(2-chloro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1034] 1 H-NMR (400MHz, CDCl3) δ7.33 (d, 1H), 7.26 (m, 2H), 7.23 (s, 1H), 7.14 (s, 1H), 7.07 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 ( m, 1H), 2.91~2.73 (m, 7H), 2.34 (s, 3H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1035] Example 224. (S)-quininecyclo-3-yl(5-(3-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1036] 1 H-NMR (400MHz, CDCl3) δ7.43 (m, 3H), 7.28 (m, 1H), 7.25 (s, 1H), 7.10 (s, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.91 (s, 3H), 3.25 ( m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.45 (t, 3H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1037] Example 225. (S)-quininecyclo-3-yl(5-(2-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1038] 1 H-NMR (400MHz, CDCl3) δ7.29 (m, 2H), 2.22 (m, 3H), 7.02 (m, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.91~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.31(m,3H),0.99(m,3H)

[1039] Example 226. (S)-quininecyclo-3-yl(5-(4-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1040] 1 H-NMR (400MHz, CDCl3) δ7.37 (m, 2H), 7.28 (m, 1H), 7.13 (m, 2H), 7.08 (m, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.96 (s, 3H), 3.25(m,1H),2.91~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1041] Example 227. (S)-quininecyclo-3-yl(5-(3,4-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1042] 1 H-NMR (400MHz, CDCl3) δ7.41 (m, 1H), 7.38 (m, 2H), 7.27 (m, 2H), 7.19 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.91~ 2.73(m,7H),2.33(s,3H),2.31(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1043] Example 228. (S)-quininecyclo-3-yl(5-(4-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1044] 1 H-NMR (400MHz, CDCl3) δ7.25(m, 1H), 7.17~7.08(m, 3H), 6.98~6.90(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m,7H),2.25(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1045] Example 229. (S)-quininecyclo-3-yl(5-(2-fluoro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1046] 1H-NMR (400MHz, CDCl3) δ7.54 (m, 1H), 7.46 (m, 1H), 7.41~7.36 (m, 4H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1 H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1047] Example 230. (S)-quininecyclo-3-yl(5-(2-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1048] 1 H-NMR (400MHz, CDCl3) δ7.39~7.27 (m, 3H), 7.04 (t, 1H), 6.91 (m, 1H), 6.83 (m, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.83 (s, 3 H), 3.25 (m, 1H), 2.91~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1049] Example 231. (S)-quininecyclo-3-yl(5-(2-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1050] 1 H-NMR (400MHz, CDCl3) δ7.40~7.27 (m, 3H), 7.12 (t, 1H), 6.97 (m, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.93 (s, 3H), 3.2 5(m,1H),2.91~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1051] Example 232. (S)-quininecyclo-3-yl(5-(5-isopropyl-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1052] 1 H-NMR (400MHz, CDCl3) δ7.40 (m, 1H), 7.36 (s, 1H), 7.27 (m, 1H), 7.18 (m, 2H ), 6.91(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.80(s, 3H), 3.25( m, 1H), 2.91 (m, 1H), 2.90~2.75 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 ( br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 1.26 (d, 6H), 0.99 (m, 3H)

[1053] Example 233. (S)-quininecyclo-3-yl(5-(2-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1054] 1 H-NMR (400MHz, CDCl3) δ7.36~7.27 (m, 4H), 6.98 (m, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.91~2.7 4(m,7H),2.39(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1055] Example 234. (S)-quininecyclo-3-yl(5-(5-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1056] 1 H-NMR (400MHz, CDCl3) δ7.37 (m, 1H), 7.31 (s, 1H), 7.27 (m, 1H), 7.02 (m, 1H), 6.97 (m, 1H), 6.91 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.79(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1057] Example 235. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(5-methylfuran-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1058] 1 H-NMR (400MHz, CDCl3) δ7.47 (m, 1H), 7.45 (s, 1H), 7.19 (m, 1H), 6.51 (s, 1H), 6.04 (s, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 ( m, 1H), 2.91~2.73 (m, 7H), 2.31 (s, 3H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1059] Example 236. (S)-quininecyclo-3-yl(5-(3-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1060] 1 H-NMR (400MHz, CDCl3) δ7.36~7.26 (m, 3H), 7.07 (m, 3H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.73 (s, 3H), 3.25 (m, 1 H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 6H)

[1061] Example 237. (S)-quininecyclo-3-yl(5-(2-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1062] 1 H-NMR (400MHz, CDCl3) δ7.30~7.23 (m, 4H), 7.13 (m, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.9 1~2.74(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,6H)

[1063] Example 238. (S)-quininecyclo-3-yl(5-(benzo[b]thiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1064] 1 H-NMR (400MHz, CDCl3) δ7.92 (m, 2H), 7.46~7.33 (m, 6H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.9 1~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.30(m,3H),0.99(m,3H)

[1065] Example 239. (S)-quininecyclo-3-yl(5-(4-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1066] 1 H-NMR (400MHz, CDCl3) δ7.35 (m, 1H), 7.30 (s, 1H), 7.25 (m, 2H), 6.70 (m, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.91 (t, 2H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (m, 3H), 1.60 (br, 1H), 1.40 (br, 1H), 1.30 (m, 3H), 0.99 (m, 6H)

[1067] Example 240. (S)-quininecyclo-3-yl(5-(3-(tert-butyl)-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1068] 1 H-NMR (400MHz, CDCl3) δ7.44 (m, 1H), 7.40 (s, 2H), 7.26 (m, 1H), 7.20 (s, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.91~ 2.74(m,7H),2.42(s,3H),2.10(br,1H),1.85(br,1H),1.70(m,3H),1.60(br,1H),1.40(br,1H),1.37(s,9H),1.30(m,3H),0.99(m,6H)

[1069] Example 241. (S)-quininecyclo-3-yl(5-(2-chloro-5-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1070] 1 H-NMR (400MHz, CDCl3) δ7.34 (d, 1H), 7.28 (d, 2H), 7.23 (s, 1H), 6.85 (s, 1H), 6.81 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 4.00 (q, 2H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (m, 3H), 1.60 (br, 1H), 1.41 (m, 4H), 1.30 (m, 3H), 0.99 (m, 6H)

[1071] Example 242. (S)-quininecyclo-3-yl(5-(4-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1072] 1 H-NMR (400MHz, CDCl3) δ7.44(m, 1H), 7.37(m, 3H), 7.28(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.41(br,1H),1.30(m,3H),0.99(m,3H)

[1073] Example 243. (S)-quininecyclo-3-yl(5-(2-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1074] 1H-NMR (400MHz, CDCl3) δ7.38 (m, 2H), 7.35~7.23 (m, 2H), 7.14 (m, 1H), 7.08 (t, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1 H), 2.91~2.74(m, 7H), 2.34(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1075] Example 244. (S)-quininecyclo-3-yl(5-(5-cyano-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1076] 1 H-NMR (400MHz, CDCl3) δ7.64 (d, 1H), 7.57 (s, 1H), 7.31 (m, 3H), 7.02 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.88 (s, 3H), 3.25(m,1H),2.91~2.74(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.41(br,1H),1.30(m,3H),0.99(m,3H)

[1077] Example 245. (S)-quininecyclo-3-yl(5-(3-ethoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1078] 1 H-NMR (400MHz, CDCl3) δ7.43 (d, 1H), 7.38 (s, 2H), 7.30 (m, 2H), 7.09 (s, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 4.13 (m, 2H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.41 (m, 3H), 1.30 (m, 3H), 0.99 (m, 3H)

[1079] Example 246. (S)-Quininecyclo-3-yl(5-(3-fluoro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1080] 1 H-NMR (400MHz, CDCl3) δ7.61 (s, 1H), 7.45 (m, 2H), 7.32 (s, 1H), 7.30 ~ 7.27 (m, 2H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.2 5(m,1H),2.91~2.74(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.41(br,1H),1.30(m,3H),0.99(m,3H)

[1081] Example 247. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(3-methyl-4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1082] 1 H-NMR (400MHz, CDCl3) δ7.43 (s, 1H), 7.38 (m, 3H), 7.26 (m, 3H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.91~ 2.74(m,7H),2.38(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.41(br,1H),1.30(m,3H),0.99(m,3H)

[1083] Example 248. (S)-Quininecyclo-3-yl(2,2-dimethyl-5-(3-(methylthio)-5-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1084] 1 H-NMR (400MHz, CDCl3) δ7.57 (d, 2H), 7.38 (m, 3H), 7.29 (m, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.91~ 2.74(m,7H),2.57(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.41(br,1H),1.30(m,3H),0.99(m,3H)

[1085] Example 249. (S)-quininecyclo-3-yl(5-(3-fluoro-4-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1086] 1 H-NMR (400MHz, CDCl3) δ7.41~7.27 (m, 6H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.91~2.7 4(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.60(br,1H),1.41(br,1H),1.30(m,3H),0.99(m,3H)

[1087] Example 250. (S)-quininecyclo-3-yl(5-(2-ethoxy-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1088] 1 H-NMR (400MHz, CDCl3) δ7.40 (m, 2H), 7.33 (s, 1H), 7.26 (m, 2H), 7.17 (s, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 4.10 (m, 2H) , 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.41 (m, 4H), 1.30 (m, 3H), 0.99 (m, 3H)

[1089] Example 251. (S)-quininecyclo-3-yl(5-(2-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1090] 1H-NMR (400MHz, CDCl3) δ7.57 (d, 1H), 7.54 (s, 1H), 7.37 (m, 1H), 7.29 (s, 2H), 7.02 (d, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.86 ( s, 3H), 3.25 (m, 1H), 2.91 ~ 2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.41 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1091] Example 252. (S)-quininecyclo-3-yl(5-(2,4-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1092] 1 H-NMR (400MHz, CDCl3) δ8.00 (s, 1H), 7.81 (d, 1H), 7.48 (d, 1H), 7.26 (m, 1H), 7.14 (m, 1H), 7.12 (s, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 ( m, 1H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.41 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1093] Example 253. (S)-quininecyclo-3-yl(5-(3-chloro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1094] 1 H-NMR (400MHz, CDCl3) δ7.36 (d, 1H), 7,26 (m, 1H), 7.17~7.08 (m, 4H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1H), 2.9 1~2.74(m,7H),2.25(s,3H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.41(br,1H),1.30(m,3H),0.99(m,3H)

[1095] Example 254. (S)-quininecyclo-3-yl(5-(3-methoxy-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1096] 1 H-NMR (400MHz, CDCl3) δ7.44 (m, 1H), 7.40 (s, 1H), 7,26 (m, 1H), 7.18 (d, 1H), 7.06 (d, 1H), 7.02 (s, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.90 (s, 3H), 3.25 (m, 1H), 2.91 ~ 2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.41 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1097] Example 255. (S)-quininecyclo-3-yl(5-(4-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1098] 1 H-NMR (400MHz, CDCl3) δ7.38~7.29 (m, 4H), 7,26 (m, 1H), 7.03 (t, 1H), 7.02 (s, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 (m, 1 H), 2.91~2.74(m, 7H), 2.34(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1099] Example 256. (S)-quininecyclo-3-yl(5-(2-ethoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1100] 1H-NMR (400MHz, CDCl3) δ7.40 (m, 1H), 7.33 (s, 1H), 7.25 (m, 1H), 7.05 (m, 1H), 6.95 (m, 1H), 6.88 (m, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.99 (m, 2H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.41 (br, 1H), 1.30 (m, 6H), 0.99 (m, 3H)

[1101] Example 257. (S)-quininecyclo-3-yl(5-(3-fluoro-5-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1102] 1 H-NMR (400MHz, CDCl3) δ7.37 (m, 1H), 7.35 (s, 1H), 7.27 (m, 1H), 7.02 (t, 1H ), 6.92(m, 1H), 6.81(m, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.93( m, 2H), 3.25 (m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (m, 3H), 1.70 (b r, 1H), 1.59 (br, 1H), 1.41 (br, 1H), 1.30 (m, 3H), 1.05 (t, 3H), 0.99 (m, 3H)

[1103] Example 258. (S)-quininecyclo-3-yl(5-(3,5-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1104] 1 H-NMR (400MHz, CDCl3) δ7.99 (s, 2H), 7.85 (s, 1H), 7.44 (m, 2H), 7.32 (m, 1H), 4.99 (m, 1H), 4.88 (m, 1H), 4.80 (m, 1H), 3.25 ( m, 1H), 2.91~2.74 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.41 (br, 1H), 1.30 (m, 3H), 0.99 (m, 3H)

[1105] Example 259. (S)-quininecyclo-3-yl(5-(3-chloro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1106] 1 H-NMR (400MHz, CDCl3) δ7.56 (s, 1H), 7.36 (m, 3H), 7.28 (m, 2H), 4.96 (s, 2H), 4.80 (br, 1H), 3.25 (m, 1H), 2.89~2.73 ( m, 7H), 2.39 (s, 3H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (br, 1H), 1.40 (br, 1H), 1.29 (m, 3H), 0.98 (m, 3H)

[1107] Example 260. (S)-quininecyclo-3-yl(5-(2,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1108] 1 H-NMR (400MHz, CDCl3) δ7.25 (m, 1H), 7.16 (t, 3H), 7.06 (m, 2H), 4.96 (s, 2H), 4.80 (br, 1H), 3.25 (m, 1H), 2.89~2.73 (m, 7H), 2.34(s, 3H), 2.20(s, 3H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1109] Example 261. (S)-quininecyclo-3-yl(5-(3-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1110] 1 H-NMR (400MHz, CDCl3) δ7.60 (d, 1H), 7.42 (m, 1H), 7.35 (m, 3H), 7.19 (t, 1H), 4.96 (s, 2H), 4.80 (br, 1H), 3.25 (m, 1H) , 2.89~2.73(m,7H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(br,1H),1.40(br,1H),1.29(m,3H),0.98(m,3H)

[1111] Example 262. (S)-quininecyclo-3-yl(5-(6-ethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1112] 1 H-NMR (400MHz, CDCl3) δ8.33 (s, 1H), 7.76 (d, 1H), 7.69 (m, 1H), 7.51 (m, 1H), 7.46 (m, 1H), 7.36~7.27 (m, 1H), 6.77 (d, 1H), 4.96 (s, 2H), 4.80 (br, 1H), 4.37(m, 2H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.05(br, 1H), 1.85(br , 1H), 1.68(br, 1H), 1.58(br, 1H), 1.39(m, 4H), 1.29(m, 3H), 0.98(m, 3H)

[1113] Example 263. (S)-quininecyclo-3-yl(5-(2-ethoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1114] 1 H-NMR (400MHz, CDCl3) δ8.17 (d, 1H), 7.46 (m, 2H), 7.30 (m, 1H), 7.06 (d, 1H), 6.91 (s, 1H), 4.97 (m, 2H), 4.80 (br, 1H), 4.38 (m, 2H) , 3.24 (m, 1H), 2.89~2.73 (m, 7H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (br, 1H), 1.40 (m, 4H), 1.30 (m, 3H), 0.96 (m, 3H)

[1115] Example 264. (S)-quininecyclo-3-yl(5-(2-isopropoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1116] 1H-NMR (400MHz, CDCl3) δ8.17 (d, 1H), 7.44 (m, 2H), 7.31 (m, 1H), 7.04 (d, 1H), 6.87 (s, 1H), 5.34 (m, 1H), 4.97 (s, 2H), 4.80 (br, 1H), 3.24 ( m, 1H), 2.89~2.73 (m, 7H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (br, 1H), 1.40 (br, 1H), 1.36 (d, 6H), 1.28 (m, 3H), 0.97 (m, 3H)

[1117] Example 265. (S)-quininecyclo-3-yl(2,2-dimethyl-5-(6-propoxypyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1118] 1 H-NMR (400MHz, CDCl3) δ8.34 (s, 1H), 7.76 (d, 1H), 7.34~7.32 (m, 3H), 6.79 (d, 1H), 4.96 (m, 2H), 4.80 (br, 1H), 4.28 (m, 2H), 3.25 (m, 1H), 2. 89~2.74(m,7H),2.05(br,1H),1.85(br,1H),1.81(m,2H),1.68(br,1H),1.58(br,1H),1.40(br,1H),1.29(m,3H),1.06(t,3H),0.98(m,3H)

[1119] Example 266. (S)-quininecyclo-3-yl(5-(6-butoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1120] 1 H-NMR (400MHz, CDCl3) δ8.33 (s, 1H), 7.76 (d, 1H), 7.34~7.31 (m, 3H), 6.78 (d, 1H), 4.96 (s, 2H), 4.80 (br, 1H), 4.31 (m, 2H), 3.25 (m, 1H), 2.89~2.7 3(m,7H),2.05(br,1H),1.85(br,1H),1.78(m,2H),1.68(br,1H),1.58(b r, 1H), 1.48 (m, 2H), 1.40 (br, 1H), 1.29 (m, 3H), 1.06 (t, 3H), 0.98 (m, 6H)

[1121] Example 267. (S)-Quininecyclo-3-yl(5-(6-(2-methoxyethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1122] 1 H-NMR (400MHz, CDCl3) δ8.32 (s, 1H), 7.76 (d, 1H), 7.36~7.28 (m, 3H), 6.86 (d, 1H), 4.96 (m, 2H), 4.80 (br, 1H), 4.51 (m, 2H), 3.78 (m, 2H), 3. 45(s, 3H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1123] Example 268. (S)-quininecyclo-3-yl(5-(6-isobutoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1124] 1 H-NMR (400MHz, CDCl3) δ8.34 (s, 1H), 7.76 (d, 1H), 7.35~7.27 (m, 3H), 6.80 (d, 1H), 4.96 (m, 2H), 4.78 (br, 1H), 4.10 (m, 2H), 3.27 (m, 1 H), 2.89~2.74(m, 7H), 2.08(br, 1H), 1.86(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.42(br, 1H), 1.29(m, 3H), 1.00(d, 6H), 0.98(m, 3H)

[1125] Example 269. (S)-quininecyclo-3-yl(5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1126] 1H-NMR (400MHz, CDCl3) δ7.45~7.27 (m, 6H), 7.12 (d, 1H), 4.97 (m, 2H), 4.80 (br, 1H), 3.27 (m, 1H), 2.89~2.74 (m, 7H), 2.5 3(d,2H),2.08(br,1H),1.86(br,1H),1.69(br,1H),1.58(br,1H),1.42(br,1H),1.29(m,3H),0.98(m,3H),0.93(d,6H)

[1127] Example 270. (S)-quininecyclo-3-yl(5-(4-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1128] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.39 (m, 2H), 7.28 (m, 1H), 6.96 (d, 2H), 4.97 (m, 2H), 4.80 (br, 1H), 4.02 (m, 1H), 3.27 (m, 1H), 2.89~2.74 ( m, 7H), 2.53 (d, 2H), 2.08 (br, 1H), 1.86 (br, 1H), 1.77 (m, 2H), 1.69 (br, 1H), 1.58 (br, 1H), 1.52 (m, 2H), 1.42 (br, 1H), 1.29 (m, 3H), 0.98 (m, 6H)

[1129] Example 271. (S)-quininecyclo-3-yl(5-(2,4-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1130] 1 H-NMR (400MHz, CDCl3) δ7.56 (d, 1H), 7.38 (m, 1H), 7.30 (s, 1H), 7.28 (m, 1H), 6.38 (d, 1H), 4.97 (m, 2H), 4.80 (br, 1H), 3.96 (s, 6H) , 3.27 (m, 1H), 2.89~2.74 (m, 7H), 2.08 (br, 1H), 1.86 (br, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.42 (br, 1H), 1.28 (m, 3H), 0.97 (m, 3H)

[1131] Example 272. (S)-quininecyclo-3-yl(5-(2-acetylthiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1132] 1 H-NMR (400MHz, CDCl3) δ7.53 (d, 1H), 7.30~7.19 (m, 3H), 7.03 (d, 1H), 5.02 (m, 1H), 4.94 (m, 1H), 4.79 (br, 1H), 3.28 (m, 1H), 2. 89~2.72(m,7H),2.16(s,3H),2.08(br,1H),1.86(br,1H),1.69(br,1H),1.58(br,1H),1.42(br,1H),1.30(m,3H),0.97(m,3H)

[1133] Example 273. (S)-quininecyclo-3-yl(5-((E)-3-fluorostyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1134] 1 H-NMR (400MHz, CDCl3) δ7.35~7.19 (m, 6H), 7.06 (d, 2H), 6.97 (m, 1H), 4.94 (m, 2H), 4.79 (br, 1H), 3.28 (m, 1H), 2. 89~2.71(m,7H),2.08(br,1H),1.86(br,1H),1.69(br,1H),1.58(br,1H),1.42(br,1H),1.29(m,3H),0.96(m,3H)

[1135] Example 274. (S)-quininecyclo-3-yl(5-((E)-4-ethylstyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1136] 1 H-NMR (400MHz, CDCl3) δ7.44 (d, 2H), 7.34 (s, 1H), 7.21 (m, 4H), 7.07 (s, 2H), 4.94 (m, 2H), 4.79 (br, 1H), 3.28 (m, 1H), 2.89~ 2.71 (m, 7H), 2.63 (m, 2H), 2.08 (br, 1H), 1.86 (br, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.42 (br, 1H), 1.27 (m, 6H), 0.94 (m, 3H)

[1137] Example 275. (S)-quininecyclo-3-yl(5-((E)-2-cyclohexylvinyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1138] 1 H-NMR (400MHz, CDCl3) δ7.18~7.12 (m, 3H), 6.35 (m, 1H), 6.16 (m, 1H), 4.94 (m, 2H), 4.79 (br, 1H), 3.28 (m, 1H), 2.89~2.71 (m, 7 H), 2.08 (br, 1H), 1.86 (br, 1H), 1.76 (m, 5H), 1.69 (br, 2H), 1.58 (br, 1H), 1.42 (br, 1H), 1.27 (m, 3H), 1.15 (m, 3H), 0.94 (m, 3H)

[1139] Examples 276 to 311

[1140] The title compounds of Examples 276 to 311 were prepared using the (S)-quininecyclo-3-yl(5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-yl) carbamate obtained in Preparation Example 5 and the corresponding substituted boric acid, respectively, following the same steps as in Example 1.

[1141] Example 276. (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1142] 1 H-NMR (400MHz, CDCl3) δ7.52 (m, 2H), 7.50~7.27 (m, 3H), 7.11 (t, 2H), 5.13 (m, 1H), 4.90 (m, 1H), 4.78 (m, 1H), 3.26 (m, 1 H), 2.87~2.73(m, 7H), 2.11(br, 1H), 1.88(br, 1H), 1.61(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.95(m, 3H), 0.85(m, 3H)

[1143] Example 277. (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1144] 1H-NMR (400MHz, CDCl3) δ7.49 (d, 2H), 7.40 (m, 1H), 7.25 (m, 3H), 5.12 (m, 1H), 4.93 (m, 1H), 4.78 (m, 1H), 3.26 (m, 1H), 2.87~2.69 ( m, 7H), 2.67 (m, 2H), 2.11 (br, 1H), 1.88 (br, 1H), 1.61 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 1.26 (t, 3H), 0.95 (m, 3H), 0.86 (m, 3H)

[1145] Example 278. (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1146] 1 H-NMR (400MHz, CDCl3) δ7.48 (d, 2H), 7.40 (m, 1H), 7.27 (m, 1H), 7.25 (d, 2H), 5.11 (m, 1H), 4.96 (m, 1H), 4.78 (m, 1H), 3.26 (m, 1H) , 2.87~2.72(m,7H),2.62(m,2H),2.11(br,1H),1.88(br,1H),1.69(m,3H),1.58(m,3H),1.37(br,1H),0.97(m,6H),0.85(m,3H)

[1147] Example 279. (S)-quininecyclo-3-yl(5-(4-(tert-butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1148] 1 H-NMR (400MHz, CDCl3) δ7.51 (d, 2H), 7.45 (d, 3H), 7.37 (m, 1H), 7.27 (m, 1H), 5.12 (m, 1H), 4.94 (m, 1H), 4.78 (m, 1H), 3.26 (m, 1H) , 2.87~2.71(m,7H),2.11(br,1H),1.88(br,1H),1.69(br,1H),1.58(m,3H),1.38(br,1H),1.36(s,9H),0.97(m,6H),0.86(m,3H)

[1149] Example 280. (S)-quininecyclo-3-yl(5-(4-butylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1150] 1 H-NMR (400MHz, CDCl3) δ7.48 (d, 2H), 7.42 (m, 2H), 7.30 (m, 1H), 7.26 (d, 2H), 5.11 (m, 1H), 4.94 (m, 1H), 4.78 (m, 1H), 3.26 (m , 1H), 2.87~2.71(m, 7H), 2.63(m, 2H), 2.11(br, 1H), 1.85(br, 1H), 1.69~1.57(m, 6H), 1.38(m, 3H), 0.94(m, 6H), 0.87(m, 3H)

[1151] Example 281. (S)-quininecyclo-3-yl(5-(4-cyclopropylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1152] 1 H-NMR (400MHz, CDCl3) δ7.46 (d, 2H), 7.40 (m, 1H), 7.30 (m, 1H), 7.28 (m, 1H), 7.14 (d, 2H), 5.12 (m, 1H), 4.94 (m, 1H), 4.78 (m, 1H), 3.26 (m, 1H) , 2.87~2.71(m,7H),2.11(br,1H),1.94(m,1H),1.85(br,1H),1.60(br,1H),1.58(m,3H),1.37(br,1H),0.95(m,5H),0.87(m,3H),0.74(m,2H)

[1153] Example 282. (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1154] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.41 (m, 1H), 7.30 (m, 1H), 7.28 (m, 3H), 5.11 (m, 1H), 4.95 (m, 1H), 4.78 (m, 1H), 3.26 (m, 1H), 2.94 ( m, 1H), 2.88~2.73 (m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 1.29 (d, 6H), 0.98 (m, 3H), 0.87 (m, 3H)

[1155] Example 283. (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1156] 1 H-NMR (400MHz, CDCl3) δ7.50 (d, 2H), 7.38 (m, 1H), 7.30 (m, 2H), 6.96 (d, 2H), 5.12 (m, 1H), 4.91 (m, 1H), 4.88 (m, 1H), 3.85 (s, 3H) , 3.26 (m, 1H), 2.88~2.71 (m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.97 (m, 3H), 0.87 (m, 3H)

[1157] Example 284. (S)-quininecyclo-3-yl(5-(4-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1158] 1 H-NMR (400MHz, CDCl3) δ7.49 (d, 2H), 7.35 (m, 1H), 7.28 (m, 2H), 6.95 (d, 2H), 5.12 (m, 1H), 4.91 (m, 1H), 4.88 (m, 1H), 4.10 (m, 2H), 3.26 ( m, 1H), 2.88~2.71 (m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.41 (t, 3H), 1.37 (br, 1H), 0.97 (m, 3H), 0.87 (m, 3H)

[1159] Example 285. (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1160] 1H-NMR (400MHz, CDCl3) δ7.49 (d, 2H), 7.35 (m, 1H), 7.28 (m, 2H), 6.96 (d, 2H), 5.12 (m, 1H), 4.91 (m, 1H), 4.88 (m, 1H), 3.98 (t, 2H), 3.26 (m, 1H), 2.88~2.71 (m, 7H), 2.11 (br, 1H), 1.85 (m, 3H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 1.06 (t, 3H), 0.97 (m, 3H), 0.87 (m, 3H)

[1161] Example 286. (S)-quininecyclo-3-yl(2,2-diethyl-5-(4-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1162] 1 H-NMR (400MHz, CDCl3) δ7.49 (d, 2H), 7.35 (m, 1H), 7.28 (m, 2H), 6.96 (d, 2H), 5.12 (m, 1H), 4.91 (m, 1H), 4.78 (m, 1H), 4.77 (m, 1H), 3.26 ( m, 1H), 2.88~2.71 (m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 1.36 (d, 6H), 0.96 (m, 3H), 0.87 (m, 3H)

[1163] Example 287. (S)-Quininecyclo-3-yl(2,2-diethyl-5-(4-isobutylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1164] 1 H-NMR (400MHz, CDCl3) δ7.48 (d, 2H), 7.38 (m, 1H), 7.28 (m, 2H), 7.20 (d, 2H), 5.13 (m, 1H), 4.92 (m, 1H), 4.78 (m, 1H), 3.26 (m, 1H), 2.88~2.73 ( m, 7H), 2.51 (d, 2H), 2.11 (br, 1H), 1.92 (m, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.96 (m, 3H), 0.93 (d, 6H), 0.86 (m, 3H)

[1165] Example 288. (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1166] 1 H-NMR (400MHz, CDCl3) δ7.41~7.02 (m, 6H), 7.02 (t, 1H), 5.14 (m, 1H), 4.92 (m, 1H), 4.79 (m, 1H), 3.24 (m, 1H), 2. 88~2.74(m,7H),2.11(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.37(br,1H),0.96(m,3H),0.86(m,3H)

[1167] Example 289. (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1168] 1 H-NMR (400MHz, CDCl3) δ7.43 (m, 1H), 7.37~7.27 (m, 3H), 7.17 (d, 1H), 7.15 (s, 1H), 6.88 (d, 1H), 5.13 (m, 1H), 4.91 (m, 1H), 4.79 (m, 1H), 3. 87 (s, 3H), 3.25 (m, 1H), 2.88 ~ 2.74 (m, 7H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.96 (m, 3H), 0.86 (m, 3H)

[1169] Example 290. (S)-quininecyclo-3-yl(5-(3-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1170] 1H-NMR (400MHz, CDCl3) δ7.41 (m, 1H), 7.38~7.27 (m, 3H), 7.15 (d, 1H), 7.13 (s, 1H), 6.89 (d, 1H), 5.13 (m, 1H), 4.91 (m, 1H), 4.79 (m, 1H), 4.12 (m, 2 H), 3.25(m, 1H), 2.88~2.74(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(b r, 1H), 1.58 (m, 3H), 1.43 (t, 3H), 1.37 (br, 1H), 0.96 (m, 3H), 0.87 (m, 3H)

[1171] Example 291. (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1172] 1 H-NMR (400MHz, CDCl3) δ7.41 (m, 1H), 7.39~7.27 (m, 3H), 7.12 (d, 1H), 7.09 (s, 1H), 6.88 (d, 1H), 5.13 (m, 1H), 4.91 (m, 1H), 4.78 (m, 1H), 4.62 (m, 1 H), 3.25(m, 1H), 2.88~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(b r, 1H), 1.58 (m, 3H), 1.29 (br, 1H), 1.26 (d, 6H), 0.97 (m, 3H), 0.86 (m, 3H)

[1173] Example 292. (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1174] 1 H-NMR (400MHz, CDCl3) δ7.44~7.27 (m, 6H), 7.18 (d, 1H), 5.13 (m, 1H), 4.93 (m, 1H), 4.78 (m, 1H), 3.27 (m, 1H), 2.85~2.71 (m, 7 H), 2.68(m, 2H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.39(br, 1H), 1.29(t, 3H), 0.97(m, 3H), 0.86(m, 3H)

[1175] Example 293. (S)-quininecyclo-3-yl(2,2-diethyl-5-(3-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1176] 1 H-NMR (400MHz, CDCl3) δ7.44~7.27 (m, 6H), 7.21 (d, 1H), 5.14 (m, 1H), 4.92 (m, 1H), 4.79 (m, 1H), 3.27 (m, 1H), 2.99 (m, 1H), 2. 85~2.71(m,7H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.39(br,1H),1.27(d,6H),0.98(m,3H),0.86(m,3H)

[1177] Example 294. (S)-quininecyclo-3-yl(5-(3-(tert-butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1178] 1 H-NMR (400MHz, CDCl3) δ7.58 (s, 1H), 7.41~7.27 (m, 6H), 5.11 (m, 1H), 4.92 (m, 1H), 4.79 (m, 1H), 3.27 (m, 1H), 2.86~2.7 5(m,7H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.39(br,1H),1.38(s,9H),0.96(m,3H),0.87(m,3H)

[1179] Example 295. (S)-quininecyclo-3-yl(5-(2,3-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1180] 1 H-NMR (400MHz, CDCl3) δ7.37~7.26 (m, 3H), 7.10 (m, 1H), 6.92 (d, 2H), 5.14 (m, 1H), 4.92 (m, 1H), 4.77 (m, 1H), 3.91 (s, 3H), 3.59 (s, 3 H), 3.25 (m, 1H), 2.86~2.73 (m, 7H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.96 (m, 3H), 0.85 (m, 3H)

[1181] Example 296. (S)-quininecyclo-3-yl(5-(2,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1182] 1 H-NMR (400MHz, CDCl3) δ7.33 (m, 1H), 7.28~7.21 (m, 3H), 6.57 (m, 2H), 5.11 (m, 1H), 4.90 (m, 1H), 4.85 (m, 1H), 3.85 (s, 3H), 3.80 (s, 3 H), 3.24 (m, 1H), 2.86~2.71 (m, 7H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.95 (m, 3H), 0.87 (m, 3H)

[1183] Example 297. (S)-quininecyclo-3-yl(5-(2,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1184] 1 H-NMR (400MHz, CDCl3) δ7.35(m, 1H), 7.30~7.27(m, 2H), 6.92~6.83(m, 3H), 5.12(m, 1H), 4.90(m, 1H), 4.85(m, 1H), 3.80(s, 3H), 3.75( s, 3H), 3.24 (m, 1H), 2.86~2.72 (m, 7H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.96 (m, 3H), 0.87 (m, 3H)

[1185] Example 298. (S)-quininecyclo-3-yl(5-(3,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1186] 1H-NMR (400MHz, CDCl3) δ7.39 (m, 1H), 7.31 (s, 1H), 7.28 (m, 1H), 7.13 (d, 1H ), 7.08(s, 1H), 6.93(d, 1H), 5.12(m, 1H), 4.91(m, 1H), 4.85(m, 1H), 3.95( s, 3H), 3.92 (s, 3H), 3.24 (m, 1H), 2.86~2.72 (m, 7H), 2.05 (br, 1H), 1.85 (b r, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.95 (m, 3H), 0.86 (m, 3H)

[1187] Example 299. (S)-quininecyclo-3-yl(5-(3,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1188] 1 H-NMR (400MHz, CDCl3) δ7.40 (m, 1H), 7.39 (s, 1H), 7.29 (m, 1H), 6.70 (s, 2H), 6.45 (m, 1H), 5.13 (m, 1H), 4.92 (m, 1H), 4.85 (brs, 1H), 3.85 (s, 6H), 3.24 (m, 1H), 2.86~2.73 (m, 7H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.96 (m, 3H), 0.87 (m, 3H)

[1189] Example 300. (S)-quininecyclo-3-yl(5-(2,6-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1190] 1 H-NMR (400MHz, CDCl3) δ7.30~7.26 (m, 2H), 7.18 (d, 1H), 7.14 (s, 1H), 6.65 (d, 2H), 5.12 (m, 1H), 4.92 (m, 1H), 4.77 (m, 1H), 3.73 (s, 6 H), 3.24 (m, 1H), 2.85~2.71 (m, 7H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.96 (m, 3H), 0.88 (m, 3H)

[1191] Example 301. (S)-quininecyclo-3-yl(5-(3-(difluoromethyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1192] 1 H-NMR (400MHz, CDCl3) δ7.70 (m, 2H), 7.53~7.39 (m, 4H), 7.31 (m, 1H), 6.85~6.56 (t, 1H), 5.15 (m, 1H), 4.92 (m, 1H), 4.79 (m, 1H), 3.24(m,1H),2.85~2.74(m,7H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.37(br,1H),0.96(m,3H),0.86(m,3H)

[1193] Example 302. (S)-quininecyclo-3-yl(5-(3-(dimethylamino)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1194] 1 H-NMR (400MHz, CDCl3) δ7.43 (m, 1H), 7.38 (s, 1H), 7.27 (m, 2H), 6.91 (m, 2H), 6.73 (d, 1H), 5.13 (m, 1H), 4.88 (m, 1H), 4.79 (m, 1H), 3.24 ( m, 1H), 3.00 (s, 6H), 2.85~2.74 (m, 7H), 2.05 (br, 1H), 1.85 (br, 1H), 1.68 (br, 1H), 1.58 (m, 3H), 1.37 (br, 1H), 0.96 (m, 3H), 0.87 (m, 3H)

[1195] Example 303. (S)-quininecyclo-3-yl(5-(4-ethoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1196] 1H-NMR (400MHz, CDCl3) δ7.38~7.33 (m, 2H), 7.28 (m, 1H), 7.21 (s, 2H), 5.12 (m, 1H), 4.88 (m, 1H), 4.79 (m, 1H), 3.89 (q, 2H), 3.25 (m, 1H), 2. 85~2.74(m,7H),2.33(s,6H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.41(t,3H),1.37(br,1H),0.95(m,3H),0.85(m,3H)

[1197] Example 304. (S)-Quininecyclo-3-yl(5-(3,5-dimethyl-4-propoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1198] 1 H-NMR (400MHz, CDCl3) δ7.38~7.30 (m, 2H), 7.28 (m, 1H), 7.20 (s, 2H), 5.11 (m, 1H), 4.93 (m, 1H), 4.79 (m, 1H), 3.77 (t, 2H), 3.25 (m, 1H), 2. 85~2.74(m,7H),2.33(s,6H),2.05(br,1H),1.85(m,3H),1.68(br,1H),1.58(m,3H),1.37(br,1H),1.09(t,3H),0.95(m,3H),0.85(m,3H)

[1199] Example 305. (S)-quininecyclo-3-yl(5-(4-butoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1200] 1 H-NMR (400MHz, CDCl3) δ7.38~7.30 (m, 2H), 7.28 (m, 1H), 7.20 (s, 2H), 5.12 (m, 1H), 4.91 (m, 1H), 4.79 (m, 1H), 3.78 (t, 2H), 3.25 (m, 1H), 2. 85~2.74(m,7H),2.33(s,6H),2.05(br,1H),1.85(m,3H),1.68(br,1H),1.58(m,5H),1.37(br,1H),0.99(t,3H),0.95(m,3H),0.86(m,3H)

[1201] Example 306. (S)-quininecyclo-3-yl(2,2-diethyl-5-(thiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1202] 1 H-NMR (400MHz, CDCl3) δ7.45~7.36 (m, 5H), 7.26 (m, 1H), 5.11 (m, 1H), 4.88 (m, 1H), 4.77 (m, 1H), 3.25 (m, 1H), 2. 85~2.72(m,7H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.37(br,1H),0.95(m,3H),0.85(m,3H)

[1203] Example 307. (S)-quininecyclo-3-yl(2,2-diethyl-5-(furan-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1204] 1 H-NMR (400MHz, CDCl3) δ7.70 (s, 1H), 7.46 (s, 1H), 7.30~7.20 (m, 3H), 6.68 (s, 1H), 5.10 (m, 1H), 4.88 (m, 1H), 4.78 (m, 1H), 3. 25(m,1H),2.85~2.69(m,7H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.37(br,1H),0.94(m,3H),0.85(m,3H)

[1205] Example 308. (S)-quininecyclo-3-yl(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1206] 1 H-NMR (400MHz, CDCl3) δ8.31 (s, 1H), 7.77 (d, 1H), 7.31 (m, 3H), 6.82 (d, 1H), 5.12 (m, 1H), 4.93 (m, 1H), 4.78 (m, 1H), 4.16 (m, 2H), 3.25 (m, 1H) , 2.85~2.72(m,7H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.37(br,1H),0.94(m,3H),0.85(m,3H),0.63(m,2H),0.37(m,2H)

[1207] Example 309. (S)-quininecyclo-3-yl(5-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1208] 1 H-NMR (400MHz, CDCl3) δ7.33~7.24 (m, 5H), 7.10 (m, 1H), 5.14 (m, 1H), 4.91 (m, 1H), 4.87 (m, 1H), 3.25 (m, 1H), 2. 85~2.73(m,7H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.37(br,1H),0.96(m,3H),0.86(m,3H)

[1209] Example 310. (S)-quininecyclo-3-yl(2,2-diethyl-5-(2-fluoro-4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1210] 1 H-NMR (400MHz, CDCl3) δ7.34~7.27 (m, 4H), 6.74 (m, 2H), 5.12 (m, 1H), 4.94 (m, 1H), 4.77 (m, 1H), 3.83 (s, 3H), 3.25 (m, 1 H), 2.85~2.72(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.86(m, 3H)

[1211] Example 311. (S)-quininecyclo-3-yl(5-(3-chloro-4-isopropoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1212] 1 H-NMR (400MHz, CDCl3) δ7.59 (s, 1H), 7.40~7.01 (m, 4H), 7.00 (d, 1H), 5.13 (m, 1H), 4.94 (m, 1H), 4.77 (m, 1H), 3.83 (s, 3H), 3. 25(m,1H),2.85~2.72(m,7H),2.05(br,1H),1.85(br,1H),1.68(br,1H),1.58(m,3H),1.37(br,1H),0.96(m,3H),0.86(m,3H)

[1213] Examples 312 to 348

[1214] The title compounds of Examples 312 to 348 were prepared using (S)-quininecyclo-3-yl(5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate obtained in Preparation Example 6 and the corresponding substituted boric acid, following the same steps as in Example 1.

[1215] Example 312. (S)-quininecyclo-3-yl(5-(4-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1216] 1 H-NMR (400MHz, CDCl3) δ7.42 (d, 2H), 7.24 (m, 3H), 6.85 (d, 1H), 4.94 (m, 1H), 4.82 (m, 1H), 4.74 (br, 1H), 3.79 (d, 3H), 3.29 (m, 1H), 2.91 ( m, 2H), 2.89~2.70 (m, 5H), 2.69 (m, 2H), 2.11 (br, 1H), 1.88 (br, 1H), 1.72 (br, 1H), 1.61 (br, 1H), 1.44 (br, 1H), 1.30 (m, 6H), 1.00 (m, 3H)

[1217] Example 313. (S)-quininecyclo-3-yl(6-methoxy-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1218] 1 H-NMR (400MHz, CDCl3) δ7.41 (d, 2H), 7.22 (d, 2H), 7.11 (s, 1H), 6.85 (d, 1H), 4.95 (m, 1H), 4.82 (m, 1H), 4.74 (br, 1H), 3.79 (d, 3H), 3.29 (m, 1H), 2 .90(m, 2H), 2.89~2.71(m, 5H), 2.62(m, 2H), 2.11(br, 1H), 1.88(br, 1H), 1.72~1.67(m,3H), 1.61(br,1H), 1.43(br,1H), 1.32(m,3H), 1.00(m,6H)

[1219] Example 314. (S)-quininecyclo-3-yl(5-(4-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1220] 1 H-NMR (400MHz, CDCl3) δ7.43 (d, 2H), 7.26 (d, 2H), 7.11 (s, 1H), 6.85 (d, 1H), 4.95 (m, 1H), 4.82 (m, 1H), 4.74 (br, 1H), 3.80 (d, 3H), 3.29 ( m, 1H), 2.92 (m, 3H), 2.89~2.71 (m, 5H), 2.11 (br, 1H), 1.88 (br, 1H), 1.71 (br, 1H), 1.62 (br, 1H), 1.44 (br, 1H), 1.30 (m, 9H), 1.00 (m, 3H)

[1221] Example 315. (S)-quininecyclo-3-yl(5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1222] 1 H-NMR (400MHz, CDCl3) δ7.41 (d, 2H), 7.17 (d, 2H), 7.11 (s, 1H), 6.85 (d, 1H), 4.95 (m, 1H), 4.82 (m, 1H), 4.74 (br, 1H), 3.80 (d, 3H), 3.29 (m, 1H) , 2.90~2.71(m,7H),2.50(d,2H),2.11(br,1H),1.92(m,2H),1.71(br,1H),1.62(br,1H),1.44(br,1H),1.30(m,3H),1.00(m,3H),0.99(d,6H)

[1223] Example 316. (S)-quininecyclo-3-yl(5-(4-(tert-butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1224] 1 H-NMR (400MHz, CDCl3) δ7.46 (m, 4H), 7.12 (s, 1H), 6.85 (d, 1H), 4.95 (m, 1H), 4.82 (m, 1H), 4.74 (br, 1H), 3.81 (d, 3H), 3.29 (m, 1H), 2.93~ 2.66(m,7H),2.50(d,2H),2.11(br,1H),1.88(br,1H),1.71(br,1H),1.62(br,1H),1.44(br,1H),1.40(s,9H),1.30(m,3H),1.00(m,3H)

[1225] Example 317. (S)-quininecyclo-3-yl(5-(4-cyclopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1226] 1 H-NMR (400MHz, CDCl3) δ7.39 (d, 2H), 7.10 (d, 3H), 6.85 (d, 1H), 4.95 (m, 1H ), 4.82(m, 1H), 4.74(br, 1H), 3.81(d, 3H), 3.29(m, 1H), 2.93~2.66(m, 7H), 2.50(d,2H),2.11(br,1H),1.90(m,1H),1.88(br,1H),1.71(br,1H),1.62 (br, 1H), 1.44 (br, 1H), 1.30 (m, 3H), 1.00 (m, 3H), 0.98 (d, 2H), 0.75 (m, 2H)

[1227] Example 318. (S)-quininecyclo-3-yl(5-(4-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1228] 1 H-NMR (400MHz, CDCl3) δ7.42 (d, 2H), 7.09 (s, 1H), 6.93 (d, 2H), 6.81 (d, 1H), 4.94 (m, 2H), 4.81 (m, 1H), 4.09 (m, 2H), 3.80 (d, 3H), 3.28 ( m, 1H), 2.90 ~ 2.671 (m, 7H), 2.11 (br, 1H), 1.90 (m, 1H), 1.88 (br, 1H), 1.71 (br, 1H), 1.62 (br, 1H), 1.43 (t, 4H), 1.26 (m, 3H), 0.97 (m, 3H)

[1229] Example 319. (S)-quininecyclo-3-yl(6-methoxy-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1230] 1H-NMR (400MHz, CDCl3) δ7.42 (d, 2H), 7.09 (s, 1H), 6.94 (d, 2H), 6.82 (d, 1H ), 4.94(m, 2H), 4.81(m, 1H), 3.95(m, 2H), 3.80(d, 3H), 3.28(m, 1H), 2.90~ 2.67(m, 7H), 2.11(br, 1H), 1.90(m, 1H), 1.88(br, 1H), 1.83(m, 2H), 1.71( br, 1H), 1.62 (br, 1H), 1.43 (br, 1H), 1.26 (m, 3H), 1.07 (t, 3H), 0.97 (m, 3H)

[1231] Example 320. (S)-quininecyclo-3-yl(5-(4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1232] 1 H-NMR (400MHz, CDCl3) δ7.42 (d, 2H), 7.09 (s, 1H), 6.90 (d, 2H), 6.85 (d, 1H), 4.93 (m, 2H), 4.81 (m, 1H), 4.59 (m, 1H), 3.80 (d, 3H), 3.28 ( m, 1H), 2.90 ~ 2.72 (m, 7H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.43 (br, 1H), 1.37 (d, 6H), 1.28 (m, 3H), 0.97 (m, 3H)

[1233] Example 321. (S)-quininecyclo-3-yl(5-(3,5-dimethyl-4-propoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1234] 1 H-NMR (400MHz, CDCl3) δ7.13 (s, 2H), 7.07 (s, 1H), 6.82 (d, 1H), 4.93 (m, 2H), 4.81 (m, 1H), 3.78 (m, 5H), 3.27 (m, 1H), 2.90~2.69 (m, 7H), 2.31 (s, 6H), 2.10 (br, 1H), 1.86 (br, 1H), 1.71 (br, 1H), 1.69 (m, 2H), 1.60 (br, 1H), 1.43 (br, 1H), 1.28 (m, 3H), 1.09 (t, 3H), 0.93 (m, 3H)

[1235] Example 322. (S)-quininecyclo-3-yl(5-(3-chloro-4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1236] 1 H-NMR (400MHz, CDCl3) δ7.52 (s, 1H), 7.33 (d, 1H), 7.07 (s, 1H), 6.96 (d, 1H), 6.83 (d, 1H), 4.93 (m, 2H), 4.81 (m, 1H), 4.58 (m, 1H), 3.78 (m, 3H), 3.27(m,1H),2.90~2.70(m,7H),2.10(br,1H),1.86(br,1H),1.71(br,1H),1.60(br,1H),1.43(br,1H),1.40(d,6H),1.28(m,3H),0.96(m,3H)

[1237] Example 323. (S)-quininecyclo-3-yl(5-(2-fluoro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1238] 1 H-NMR (400MHz, CDCl3) δ7.24 (m, 1H), 7.03 (s, 1H), 6.87 (d, 1H), 6.75~6.67 (m, 2H), 4.96 (m, 2H), 4.81 (m, 1H), 3.80 (s, 3H), 3.78 (m, 3 H), 3.27 (m, 1H), 2.90~2.70 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.58 (br, 1H), 1.41 (br, 1H), 1.28 (m, 3H), 0.97 (m, 3H)

[1239] Example 324. (S)-quininecyclo-3-yl(5-(4-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1240] 1H-NMR (400MHz, CDCl3) δ7.42 (d, 2H), 7.09 (s, 1H), 6.93 (d, 2H), 6.83 (d, 1H), 4.93 (m, 2H), 4.81 (m, 1H), 3.98 (m, 2H), 3.79 (m, 3H), 3.27 (m, 1H), 2.90~2.71(m,7H),2.10(br,1H),1.85(br,1H),1.71(m,2H),1.69(br,1H),1.59(br,1H),1.52(m,2H),1.43(br,1H),1.27(m,3H),0.99(m,6H)

[1241] Example 325. (S)-quininecyclo-3-yl(5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1242] 1 H-NMR (400MHz, CDCl3) δ7.42 (d, 2H), 7.09 (s, 1H), 6.93 (d, 2H), 6.83 (d, 1H), 4.93 (m, 2H), 4.81 (m, 1H), 3.79 (m, 5H), 3.27 ( m, 1H), 2.90 ~ 2.71 (m, 7H), 2.10 (m, 2H), 1.85 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.43 (br, 1H), 1.27 (m, 3H), 0.99 (m, 6H)

[1243] Example 326. (S)-quininecyclo-3-yl(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1244] 1 H-NMR (400MHz, CDCl3) δ8.24 (s, 1H), 7.74 (d, 1H), 7.07 (s, 1H), 6.86 (d, 1H ), 6.80(d, 1H), 4.93(m, 2H), 4.81(m, 1H), 4.15(m, 2H), 3.79(m, 3H), 3.27( m, 1H), 2.90 ~ 2.71 (m, 7H), 2.10 (m, 1H), 1.85 (br, 1H), 1.69 (br, 1H), 1.59 ( br, 1H), 1.43 (br, 1H), 1.27 (m, 3H), 0.97 (m, 3H), 0.62 (m, 2H), 0.38 (m, 2H)

[1245] Example 327. (S)-quininecyclo-3-yl(5-(5-chloro-2-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1246] 1 H-NMR (400MHz, CDCl3) δ7.25 (s, 1H) 7.19 (m, 1H), 7.00 (s, 1H), 6.89~6.82 (m, 2H), 4.93 (m, 2H), 4.81 (m, 1H), 3.79 (m, 6H), 3.2 9(m,1H),2.92~2.65(m,7H),2.10(m,1H),1.85(br,1H),1.69(br,1H),1.59(br,1H),1.43(br,1H),1.29(m,3H),0.98(m,3H)

[1247] Example 328. (S)-quininecyclo-3-yl(5-(4-butylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1248] 1 H-NMR (400MHz, CDCl3) δ7.40 (d, 2H) 7.20 (d, 2H), 7.10 (s, 1H), 6.84 (d, 1H), 4.95 (s, 2H), 4.80 (br, 1H), 3.78 (d, 3H), 3.25 (m, 1H), 2.92~2.65 ( m, 7H), 2.64 (m, 2H), 2.10 (m, 1H), 1.85 (br, 1H), 1.69 (br, 1H), 1.60 (m, 2H), 1.59 (br, 1H), 1.43 (m, 3H), 1.29 (m, 3H), 0.98 (m, 3H), 0.92 (t, 3H)

[1249] Example 329. (S)-quininecyclo-3-yl(6-methoxy-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1250] 1H-NMR (400MHz, CDCl3) δ7.14 (s, 2H) 7.07 (s, 1H), 6.82 (d, 1H), 4.94 (s, 2H), 4.80 (br, 1H), 3.78 (d, 3H), 3.76 (s, 3H), 3.25 (m, 1H) , 2.92~2.65(m,7H),2.32(s,6H),2.10(m,1H),1.85(br,1H),1.69(br,1H),1.58(br,1H),1.40(br,1H),1.28(m,3H),0.98(m,3H)

[1251] Example 330. (S)-quininecyclo-3-yl(5-(4-ethoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1252] 1 H-NMR (400MHz, CDCl3) δ7.14 (s, 2H) 7.07 (s, 1H), 6.83 (d, 1H), 4.94 (s, 2H), 4.80 (br, 1H), 3.89 (m, 2H), 3.78 (d, 3H), 3.25 (m, 1H) , 2.92~2.65(m,7H),2.31(s,6H),2.10(m,1H),1.85(br,1H),1.69(br,1H),1.59(br,1H),1.43(t,4H),1.28(m,3H),0.98(m,3H)

[1253] Example 331. (S)-quininecyclo-3-yl(5-(4-butoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1254] 1 H-NMR (400MHz, CDCl3) δ7.13 (s, 2H), 7.07 (s, 1H), 6.83 (d, 1H), 4.93 (m, 2H), 4.80 (br, 1H), 3.80 (m, 3H), 3.25 (m, 1H), 2.92~2.71 (m, 7H), 2.69 (m, 2H), 2.31 (s, 6H), 2.10 (m, 1H), 1.85 (br, 1H), 1.77 (m, 2H), 1.69 (br, 1H), 1.60 (m, 2H), 1.59 (m, 3H), 1.43 (br, 1H), 1.29 (m, 3H), 0.98 (m, 6H)

[1255] Example 332. (S)-quininecyclo-3-yl(6-methoxy-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1256] 1 H-NMR (400MHz, CDCl3) δ8.15 (d, 1H), 7.11 (s, 1H), 7.03 (d, 1H), 6.89 (s, 1H), 6.85 (d, 1H), 4.93 (m, 2H), 4.80 (br, 1H), 3.97 (s, 3H), 3.79 ( d, 3H), 3.25 (m, 1H), 2.92~2.71 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.43 (br, 1H), 1.29 (m, 3H), 0.98 (m, 6H)

[1257] Example 333. (S)-quininecyclo-3-yl(5-(3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1258] 1 H-NMR (400MHz, CDCl3) δ7.34 (m, 1H), 7.25 (m, 2H), 7.10 (s, 1H), 7.02 (m, 1H), 6.86 (m, 1H), 4.95 (s, 2H), 4.80 (br, 1H), 3.81 (m, 3H) , 3.25 (m, 1H), 2.90~2.71 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H)

[1259] Example 334. (S)-quininecyclo-3-yl(5-(3-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1260] 1H-NMR (400MHz, CDCl3) δ7.33 (s, 3H), 7.17 (m, 1H), 7.16 (s, 1H), 6.86 (m, 1H), 4.95 (m, 2H), 4.80 (br, 1H), 3.80 (m, 3H), 3.25 (m, 1H) , 2.90~2.80(m,7H),2.70(m,2H),2.10(br,1H),1.85(br,1H),1.69(br,1H),1.59(br,1H),1.46(br,1H),1.28(m,6H),0.98(m,3H)

[1261] Example 335. (S)-quininecyclo-3-yl(5-(3-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1262] 1 H-NMR (400MHz, CDCl3) δ7.32~7.27 (m, 3H), 7.11 (m, 2H), 6.85 (m, 1H), 4.95 (m, 2H), 4.80 (br, 1H), 3.79 (m, 3H), 3.25 (m, 1H), 2.90~2.72 (m, 7 H), 2.53(d, 2H), 2.10(br, 1H), 1.90(m, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H), 0.90(d, 6H)

[1263] Example 336. (S)-quininecyclo-3-yl(5-(3-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1264] 1 H-NMR (400MHz, CDCl3) δ7.33 (m, 3H), 7.20 (m, 1H), 7.12 (s, 1H), 6.85 (m, 1H), 4.95 (m, 2H), 4.80 (br, 1H), 3.80 (m, 3H), 3.25 (m, 1H) , 2.95 (m, 1H), 2.90 ~ 2.72 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 9H), 0.98 (m, 3H)

[1265] Example 337. (S)-quininecyclo-3-yl(5-(3-(tert-butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1266] 1 H-NMR (400MHz, CDCl3) δ7.52 (s, 1H), 7.33 (m, 3H), 7.12 (s, 1H), 6.86 (m, 1H), 4.95 (m, 2H), 4.80 (br, 1H), 3.80 (m, 3H), 3.25 (m, 1H) , 2.90~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.46(br,1H),1.37(s,9H),1.28(m,3H),0.98(m,3H)

[1267] Example 338. (S)-quininecyclo-3-yl(6-methoxy-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1268] 1 H-NMR (400MHz, CDCl3) δ7.31 (m, 1H), 7.11~7.06 (m, 3H), 6.87 (m, 2H), 4.95 (m, 2H), 4.80 (br, 1H), 3.84 (s, 3H), 3.80 (m, 3H), 3. 25(m,1H),2.90~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.46(br,1H),1.28(m,3H),0.98(m,3H)

[1269] Example 339. (S)-quininecyclo-3-yl(5-(3-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1270] 1H-NMR (400MHz, CDCl3) δ7.30 (m, 1H), 7.11 (s, 1H), 7.07 (m, 2H), 6.85 (m, 2H), 4.95 (m, 2H), 4.80 (br, 1H), 4.08 (m, 2H), 3.79 (m, 3H), 3.25 ( m, 1H), 2.90 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.43 (t, 3H), 1.28 (m, 3H), 0.98 (m, 3H)

[1271] Example 340. (S)-Quininecyclo-3-yl(6-methoxy-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1272] 1 H-NMR (400MHz, CDCl3) δ7.28 (m, 1H), 7.11 (s, 1H), 7.06 (m, 2H), 6.86 (m, 2H), 4.95 (m, 2H), 4.80 (br, 1H), 3.96 (m, 2H), 3.79 (m, 3H), 3.25 ( m, 1H), 2.90 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.80 (m, 2H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 6H)

[1273] Example 341. (S)-quininecyclo-3-yl(5-(3-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1274] 1 H-NMR (400MHz, CDCl3) δ7.28 (m, 1H), 7.11 (s, 1H), 7.05 (m, 2H), 6.85 (d, 2H), 4.95 (m, 2H), 4.80 (br, 1H), 4.59 (m, 1H), 3.80 (m, 3H), 3.25 ( m, 1H), 2.90 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.35 (d, 6H), 1.28 (m, 3H), 0.98 (m, 3H)

[1275] Example 342. (S)-quininecyclo-3-yl(5-(3-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1276] 1 H-NMR (400MHz, CDCl3) δ7.28 (m, 1H), 7.10 (s, 1H), 7.05 (m, 2H), 6.86 (d, 2H), 4.95 (m, 2H), 4.80 (br, 1H), 3.98 (m, 2H), 3.80 (m, 3H), 3.25 (m, 1H) , 2.90~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.78(m,2H),1.70(br,1H),1.59(br,1H),1.55(m,2H),1.46(br,1H),1.28(m,3H),0.98(m,6H)

[1277] Example 343. (S)-quininecyclo-3-yl(5-(3-isobutoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1278] 1 H-NMR (400MHz, CDCl3) δ7.28 (m, 1H), 7.11 (s, 1H), 7.05 (m, 2H), 6.85 (d, 2H), 4.95 (m, 2H), 4.80 (br, 1H), 3.80 (m, 3H), 3.75 (d, 2H) , 3.25 (m, 1H), 2.90~2.73 (m, 7H), 2.10 (m, 2H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 9H)

[1279] Example 344. (S)-quininecyclo-3-yl(5-(2,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1280] 1H-NMR (400MHz, CDCl3) δ7.03 (s, 1H), 7.03~6.80 (m, 4H), 4.95 (s, 2H), 4.80 (br, 1H), 3.78 (m, 6H), 3.73 (s, 3H), 3.25 (m, 1 H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1281] Example 345. (S)-quininecyclo-3-yl(5-(3,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1282] 1 H-NMR (400MHz, CDCl3) δ7.11 (s, 1H), 6.85 (m, 1H), 6.65 (s, 2H), 6.45 (s, 1H), 4.95 (s, 2H), 4.80 (br, 1H), 3.80 (m, 9H), 3.25 ( m, 1H), 2.90 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H)

[1283] Example 346. (S)-quininecyclo-3-yl(5-(2-chloro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1284] 1 H-NMR (400MHz, CDCl3) δ7.17 (d, 1H), 7.00 (s, 1H), 6.96 (s, 1H), 6.84 (m, 2H), 4.95 (s, 2H), 4.80 (br, 1H), 3.82 (s, 3H), 3.75 (m, 3H) , 3.25 (m, 1H), 2.90 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H)

[1285] Example 347. (S)-Quinylcyclo-3-yl(5-(4-ethoxy-3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1286] 1 H-NMR(400MHz, CDCl3)δ7.30(m 1H), 7.18(d, 1H), 7.08(s, 1H), 6.98(t, 1H), 6.84(d, 1H), 4.95(s, 2H), 4.80(br, 1H), 4.14(m, 2H), 3.79(m, 3H), 3.25(m, 1H), 2. 90~2.73(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.47(t,3H),1.45(br,1H),1.28(m,3H),0.98(m,3H)

[1287] Example 348. (S)-quininecyclo-3-yl(5-(4-isopropoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1288] 1 H-NMR (400MHz, CDCl3) δ7.13 (s, 2H), 7.08 (s, 1H), 6.82 (d, 1H), 4.95 (s, 2H), 4.80 (br, 1H), 4.22 (m, 1H), 3.78 (m, 3H), 3.25 (m, 1H), 2.90~ 2.73(m,7H),2.30(s,6H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.45(br,1H),1.30(d,6H),1.28(m,3H),0.98(m,3H)

[1289] Examples 349 to 388

[1290] The title compounds of Examples 349 to 388 were prepared using the (S)-quininecyclo-3-yl (5-bromo-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate obtained in Preparation Example 7 and the corresponding substituted boric acid, following the same steps as in Example 1.

[1291] Example 349. (S)-quininecyclo-3-yl(5-(4-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1292] 1H-NMR (400MHz, CDCl3) δ7.44 (d, 2H), 7.27 (d, 2H), 7.20 (d, 1H), 7.03~6.97 (m, 1H), 4.93 (m, 2H), 4.79 (br, 1H), 3.28 (m, 1H), 2. 90~2.71(m,7H),2.69(m,2H),2.11(br,1H),1.85(br,1H),1.72(br,1H),1.59(br,1H),1.43(br,1H),1.32(m,6H),0.97(m,3H)

[1293] Example 350. (S)-quininecyclo-3-yl(6-fluoro-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1294] 1 H-NMR (400MHz, CDCl3) δ7.44 (d, 2H), 7.27 (m, 2H), 7.00 (m, 1H), 7.03~6.97 (m, 1H), 4.92 (m, 2H), 4.79 (br, 1H), 3.28 (m, 1H), 2.90~2.7 1(m,7H),2.63(m,2H),2.11(br,1H),1.85(br,1H),1.72(br,1H),1.68(m,2H),1.60(br,1H),1.43(br,1H),1.32(m,6H),0.97(m,3H)

[1295] Example 351. (S)-quininecyclo-3-yl(6-fluoro-5-(4-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1296] 1 H-NMR (400MHz, CDCl3) δ7.44 (d, 2H), 7.27 (m, 2H), 7.00 (m, 1H), 7.03~6.97 (m, 1H), 4.92 (m, 2H), 4.79 (br, 1H), 3.28 (m, 1H), 2. 96 (m, 1H), 2.90 ~ 2.72 (m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.72 (br, 1H), 1.60 (br, 1H), 1.43 (br, 1H), 1.28 (m, 9H), 0.97 (m, 3H)

[1297] Example 352. (S)-Quininecyclo-3-yl(6-fluoro-5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1298] 1 H-NMR (400MHz, CDCl3) δ7.44 (d, 2H), 7.22 (d, 3H), 7.03~6.97 (m, 1H), 4.92 (m, 2H), 4.79 (br, 1H), 3.28 (m, 1H), 2.90~2.72 (m, 7H), 2.5 2(d,2H),2.11(br,1H),1.94(m,1H),1.85(br,1H),1.72(br,1H),1.60(br,1H),1.43(br,1H),1.30(m,3H),0.98(m,3H),0.94(d,6H)

[1299] Example 353. (S)-quininecyclo-3-yl(5-(4-(tert-butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1300] 1 H-NMR (400MHz, CDCl3) δ7.46 (s, 4H), 7.21 (d, 1H), 7.03~6.97 (m, 1H), 4.99~4.90 (m, 2H), 4.79 (br, 1H), 3.29 (m, 1H), 2.90~2.69 (m , 7H), 2.11(br, 1H), 1.94(m, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.33(s, 9H), 1.30(m, 3H), 0.98(m, 3H)

[1301] Example 354. (S)-quininecyclo-3-yl(5-(4-cyclopropylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1302] 1 H-NMR (400MHz, CDCl3) δ7.42 (d, 2H), 7.20 (d, 1H), 7.13 (d, 2H), 7.02 ~ 6.99 (m, 1H), 4.98 ~ 4.88 (m, 2H), 4.79 (br, 1H), 3.28 (m, 1H), 2.88 ~ 2.68 (m , 7H), 2.11(br, 1H), 1.95(m, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.29(m, 3H), 1.00(m, 2H), 0.98(m, 3H), 0.75(m, 2H)

[1303] Example 355. (S)-quininecyclo-3-yl(6-fluoro-5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1304] 1 H-NMR (400MHz, CDCl3) δ7.46 (d, 2H), 7.19 (d, 1H), 6.99 (m, 3H), 4.98 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 3.96 (s, 3H), 3.28 ( m, 1H), 2.88~2.68 (m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.72 (br, 1H), 1.60 (br, 1H), 1.43 (br, 1H), 1.29 (m, 3H), 0.98 (m, 3H)

[1305] Example 356. (S)-quininecyclo-3-yl(5-(4-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1306] 1 H-NMR (400MHz, CDCl3) δ7.44 (d, 2H), 7.18 (d, 1H), 6.98 (m, 3H), 4.98 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 4.11 (m, 2H), 3.28 (m, 1H) , 2.88~2.68(m,7H),2.11(br,1H),1.85(br,1H),1.72(br,1H),1.60(br,1H),1.45(t,3H),1.44(br,1H),1.29(m,3H),0.98(m,3H)

[1307] Example 357. (S)-Quininecyclo-3-yl(6-fluoro-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1308] 1H-NMR (400MHz, CDCl3) δ7.44 (d, 2H), 7.18 (d, 1H), 6.98 (m, 3H), 4.98 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 3.97 (t, 2H), 3.28 (m, 1H), 2.88 ~2.68(m,7H),2.11(br,1H),1.85(m,3H),1.72(br,1H),1.60(br,1H),1.45(t,3H),1.44(br,1H),1.29(m,3H),1.05(t,3H),0.98(m,3H)

[1309] Example 358. (S)-quininecyclo-3-yl(6-fluoro-5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1310] 1 H-NMR (400MHz, CDCl3) δ7.43 (d, 2H), 7.18 (d, 1H), 7.02 (m, 1H), 6.94 (d, 2H), 4.98 (m, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 4.58 (m, 1H), 3.28 ( m, 1H), 2.88~2.68 (m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.72 (br, 1H), 1.60 (br, 1H), 1.44 (br, 1H), 1.31 (d, 6H), 1.29 (m, 3H), 0.98 (m, 3H)

[1311] Example 359. (S)-quininecyclo-3-yl(5-(3-chloro-4-isopropoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1312] 1 H-NMR (400MHz, CDCl3) δ7.54 (s, 1H), 7.37 (d, 1H), 7.18 (d, 1H), 7.02 (m, 2H), 4.98 (m, 2H), 4.79 (br, 1H), 4.57 (m, 1H), 3.28 (m, 1H) , 2.88~2.68(m,7H),2.11(br,1H),1.85(br,1H),1.72(br,1H),1.60(br,1H),1.44(br,1H),1.42(d,6H),1.28(m,3H),0.98(m,3H)

[1313] Example 360. (S)-Quininecyclo-3-yl(6-fluoro-5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1314] 1 H-NMR (400MHz, CDCl3) δ7.28 (m, 1H), 7.14 (d, 1H), 7.00 (m, 1H), 6.75 (m, 2H), 4.98 (m, 2H), 4.79 (br, 1H), 3.84 (s, 3H), 3.28 ( m, 1H), 2.88~2.68 (m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.72 (br, 1H), 1.60 (br, 1H), 1.43 (br, 1H), 1.29 (m, 3H), 0.98 (m, 3H)

[1315] Example 361. (S)-quininecyclo-3-yl(5-(4-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1316] 1 H-NMR (400MHz, CDCl3) δ7.44 (d, 12), 7.18 (d, 1H), 6.98 (m, 3H), 4.98 (m, 2H), 4.79 (br, 1H), 4.01 (t, 2H), 3.28 (m, 1H), 2.88~2.68 ( m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.81 (m, 2H), 1.72 (br, 1H), 1.60 (br, 1H), 1.51 (m, 2H), 1.43 (br, 1H), 1.29 (m, 3H), 0.98 (m, 6H)

[1317] Example 362. (S)-Quininecyclo-3-yl(6-fluoro-5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1318] 1H-NMR (400MHz, CDCl3) δ7.44 (d, 2H), 7.18 (d, 1H), 6.97 (m, 3H), 4.98 (m, 2H), 4.79 (br, 1H), 3.77 (d, 2H), 3.28 (m, 1H), 2.88~2.68 (m, 7H) , 2.11 (m, 3H), 1.85 (br, 1H), 1.81 (m, 2H), 1.72 (br, 1H), 1.60 (br, 1H), 1.51 (m, 2H), 1.43 (br, 1H), 1.29 (m, 3H), 1.05 (d, 6H), 0.98 (m, 6H)

[1319] Example 363. (S)-quininecyclo-3-yl(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1320] 1 H-NMR (400MHz, CDCl3) δ8.27 (s, 1H), 7.74 (d, 1H), 7.16 (d, 1H), 7.00 (m, 1H ), 6.83(d, 1H), 4.98(m, 1H), 4.90(m, 1H), 4.79(br, 1H), 4.18(d, 2H), 3.28( m, 1H), 2.88~2.68 (m, 7H), 2.11 (br, 1H), 1.85 (br, 1H), 1.72 (br, 1H), 1.60 (br, 1H), 1.43 (br, 1H), 1.29 (m, 4H), 0.98 (m, 3H), 0.64 (m, 2H), 0.37 (m, 2H)

[1321] Example 364. (S)-quininecyclo-3-yl(5-(5-chloro-2-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1322] 1 H-NMR (400MHz, CDCl3) δ7.31 (m, 2H), 7.09 (d, 1H), 6.97 (m, 1H), 6.89 (d, 1H), 4.98 (m, 1H), 4.90 (m, 1H), 4.79 (br, 1H), 3,78 (s, 3H), 3.28 (m, 1H) , 2.88~2.68(m,7H),2.11(br,1H),1.85(br,1H),1.72(br,1H),1.60(br,1H),1.43(br,1H),1.29(m,4H),0.98(m,3H),0.64(m,2H),0.37(m,2H)

[1323] Example 365. (S)-quininecyclo-3-yl(5-(4-butylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1324] 1 H-NMR (400MHz, CDCl3) δ7.42 (d, 2H) 7.25 (m, 3H), 6.97 (m, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H), 2.92~2.65 ( m, 7H), 2.64 (m, 2H), 2.10 (m, 1H), 1.85 (br, 1H), 1.69 (br, 1H), 1.60 (m, 2H), 1.59 (br, 1H), 1.43 (m, 3H), 1.29 (m, 3H), 0.98 (m, 6H)

[1325] Example 366. (S)-Quininecyclo-3-yl(6-fluoro-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1326] 1 H-NMR (400MHz, CDCl3) δ7.17 (s, 4H), 7.98 (m, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.77 (s, 3H), 3.25 (m, 1H), 2.92~ 2.65(m,7H),2.34(s,6H),2.10(br,1H),1.85(br,1H),1.69(br,1H),1.58(br,1H),1.40(br,1H),1.28(m,3H),0.98(m,3H)

[1327] Example 367. (S)-quininecyclo-3-yl(5-(4-ethoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1328] 1H-NMR (400MHz, CDCl3) δ7.17 (s, 4H), 6.98 (m, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.88 (d, 3H), 3.25 (m, 1H), 2.92 ~2.65(m,7H),2.32(s,6H),2.10(br,1H),1.85(br,1H),1.69(br,1H),1.59(br,1H),1.44(t,4H),1.28(m,3H),0.98(m,3H)

[1329] Example 368. (S)-quininecyclo-3-yl(5-(4-butoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1330] 1 H-NMR (400MHz, CDCl3) δδ7.18 (s, 4H), 6.98 (m, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.80 (m, 2H), 3.25 (m, 1H), 2.92~2.71 (m, 7H) ), 2.31(s, 6H), 2.10(m, 1H), 1.85(br, 1H), 1.77(m, 2H), 1.69(br, 1H), 1.60(m, 2H), 1.59(m, 3H), 1.43(br, 1H), 1.29(m, 3H), 0.98(m, 6H)

[1331] Example 369. (S)-Quininecyclo-3-yl(6-fluoro-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1332] 1 H-NMR (400MHz, CDCl3) δ8.19 (d, 1H), 7.23 (m, 1H), 7.03 (m, 1H), 6.89 (s, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.97 (s, 3H) , 3.25 (m, 1H), 2.92~2.71 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.43 (br, 1H), 1.29 (m, 3H), 0.98 (m, 3H)

[1333] Example 370. (S)-Quininecyclo-3-yl(6-fluoro-5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1334] 1 H-NMR (400MHz, CDCl3) δ7.38 (m, 1H), 7.36~7.19 (m, 3H), 7.05 (m, 2H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1 H), 2.90~2.71(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1335] Example 371. (S)-quininecyclo-3-yl(5-(3-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1336] 1 H-NMR (400MHz, CDCl3) δ7.34 (m, 3H), 7.20 (m, 2H), 7.00 (m, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H), 2.90~ 2.70(m,7H),2.68(m,2H),2.10(br,1H),1.85(br,1H),1.69(br,1H),1.59(br,1H),1.46(br,1H),1.28(m,6H),0.98(m,3H)

[1337] Example 372. (S)-quininecyclo-3-yl(6-fluoro-5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1338] 1H-NMR (400MHz, CDCl3) δ7.34(m, 2H), 7.27(m, 1H), 7.21(m, 1H), 7.15(m, 1H ), 6.99(m, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.90~ 2.72(m,7H),2.52(d,2H),2.10(br,1H),1.90(m,1H),1.85(br,1H),1.70( br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H), 0.90 (d, 6H)

[1339] Example 373. (S)-Quininecyclo-3-yl(6-fluoro-5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1340] 1 H-NMR (400MHz, CDCl3) δ7.37~7.34 (m, 3H), 7.22 (m, 2H), 6.99 (m, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.25 (m, 1H), 2. 95(m,1H),2.90~2.72(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.46(br,1H),1.28(m,9H),0.98(m,3H)

[1341] Example 374. (S)-quininecyclo-3-yl(5-(3-(tert-butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1342] 1 H-NMR (400MHz, CDCl3) δ7.53 (s, 1H), 7.41 (m, 1H), 7.35 (m, 1H), 7.22 (d, 1H), 7.01 (m, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.80 (m, 3H) , 3.25 (m, 1H), 2.90~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.37 (s, 9H), 1.28 (m, 3H), 0.98 (m, 3H)

[1343] Example 375. (S)-Quininecyclo-3-yl(6-fluoro-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1344] 1 H-NMR (400MHz, CDCl3) δ7.35 (m, 1H), 7.22 (m, 1H), 7.11 (m, 1H), 7.09 (s, 1H), 7.01 (m, 1H), 6.91 (d, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H) , 3.85 (s, 3H), 3.25 (m, 1H), 2.90 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H)

[1345] Example 376. (S)-quininecyclo-3-yl(5-(3-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1346] 1 H-NMR (400MHz, CDCl3) δ7.35 (m, 1H), 7.22 (m, 1H), 7.11 (m, 1H), 7.09 (s, 1H ), 7.01(m, 1H), 6.89(d, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 4.09( m, 2H), 3.25 (m, 1H), 2.90~2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 ( br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.45 (t, 3H), 1.28 (m, 3H), 0.98 (m, 3H)

[1347] Example 377. (S)-Quininecyclo-3-yl(6-fluoro-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1348] 1H-NMR (400MHz, CDCl3) δ7.33 (m, 1H), 7.22 (d, 1H), 7.11 (m, 1H), 7.09 (s, 1H), 7 .01 (m, 1H), 6.90 (d, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.96 (m, 2H) , 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.80(m, 2H), 1. 70(br,1H),1.59(br,1H),1.46(br,1H),1.28(m,3H),1.15(t,3H),0.98(m,3H)

[1349] Example 378. (S)-Quininecyclo-3-yl(6-fluoro-5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1350] 1 H-NMR (400MHz, CDCl3) δ7.32 (m, 1H), 7.22 (d, 1H), 7.11 (m, 1H), 7.09 (s, 1H), 7.01 (m, 1H), 6.87 (d, 1H), 4.95 (m, 2H), 4.80 (br, 1H), 4.57 (m, 1H) , 3.25 (m, 1H), 2.90 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.35 (d, 6H), 1.28 (m, 3H), 0.98 (m, 3H)

[1351] Example 379. (S)-quininecyclo-3-yl(5-(3-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1352] 1H-NMR (400MHz, CDCl3) δ7.34 (m, 1H), 7.22 (d, 1H), 7.10~7.01 (m, 3H), 6.89 (d, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 4.00 (m, 2H), 3.25 (m, 1 H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.78(m, 2H), 1.70(br , 1H), 1.59(br, 1H), 1.53(m, 2H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 6H)

[1353] Example 380. (S)-Quininecyclo-3-yl(6-fluoro-5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1354] 1 H-NMR (400MHz, CDCl3) δ7.33 (m, 1H), 7.22 (d, 1H), 7.11~6.91 (m, 3H), 6.89 (d, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.76 (d, 2H), 3. 25(m,1H),2.90~2.73(m,7H),2.10(m,2H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.46(br,1H),1.28(m,3H),1.05(d,6H),0.97(m,3H)

[1355] Example 381. (S)-quininecyclo-3-yl(5-(2,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1356] 1 H-NMR(400MHz, CDCl3)δ7.16(d 1H), 7.09(d, 1H), 6.97(m, 1H), 6.56(m, 2H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.85(s, 3H), 3.79(s, 3H), 3.25(m, 1H), 2.92~2.71(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1357] Example 382. (S)-quininecyclo-3-yl(5-(2,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1358] 1 H-NMR (400MHz, CDCl3) δ7.12 (d, 1H), 7.01 (m, 1H), 6.96 (m, 2H), 6.87 (s, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.79 (s, 3H), 3.76 ( s, 3H), 3.25 (m, 1H), 2.93~2.72 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H)

[1359] Example 383. (S)-quininecyclo-3-yl(5-(2,6-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1360] 1 H-NMR (400MHz, CDCl3) δ7.33 (m, 1H), 7.05 (d, 1H), 6.98 (m, 1H), 6.65 (d, 2H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.75 (s, 6H) , 3.25 (m, 1H), 2.93~2.72 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H)

[1361] Example 384. (S)-quininecyclo-3-yl(5-(3,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1362] 1H-NMR (400MHz, CDCl3) δ7.20 (d, 1H), 7.02 (m, 1H), 6.65 (s, 2H), 6.48 (s, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.83 (s, 6H) , 3.25 (m, 1H), 2.89~2.72 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H)

[1363] Example 385. (S)-quininecyclo-3-yl(5-(3,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1364] 1 H-NMR (400MHz, CDCl3) δ7.20 (d, 1H), 7.08~6.92 (m, 3H), 6.93 (d, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.93 (s, 6H), 3. 25(m,1H),2.93~2.72(m,7H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.46(br,1H),1.28(m,3H),0.98(m,3H)

[1365] Example 386. (S)-quininecyclo-3-yl(5-(2-chloro-4-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1366] 1 H-NMR (400MHz, CDCl3) δ7.21 (d, 1H), 7.06 (d, 1H), 7.03~7.00 (m, 2H), 6.86 (d, 1H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 3.84 (s, 3 H), 3.25 (m, 1H), 2.90~2.72 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.46 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H)

[1367] Example 387. (S)-quininecyclo-3-yl(5-(4-ethoxy-3-fluorophenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1368] 1 H-NMR (400MHz, CDCl3) δ7.29 (m, 1H), 7.23 (m, 1H), 7.17 (d, 1H), 7.01 (m, 2H), 4.95 (s, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 4.15 (m, 2H), 3.25 ( m, 1H), 2.90 ~ 2.73 (m, 7H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.47 (t, 3H), 1.45 (br, 1H), 1.28 (m, 3H), 0.98 (m, 3H)

[1369] Example 388. (S)-Quininecyclo-3-yl(6-fluoro-5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1370] 1 H-NMR (400MHz, CDCl3) δ7.19~7.00 (m, 3H), 6.97 (m, 1H), 4.95 (m, 1H), 4.85 (m, 1H), 4.80 (br, 1H), 4.21 (m, 1H), 3.25 (m, 1H), 2.90~2.7 3(m,7H),2.31(s,6H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(br,1H),1.45(br,1H),1.30(d,6H),1.28(m,3H),0.98(m,3H)

[1371] Examples 389 to 398

[1372] The title compounds of Examples 389 to 398 were prepared using the (S)-quininecyclo-3-yl (5'-bromo-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl) carbamate obtained in Preparation Example 8 and the corresponding substituted phenylboronic acid, respectively, following the same steps as in Example 1.

[1373] Example 389. (S)-quininecyclo-3-yl(5'-(4-fluorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1374] 1H-NMR (400MHz, CDCl3) δ7.54 (m, 2H), 7.42 (m, 2H), 7.38 (s, 1H), 7.13 (t, 2H), 5.02 (m, 1H), 4.93 (m, 1H), 4.74 (m, 1H), 3.25 (m, 1H), 3.10 (m, 1H), 2.91~2.72 (m, 6H), 2.09 (m, 1H), 1.82 (m, 1H), 1.70 (br, 1H), 1,60 (m, 1H), 1.43 (br, 1H), 0.92 (m, 2H), 0.81 (m, 1H), 0.59 (m, 1H)

[1375] Example 390. (S)-quininecyclo-3-yl(5'-(4-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1376] 1 H-NMR (400MHz, CDCl3) δ7.55 (d, 2H), 7.47 (m, 5H), 5.02 (m, 1H), 4.91 (m, 1H), 4.77 (m, 1H), 3.25 (m, 1H), 3.10 (m, 1H), 2.91 ~2.72(m,6H),2.09(m,1H),1.82(m,1H),1.70(br,1H),1,60(m,1H),1.43(br,1H),0.92(m,2H),0.81(m,1H),0.59(m,1H)

[1377] Example 391. (S)-quininecyclo-3-yl(5'-(4-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1378] 1 H-NMR (400MHz, CDCl3) δ7.69 (s, 4H), 7.47 (m, 3H), 5.04 (m, 1H), 4.95 (m, 1H), 4.77 (m, 1H), 3.25 (m, 1H), 3.10 (m, 1H), 2.91 ~2.72(m,6H),2.09(m,1H),1.82(m,1H),1.70(br,1H),1,60(m,1H),1.43(br,1H),0.91(m,2H),0.81(m,1H),0.59(m,1H)

[1379] Example 392. (S)-quininecyclo-3-yl(5'-(4-(trifluoromethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1380] 1 H-NMR (400MHz, CDCl3) δ7.58 (d, 2H), 7.46 (m, 2H), 7.40 (s, 1H), 7.29 (d, 2H), 5.03 (m, 1H), 4.94 (m, 1H), 4.76 (m, 1H), 3.25 (m, 1H), 3.09 (m, 1H), 2.95~2.76 (m, 6H), 2.09 (m, 1H), 1.82 (m, 1H), 1.72 (br, 1H), 1,62 (m, 1H), 1.43 (br, 1H), 0.92 (m, 2H), 0.81 (m, 1H), 0.59 (m, 1H)

[1381] Example 393. (S)-quininecyclo-3-yl(5'-(3-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1382] 1 H-NMR (400MHz, CDCl3) δ7.56 (s, 1H), 7.44 (m, 2H), 7.37 (m, 1H), 7.33 (m, 1H), 5.02 (m, 1H), 4.91 (m, 1H), 4.77 (m, 1H), 3.25 (m, 1H) ), 2.91~2.72(m,7H),2.09(m,1H),1.80(m,1H),1.70(br,1H),1,60(m,1H),1.43(br,1H),0.91(m,2H),0.80(m,1H),0.59(m,1H)

[1383] Example 394. (S)-quininecyclo-3-yl(5'-(3-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1384] 1 H-NMR (400MHz, CDCl3) δ7.56 (s, 1H), 7.44 (m, 2H), 7.37 (m, 1H), 7.33 (m, 1H), 5.02 (m, 1H), 4.91 (m, 1H), 4.77 (m, 1H), 3.25 (m, 1H) ), 2.91~2.72(m,7H),2.09(m,1H),1.80(m,1H),1.70(br,1H),1,60(m,1H),1.43(br,1H),0.91(m,2H),0.80(m,1H),0.59(m,1H)

[1385] Example 395. (S)-quininecyclo-3-yl(5'-(4-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1386] 1 H-NMR (400MHz, CDCl3) δ7.51 (d, 2H), 7.41 (m, 3H), 7.01 (d, 2H), 5.02 (m, 1H), 4.90 (m, 1H), 4.75 (m, 1H), 4.18 (m, 2H), 3.80 (m, 2H), 3.48 (s, 3H), 3.25 (m, 1H) , 3.08(m, 1H), 2.91~2.72(m, 5H), 2.09(m, 1H), 1.85(br, 1H), 1.80(m, 1H), 1. 70(br,1H),1,60(m,1H),1.43(br,1H),0.91(m,2H),0.81(m,1H),0.59(m,1H)

[1387] Example 396. (S)-quininecyclo-3-yl(5'-(3-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1388] 1 H-NMR (400MHz, CDCl3) δ7.46 (m, 2H), 7.45 (s, 1H), 7.35 (t, 1H), 7.18 (m, 2H), 6.93 (d , 1H), 5.04(m, 1H), 4.91(m, 1H), 4.75(m, 1H), 4.19(m, 2H), 3.79(m, 2H), 3.48(s, 3H) , 3.25(m, 1H), 3.08(m, 1H), 2.91~2.72(m, 5H), 2.09(m, 1H), 1.85(br, 1H), 1.80(m, 1 H), 1.70 (br, 1H), 1,60 (m, 1H), 1.43 (br, 1H), 0.91 (m, 2H), 0.81 (m, 1H), 0.59 (m, 1H)

[1389] Example 397. (S)-quininecyclo-3-yl(5'-(4-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1390] 1H-NMR (400MHz, CDCl3) δ7.51 (d, 2H), 7.43 (d, 2H), 7.39 (s, 1H), 7.11 (d, 2H), 5.22(s, 2H), 5.02(m, 1H), 4.92(m, 1H), 4.75(m, 1H), 3.52(s, 3H), 3.25(m, 1H) , 3.08(m, 1H), 2.91~2.72(m, 5H), 2.09(m, 1H), 1.85(br, 1H), 1.80(m, 1H), 1. 70(br,1H),1,60(m,1H),1.43(br,1H),0.91(m,2H),0.79(m,1H),0.59(m,1H)

[1391] Example 398. (S)-quininecyclo-3-yl(5'-(3-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-indene]-1'-yl)carbamate

[1392] 1 H-NMR (400MHz, CDCl3) δ7.46 (m, 2H), 7.45 (s, 1H), 7.35 (t, 1H), 7.18 (m, 2H), 6.9 3(d,1H),5.22(s,2H),5.02(m,1H),4.92(m,1H),4.75(m,1H),3.51(s,3H),3.25 (m, 1H), 3.08 (m, 1H), 2.91~2.72 (m, 5H), 2.09 (m, 1H), 1.85 (br, 1H), 1.80 (m, 1H) ,1.70(br,1H),1,60(m,1H),1.43(br,1H),0.91(m,2H),0.80(m,1H),0.59(m,1H)

[1393] Examples 399 to 403

[1394] The title compounds of Examples 399 to 403 were prepared using the (S)-quininecyclo-3-yl(5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate obtained in Preparation Example 9 and the corresponding substituted phenylboronic acid, respectively, following the same steps as in Example 1.

[1395] Example 399. (S)-quininecyclo-3-yl(5-(3-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1396] 1H NMR (400MHz, CD3OD) δ7.62~7.49 (m, 2H), 7.48~7.29 (m, 5H), 5.23 (d, 1H), 4.80 (brs, 1H), 4.14~4.08 (m, 1H), 3.29~3.24 (m, 1H), 2.92~2.72 (m, 5H), 2.43~2.37(m, 1H), 2.12~2.05(m, 1H), 2.00~1.93(m, 1H), 1.88~1.75(m, 2H), 1.70~1.63(m, 1H), 1.54~1.43(m, 4H), 1.26(brs, 3H)

[1397] Example 400. (S)-quininecyclo-3-yl(5-(2-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1398] 1 H NMR (400MHz, CD3OD) δ7.52~7.45(m, 1H), 7.38~7.22(m, 6H), 5.29~5.21(m, 1H), 4. 94~4.90 (m, 7H), 4.86~4.77 (m, 1H), 4.15~4.07 (m, 1H), 3.31~3.22 (m, 1H), 2.93~2 .71(m, 4H), 2.46~2.37(m, 1H), 2.14~2.05(m, 1H), 2.01~1.93(m, 1H), 1.90~1.74( m, 2H), 1.73 ~ 1.61 (m, 1H), 1.57 ~ 1.48 (m, 1H), 1.48 ~ 1.40 (m, 3H), 1.28 ~ 1.24 (m, 3H)

[1399] Example 401. (S)-Quininecyclo-3-yl(3,3-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1400] 1 H NMR (400MHz, CD3OD) δ7.89~7.84(m,2H),7.66~7.63(m,2H),7.53~7.46(m,2H),7.35(dd,1H),5.26(t,1H),4.83~4.78(m,1H),3.30~3.26(m,1H) , 2.92~2.73(m, 5H), 2.42(ddd, 1H), 2.14~2.06(m, 1H), 1.96(dd, 1H), 1. 89~1.76(m,2H), 1.71~1.65(m,1H), 1.55~1.46(m,4H), 1.30~1.27(m,3H)

[1401] Example 402. (S)-quininecyclo-3-yl(3,3-dimethyl-5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1402] 1 H NMR (400MHz, CD3OD) δ7.62 (d, 1H), 7.56 ~ 7.43 (m, 4H), 7.36 ~ 7.24 (m, 2H), 5.24 (brs, 1H), 4.85 ~ 4.78 (m, 1H), 3.29 ~ 3.19 (m, 1H), 2.92 ~2.72(m, 5H), 2.41(dd, 1H), 2.10(d, 1H), 2.03~1.94(m, 1H), 1.88~1.76(m, 2H), 1.71~1.64(m, 1H), 1.54~1.44(m, 4H), 1.28(brs, 3H)

[1403] Example 403. (S)-Quininecyclo-3-yl(3,3-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1404] 1 H NMR (400MHz, CD3OD) δ7.50~7.38(m, 4H), 7.34~7.28(m, 3H), 5.26(t, 1H), 4.83~4.78(m, 1H), 3.29~3.26(m, 1H), 2.92~2.73(m, 5H) ), 2.42(dt, 1H), 2.10(dd, 1H), 2.00~1.96(m, 1H), 1.88~1.77(m, 2H), 1.70~1.66(m, 1H), 1.52(brs, 1H), 1.43(s, 3H), 1.26(s, 3H)

[1405] Examples 404 and 405

[1406] The title compounds of Examples 404 and 405 were prepared using the (S)-quinine-3-yl (6-bromo-dihydrobenzofuran-3-yl) carbamate obtained in Preparation Example 10 and the corresponding substituted phenylboronic acid, respectively, following the same steps as in Example 1.

[1407] Example 404. (S)-Quininecyclo-3-yl(6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate

[1408] 1H-NMR (400MHz, CDCl3) δ7.78 (s, 1H), 7.30~7.11 (d, 1H), 7.62~7.60 (d, 1H), 7. 56~7.52(t, 1H), 7.45~7.41(t, 1H), 7.17~7.14(m, 1H), 7.06(s, 1H), 5.42(m, 2 H), 4.76~4.72(m, 2H), 4.44~4.41(m, 1H), 3.25~3.19(m, 1H), 2.82~2.69(m, 5H) ), 2.03~2.00(m, 1H), 1.77~1.65(m, 2H), 1.59~1.57(m, 1H), 1.45~1.30(m, 1H)

[1409] Example 405. (S)-Quininecyclo-3-yl(6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate

[1410] 1 H-NMR (400MHz, CDCl3) δ7.48~7.38 (m, 4H), 7.21~7.20 (d, 1H), 7.15~7.12 (m, 1H), 7.04 (s, 1H), 5.43~5.38 (m, 2H), 4.76~4.71 (m, 2 H), 4.44~4.41(m, 1H), 3.25~3.19(m, 1H), 2.82~2.66(m, 5H), 2.03~2.01(m, 1H), 1.77~1.65(m, 2H), 1.59~1.55(m, 1H), 1.39(m, 1H)

[1411] Example 406. (S)-quininecyclo-3-yl(5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[1412] The title compound was prepared using (S)-quininecyclo-3-yl(5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate and 3-fluorophenylboronic acid obtained in Preparation Example 11, following the same steps as in Example 1.

[1413] 1H-NMR (400MHz, CDCl3) δ7.52~7.44(m, 2H), 7.38~7.27(m, 2H), 7.23~7.21(d, 1H), 7.02~6.98(t, 1H), 6.85~6.83(d, 1H), 5.22~5.19(m, 1H), 5.0 9~5.07 (m, 1H), 4.76~4.74 (m, 1H), 3.26~3.20 (m, 1H), 2.82~2.64 (m, 5H) ), 1.77~1.68(m, 2H), 1.66~1.53(m, 4H), 1.46~1.39(m, 4H), 1.27(m, 1H)

[1414] Examples 407 to 411

[1415] The title compounds of Examples 407 to 411 were prepared using (S)-quininecyclo-3-yl (6-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl) carbamate obtained in Preparation Example 12 and the corresponding substituted phenylboronic acid, respectively, following the same steps as in Example 1.

[1416] Example 407. (S)-quininecyclo-3-yl(6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[1417] 1 H-NMR (400MHz, CDCl3) δ7.39~7.31 (m, 3H), 7.27~7.22 (t, 1H), 7.12~7.09 (t, 1H), 7.06~7.02 (t, 1H), 6.95 (s, 1H), 5.36~5.30 (m, 1H), 5.06~5.0 4(d, 1H), 4.76~4.74(m, 1H), 3.24~3.19(m, 1H), 2.81~2.69(m, 5H), 1.7 6~1.67(m,2H), 1.54~1.49(m,4H), 1.45~1.43(m,4H), 1.40~1.26(m,1H)

[1418] Example 408. (S)-quininecyclo-3-yl(6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[1419] 1H-NMR (400MHz, CDCl3) δ7.53 (s, 1H), 7.43 ~ 7.31 (m, 4H), 7.1 ~ 7.09 (m, 1H), 6.95 (s, 1H), 5.18 ~ 5.14 (m, 1H), 5.07 ~ 5.05 (m, 1H), 4.77~4.75(m, 1H), 3.26~3.21(m, 1H), 2.89~2.65(m, 5H), 1.77~1.73(m, 2H), 1.69~1.68(m, 4H), 1.56~1.44(m, 4H), 1.40(m, 1H)

[1420] Example 409. (S)-Quininecyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate

[1421] 1 H-NMR (400MHz, CDCl3) δ7.79 (s, 1H), 7.73~7.71 (d, 1H), 7.62~7.60 (d, 1H), 7.5 7~7.53(t, 1H), 7.41~7.37(t, 1H), 7.15~7.12(t, 1H), 6.98(s, 1H), 5.23~5.19( t, 1H), 5.08 ~ 5.06 (d, 1H), 4.77 ~ 4.75 (m, 1H), 3.26 ~ 3.21 (m, 1H), 2.89 ~ 2.65 (m, 5H), 1.78~1.69(m, 2H), 1.57~1.53(m, 3H), 1.46~1.40(m, 4H), 1.40~1.27(m, 1H)

[1422] Example 410. (S)-Quininecyclo-3-yl(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate

[1423] 1 H-NMR (400MHz, CDCl3) δ7.47~7.43 (m, 2H), 7.39~7.35 (m, 2H), 7.22~7.20 (d, 1H), 7.13~7.09 (t, 1H), 6.96 (s, 1H), 5.19~5.14 (t, 1H), 5.08~5.0 6(d, 1H), 4.76~4.75(m, 1H), 3.27~3.21(m, 1H), 2.84~2.66(m, 5H), 1.7 7~1.68(m,2H), 1.56~1.53(m,4H), 1.46~1.40(m,4H), 1.39~1.27(m,1H)

[1424] Example 411. (S)-quininecyclo-3-yl(6-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[1425] 1 ¹H-NMR (400MHz, CDCl₃) δ 7.35–7.27 (m, 2H), 7.23–7.22 (m, 2H), 7.19–7.17 (m, 1H), 7.03 (m, 1H), 6.97 (s, 1H), 5.21–5.18 (m, 3H), 5.05–5.00 (m, 1H), 4.74–4.73 (m, 1H), 3.49 (s, 3H), 3.23–3.18 (m, 1H), 2.80–2.66 (m, 5H), 2.04 (m, 1H), 1.76–1.67 (m, 2H), 1.56–1.38 (m, 8H) Example 1: Evaluation of inhibitory activity against GCS

[1426] The inhibitory activity of the compounds of the present invention against GCS was evaluated according to the methods described in known literature (Hayashi Y et al., A sensitive and reproducible assay to measure the activity of glucosylceramide synthase and lactosylceramide synthase using HPLC and fluorescent substrates, Analytical Biochemistry 345(2005)181-186). Ibiglustat, a known GCS inhibitor, was used as a control.

[1427] (1) Materials

[1428] A549 cells (ATCC, CCL-185)

[1429] NBD C6-ceramide (Thermo Fisher, N1154)

[1430] UDP-glucose (Sigma, U4625)

[1431] Potassium chloride (Sigma, P9333)

[1432] Super Pure TM (UltraPure TM 0.5M EDTA (Invitrogen, 15575-038)

[1433] BCA protein assay kit (Thermo Fisher, 23227)

[1434] Ibiglustat (Shanghai Systeam Biochem Co., Ltd., Genz-682452)

[1435] HEPES (sigma, H3375)

[1436] Protease / phosphatase inhibitor cocktail (CST, 5872s)

[1437] DMEM (GIBCO, 11995-065)

[1438] FBS (GIBCO, 16000-044)

[1439] Antibiotic-Antimycotic (100X) (GIBCO, 15240-112)

[1440] 200 mM L-glutamine (GIBCO, 25030081)

[1441] PBS (GIBCO, 10010-023)

[1442] 0.25% Trypsin-EDTA (GIBCO, 25200-056)

[1443] Dimethyl sulfoxide (Sigma, 34869)

[1444] 2-Propanol, HPLC grade (Burdick & Jackson, AH323-4)

[1445] Hexane, HPLC grade (Burdick & Jackson, AH216-4)

[1446] Chloroform (Sigma, C2432)

[1447] Methanol (Merck, 1.06009.1011)

[1448] (2) Protocol

[1449] <1> Preparation of cell lysate

[1450] A549 cells (ATCC, CCL-185) were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS), 1x antibiotic-antifungal agent, and 1x L-glutamine in a 37°C, 5% CO2 incubator. Cells adhering to the culture dish were washed with phosphate-buffered saline (PBS), scraped off with a cell scraper, and collected by centrifugation (4000 rpm, 3 min, 4°C) into 50 ml tubes. Cell pellets were resuspended in lysis buffer (50 mM HEPES, pH 7.3, containing 1x protease / phosphatase inhibitor mixture), lysed by sonication, and the lysate was centrifuged (13000 rpm, 10 min, 4°C). The resulting supernatant was used for quantitative protein analysis. Protein levels were measured using a BCA protein assay kit, with bovine serum albumin as a standard.

[1451] <2> GCS enzyme reaction

[1452] An enzymatic reaction was initiated by sequentially adding the following reaction materials to a 96-well plate. The reaction was then carried out at 37°C for 90 minutes.

[1453] Enzyme reaction mixture (total 50 μl)

[1454]

[1455] <3> Lipid extraction

[1456] The enzymatic reaction was stopped by adding 100 μl of chloroform / methanol (2:1, v / v). After vortexing for 15 seconds, each mixture was centrifuged (4000 rpm, 10 min, 18 °C). The lower layer (50 μl) was transferred to a new 96-well plate and dried using a reduced concentrator.

[1457] <4> HPLC analysis

[1458] Lipids were dissolved in 100 μl of propanol / n-hexane / H₂O (55:44:1, v / v / v) and transferred to a glass vial for HPLC (Agilent, 8004-HP-H / i3u). The sample (100 μl) was automatically loaded onto a normal-phase column (IntersilSIL 150A-5, 4.6 x 250 mm, GL Sciences, Japan) and eluted with isopropanol / n-hexane / H₂O (55:44:1, v / v / v) at a flow rate of 2.0 mL / min. Fluorescence was measured using a fluorescence detector (Agilent, 1260FLD Spectra) with 470 nm and 530 nm as excitation and emission wavelengths, respectively.

[1459] <5> Data Analysis

[1460] Data analysis is performed using the following equation.

[1461] % area (sample) = area (GlcCer) / [area (Cer) + area (GlcCer)] × 100

[1462] %GCS activity = [Area (sample) - Area (ibiglustat)] / [Area (DMSO) - Area (ibiglustat)] × 100

[1463] The obtained %GCS activity data were analyzed using the software GraphPad Prism (Ver 5.01) to calculate IC50. 50 Values. The results are shown in Tables 1 to 4 below.

[1464] Table 1

[1465] Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> 1 9.8 41 16.9 81 2.8 2 17.2 42 23.6 82 2.5 3 21.7 43 33.4 83 7.5 4 11.0 44 18.6 84 7.3 5 3.8 45 33.3 85 3.1 6 1.7 46 8.9 86 3.6 7 1.1 47 37.5 87 9.4 8 1.2 48 58.2 88 2.9 9 2.4 49 9.3 89 8.5 10 2.9 50 9.7 90 11.0 11 22.2 51 7.1 91 2.3 12 14.8 52 14.9 92 16.1 13 9.5 53 8.1 93 1.4 14 8.9 54 20.65 94 9.5 15 11.8 55 32.42 95 11.2 16 12.7 56 32.1 96 6.9 17 3.7 57 2.5 97 3.0 18 5.3 58 2.8 98 2.8 19 12.7 59 5.44 99 6.0 20 16.0 60 16.9 100 2.1 21 12.3 61 12.7 101 1.9 22 15.1 62 13.13 102 4.6 23 10.2 63 7.55 103 1.7 24 1.6 64 3.9 104 1.9 25 65.7 65 5.5 105 1.8 26 48.1 66 30.9 106 1.2 27 55.3 67 12.3 107 1.1 28 79.2 68 15.2 108 2.3 29 38.0 69 108.8 109 3.6 30 34.0 70 20.1 110 6.0 31 41.5 71 13.0 111 3.5 32 71.2 72 10.7 112 2.5 33 25.8 73 22.5 113 6.4 34 13.7 74 24.1 114 3.8 35 20.29 75 14.9 115 3.6 36 14.28 76 5.9 116 1.8 37 33.9 77 2.9 117 3.5 38 33.9 78 2.1 118 14.2 39 26.9 79 2.6 119 10.9 40 40.4 80 3.0 120 4.2

[1466] Table 2

[1467] Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> 121 0.7 161 1.6 201 3.9 122 6.8 162 7.0 202 6.1 123 0.9 163 0.6 203 1.2 124 3.1 164 0.6 204 8.3 125 17.0 165 13.7 205 1.0 126 14.0 166 1.6 206 0.6 127 5.9 167 0.5 207 6.2 128 2.8 168 2.7 208 3.7 129 5.1 169 1.9 209 3.0 130 1.3 170 6.1 210 0.6 131 2.1 171 2.5 211 1.2 132 3.7 172 1.8 212 1.2 133 4.3 173 7.2 213 2.0 134 6.8 174 4.5 214 1.7 135 1.4 175 2.3 215 1.4 136 0.7 176 1.7 216 0.7 137 2.9 177 3.2 217 2.4 138 1.3 178 3.2 218 0.6 139 10.0 179 4.3 219 2.9 140 1.0 180 1.4 220 1.2 141 3.0 181 0.3 221 1.5 142 1.5 182 2.1 222 2.9 143 4.5 183 2.8 223 0.9 144 1.0 184 6.5 224 2.9 145 4.6 185 0.5 225 2.9 146 3.3 186 9.5 226 6.3 147 1.9 187 4.5 227 2.2 148 1.4 188 8.4 228 3.8 149 1.6 189 2.2 229 4.4 150 0.7 190 2.1 230 1.2 151 2.2 191 9.3 231 0.5 152 1.7 192 3.7 232 0.8 153 2.8 193 2.0 233 1.2 154 1.7 194 10.1 234 0.6 155 1.1 195 6.4 235 0.9 156 2.6 196 0.9 236 3.4 157 0.6 197 1.7 237 5.2 158 3.4 198 1.2 238 2.4 159 4.3 199 0.7 239 7.6 160 2.0 200 0.6 240 3.5

[1468] Table 3

[1469] Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> 241 1.3 281 0.6 321 4.3 242 5.9 282 0.7 322 4.4 243 1.4 283 1.3 323 5.4 244 1.8 284 0.8 324 0.8 245 3.0 285 0.5 325 0.8 246 3.9 286 0.4 326 0.7 247 11.9 287 0.7 327 1.8 248 3.0 288 1.2 328 0.4 249 9.0 289 0.8 329 4.9 250 4.8 290 1.4 330 5.1 251 1.1 291 1.7 331 3.7 252 7.4 292 1.6 332 5.1 253 3.4 293 2.0 333 1.7 254 7.0 294 4.0 334 0.1 255 6.2 295 2.7 335 4.3 256 1.9 296 1.2 336 4.0 257 2.1 297 0.7 337 8.9 258 5.9 298 6.6 338 1.3 259 2.8 299 2.2 339 2.1 260 1.0 300 1.4 340 1.3 261 3.1 301 1.2 341 3.2 262 1.5 302 1.4 342 1.2 263 2.6 303 4.4 343 2.3 264 3.6 304 3.5 344 2.1 265 0.7 305 4.1 345 3.8 266 0.7 306 0.8 346 2.4 267 2.8 307 1.5 347 2.6 268 0.7 308 0.3 348 6.7 269 5.2 309 0.6 349 0.8 270 1.1 310 0.7 350 0.4 271 5.1 311 2.4 351 0.5 272 9.9 312 2.2 352 0.7 273 5.2 313 1.3 353 1.2 274 2.7 314 0.9 354 0.3 275 5.1 315 0.9 355 1.1 276 1.3 316 1.9 356 0.5 277 0.8 317 2.0 357 0.3 278 0.6 318 2.3 358 0.3 279 0.8 319 1.0 359 2.4 280 0.4 320 0.9 360 0.7

[1470] Table 4

[1471] Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> 361 0.1 381 1.6 401 73 362 0.2 382 0.5 402 74.5 363 0.1 383 1.9 403 155.2 364 0.1 384 1.3 404 5.3 365 0.3 385 6.9 405 7.1 366 5.3 386 0.2 406 31.1 367 4.3 387 1.8 407 4.8 368 6.2 388 11.5 408 3.0 369 2.8 389 19.0 409 3.3 370 1.8 390 18.6 410 3.0 371 2.6 391 21.4 411 10.9 372 3.9 392 10.2 373 3.9 393 4.8 374 7.7 394 5.6 375 0.9 395 2.4 376 2.6 396 2.7 377 1.4 397 0.8 378 1.7 398 0.9 379 0.6 399 103.7 380 1.7 400 65.6

[1472] As can be seen from the results in Tables 1 to 4, the compounds of the present invention exhibit excellent inhibitory activity against GCS.

[1473] Experimental Example 2: Evaluation of the inhibitory activity against GM1 production

[1474] GM1 is the final product of sphingolipid metabolism and is expressed on the cell membrane, making it easily detectable. Furthermore, the amount of GM1 represents the conversion of ceramide to glucosceramide. Therefore, the inhibitory activity of the compounds of the present invention against GM1 production was evaluated as follows, according to the method described in the known literature (Dijkhuis et al., Gangliosides do not affect ABC transporter function in human neuroblastoma cells. The Journal of Lipid Research 47 (2006). 1187-1195). Ibiglustat, known as a GCS inhibitor, was used as a control.

[1475] (1) Materials

[1476] Jurkat leukemia cells, clone E6-1 (ATCC, TIB-152)

[1477] Cholera toxin subunit B (CTB), FITC (Sigma, C1655)

[1478] Ibiglustat (Shanghai Shuangfu Biotechnology Co., Ltd., Genz-682452)

[1479] DMSO (Sigma, D2650)

[1480] Fixation buffer (BD, 554655)

[1481] RPMI 1640 (Gibco, A1049101)

[1482] FBS (Gibco, 16000-044)

[1483] Antibiotic-antifungal agent (100X) (Gibco, 15240-122)

[1484] FACS Sheath Fluid (BD, 342003)

[1485] Leukemia cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1X antibiotic-antifungal agent. A washing solution was prepared by adding 10 ml of FBS to 490 ml of FACS sheath fluid. A CTB-FITC solution was prepared by diluting the CTB-FITC stock solution (10 mg / ml) with the washing solution to a final concentration of 2 μg / ml.

[1486] (2) Scheme

[1487] Prepare a cell suspension (1×10⁻⁶ cells / mL) using culture medium (RPMI 1640 medium supplemented with 10% FBS and 1X antibiotic-antifungal agent). 5 Cell suspension (200 μl) was added to each well of a 96-well plate (20,000 cells / well), and the mixtures were then treated with a final concentration of 0.05 to 3000 nM (3 folds, 11 spots) per well. Each mixture was incubated at 37 °C for 72 h in a CO2 incubator. After centrifugation at 1500 rpm for 3 min to remove the culture medium, the cells were resuspended in 200 μl of wash buffer per well. After centrifugation at 1500 rpm for 3 min to remove the wash buffer, the cells were resuspended in 200 μl of 2 μg / ml CTB-FITC solution. The resulting suspension was incubated at 4 °C for 60 min without light exposure. After centrifugation at 1500 rpm for 3 min to remove the CTB-FITC solution, the cells were washed with 200 μl of wash buffer. The washing process was repeated twice. The washed plate was centrifuged at 1500 rpm for 3 minutes to remove the washing buffer, and then the cells were completely resuspended in 200 μl of fixation buffer. The cells were then transported via Guava... TM The values ​​obtained from FITC fluorescence quantification using easyCyte 5HT (Merck Millipore, 0500-4005) were used to determine the IC. 50 .

[1488] Data analysis is performed using the following equation.

[1489] %MFI (median fluorescence intensity) = (fluorescence value of drug-treated group / fluorescence value of DMSO-treated group) × 100

[1490] % cells = (Cell concentration in well / Cell concentration in DMSO treatment group) × 100

[1491] The %MFI and %cell data were analyzed using the software GraphPad Prism (Ver 5.01) to calculate IC. 50 Values. The results are shown in Tables 5 through 8 below.

[1492] Table 5

[1493] Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> 1 139.2 48 65.7 88 11.1 2 201.8 49 61.4 89 50.0 3 142.5 50 52.3 90 37.9 4 95.8 51 30.2 91 25.1 5 70.2 52 82.3 92 43.9 6 39.4 53 80.0 93 10.5 7 36.8 54 161 94 23.6 8 27.4 55 172.8 95 49.7 9 93.1 56 209.9 96 16.2 10 65.5 57 49.9 97 9.3 11 123.0 58 87.8 98 7.5 12 73.0 59 164.5 99 22.2 13 41.7 60 111.7 100 21.5 14 54.3 61 39.6 101 8.7 15 34.4 62 103 102 17.4 16 56.1 63 116.7 103 19.5 17 27.6 64 74.7 104 16.9 18 31.6 65 56.2 105 15.2 19 20.3 66 127.7 106 5.8 20 125.9 67 144.0 107 6.3 21 126.6 68 91.8 108 7.6 22 89.6 69 399.8 109 7.8 23 63.7 70 70.9 110 15.1 24 17.4 71 64.3 111 32.0 25 105.9 72 58.2 112 35.6 26 67.2 73 26.0 113 54.8 27 35.7 74 13.0 114 33.7 28 52.0 75 8.3 115 38.3 29 63.0 76 3.7 116 16.7 30 106.8 77 6.3 117 41.8 31 65.5 78 3.5 118 38.4 32 120.2 79 3.9 119 38.3 37 55.2 80 4.1 120 28.4 38 62.0 81 12.2 121 4.7 39 51.9 82 3.2 122 50.8 43 182.8 83 3.7 123 9.3 44 35.2 84 4.9 124 22.3 45 57.3 85 11.6 125 9.5 46 19.2 86 13.8 126 50.5 47 26.6 87 42.8 127 18.2

[1494] Table 6

[1495] Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> 128 18.4 168 9.6 208 67.4 129 36.8 169 9.8 209 32.1 130 10.0 170 13.0 210 7.5 131 10.6 171 17.0 211 13.2 132 29.2 172 48.5 212 19.1 133 22.6 173 34.8 213 39.8 134 43.2 174 40.2 214 64.2 135 8.1 175 42.8 215 14.9 136 1.7 176 27.6 216 28.7 137 12.1 177 22.9 217 72.1 138 9.1 178 26.9 218 6.7 139 74.4 179 41.0 219 30.4 140 10.5 180 28.1 220 17.6 141 39.9 181 5.5 221 16.9 142 20.5 182 20.9 222 25.6 143 25.2 183 18.6 223 5.2 144 6.2 184 40.0 224 18.8 145 23.0 185 11.1 225 21.3 146 14.1 186 82.6 226 57.0 147 14.0 187 31.7 227 10.2 148 30.0 188 46.2 228 48.6 149 27.6 189 23.0 229 56.2 150 6.8 190 13.3 230 30.8 151 37.9 191 123.4 231 24.3 152 32.5 192 25.8 232 12.5 153 41.4 193 15.3 233 23.3 154 27.4 194 47.6 234 13.6 155 8.4 195 36.1 235 6.5 156 46.7 196 23.2 236 32.4 157 2.8 197 8.7 237 29.2 158 17.1 198 11.7 238 13.2 159 12.7 199 5.5 239 48.9 160 22.7 200 3.7 240 51.3 161 10.8 201 38.2 241 51.3 162 38.8 202 26.3 242 64.4 163 12.2 203 8.2 243 21.4 164 6.5 204 57.2 244 38.0 165 15.6 205 7.6 245 23.0 166 26.3 206 14.0 246 14.7 167 3.8 207 58.6 247 41.0

[1496] Table 7

[1497] Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> 248 14.9 288 11.2 328 11.4 249 37.0 289 7.4 329 65.8 250 33.0 290 12.3 330 52.7 251 7.2 291 13.5 331 22.6 252 43.9 292 7.8 332 158.4 253 37.2 293 8.7 333 45 254 45.2 294 10.4 334 20.9 255 35.8 295 35.0 335 50.4 256 24.6 296 15.6 336 48 257 27.4 297 3.0 337 65 258 17.4 298 63.2 338 53.7 259 10.2 299 25.3 339 62.5 260 14.4 300 23.0 340 43.8 261 51.5 301 9.6 341 61.9 262 34.4 302 4.0 342 21.6 263 34.9 303 27.2 343 45.7 264 14.4 304 23.5 344 51 265 6.7 305 9.8 345 45.7 266 4.7 306 27.5 346 38.3 267 83.1 307 30.2 347 46.8 268 2.5 308 5.5 348 44.1 269 6.5 309 11.2 349 10.3 270 2.3 310 16.3 350 4.5 271 30.6 311 27.0 351 7.4 272 49.3 312 13.1 352 5.7 273 13.4 313 7.3 353 12.7 274 10.3 314 7.7 354 5.9 275 25.0 315 11.3 355 62.8 276 33.2 316 13.3 356 21.6 277 2.7 317 10.3 357 5.3 278 6.0 318 20.0 358 7.7 279 7.3 319 7.7 359 33.1 280 1.6 320 8.5 360 39.0 281 5.0 321 31.9 361 2.1 282 5.6 322 24.4 362 2.5 283 17.2 323 78.9 363 8.7 284 8.5 324 5.8 364 17.2 285 3.7 325 2.1 365 2.4 286 4.1 326 10.8 366 79.4 287 4.1 327 16.8 367 68.2

[1498] Table 8

[1499] Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> Example <![CDATA[IC 50 (nM)]]> 368 99.9 388 93.1 408 15.8 369 171.7 389 76.5 409 14.9 370 39.3 390 44.1 410 13.0 371 24.8 391 55.3 411 79.3 372 46.2 392 41.9 373 31.2 393 54.9 374 26.5 394 48.8 375 23 395 30.9 376 85.9 396 39.6 377 35.5 397 17.4 378 87.5 398 36.6 379 15.8 399 43.59 380 36.5 400 107.5 381 59.9 401 15.13 382 31.3 402 19.5 383 123.1 403 85.31 384 83.2 404 25.9 385 331.6 405 44.7 386 29.5 406 119.7 387 48.2 407 44.4

[1500] As can be seen from the results in Tables 5 to 8, the compounds of the present invention exhibit excellent inhibitory activity against the production of GM1.

Claims

1. A method for preparing a compound of formula 1a or a pharmaceutically acceptable salt thereof, the method comprising: The compound of formula 5 is reacted with AW-boronic acid substituted with X1, X2, X3 or X4 to obtain the compound of formula 1a; and optionally converting the compound of formula 1a into a pharmaceutically acceptable salt thereof: <Formula 1a> <Formula 5> in, Z is -CR1R2-; Y is -O- or -CR1R2-; R1 and R2 are independently hydrogen or C1-C6 alkyl; or R1 and R2 together with the carbon atom to which they are attached form a C3-C 10 Cycloalkyl, X is hydrogen; halogen; C1-C6 alkyl; C1-C6 alkyl substituted by 1 to 3 halogen atoms; C1-C6 alkyl having a nitrogen atom, an oxygen atom or a sulfur atom; C1-C6 alkoxy; or C1-C6 alkoxy substituted by 1 to 3 halogen atoms, W is a bond or -CH=CH-, Ring A is a 6- to 12-membered aryl group selected from phenyl, naphthyl or biphenyl; a 5- to 12-membered heteroaryl group selected from benzodioxolyl, pyridyl, thienyl, quinolyl, isoquinolyl, benzofuranyl, benzo[b]thienyl, quinoxalinyl or furanyl; C3 to C 10 cycloalkyl; or a 3- to 12-membered heterocyclic ring selected from 2,3-dihydrobenzodioxinyl, 2,3-dihydrobenzofuranyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, chromanyl or 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, and X1, X2, X3 and X4 are independently hydrogen; cyano; halogen; C1-C6 alkyl; C1-C6 alkoxy-C1-C6 alkyl; C1-C6 alkyl substituted with 1 to 3 halogen atoms; C3-C 10 Cycloalkyl; morpholinyl; C1-C6 alkoxy; C1-C6 alkoxy substituted by 1 to 3 halogen atoms; C1-C6 alkoxy-C1-C6 alkoxy; morpholinyl-C1-C6 alkoxy; mono- or di-C1-C6 alkylamino-C1-C6 alkoxy; C3-C 10 Cycloalkyl-C1~C6 alkoxy; C1~C6 alkylthio; mono- or di-C1~C6 alkylamino; or C1~C6 alkylcarbonyl.

2. The method according to claim 1, wherein the reaction between the compound of Formula 5 and the AW-boric acid substituted by X1, X2, X3 or X4 is carried out using a palladium catalyst, optionally using tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4), palladium(II) acetate (Pd(OAc)2), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2).

3. The method according to claim 1 or 2, wherein the reaction between the compound of formula 5 and the AW-boric acid substituted by X1, X2, X3 or X4 is carried out in the presence of an inorganic base, optionally in the presence of cesium carbonate (Cs2CO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3) or potassium phosphate (K3PO4).

4. The method according to any one of claims 1 to 3, wherein the compound of formula 5 is obtained by coupling the compound of formula 3 with quinuclidinol: <Formula 3> in, X, Y and Z are the same as defined in claim 1.

5. The process according to claim 4, wherein the coupling is carried out by a condensation reaction comprising the removal of ethanol, optionally in the presence of a base, optionally in the presence of sodium hydride.

6. The method according to claim 4 or 5, wherein the compound of formula 3 is obtained by reacting the compound of formula 2 or its salt with ethyl chloroformate: <Formula 2> in, X, Y and Z are the same as defined in claim 1.

7. The method according to claim 6, wherein the reaction between the compound of Formula 2 or a salt thereof and ethyl chloroformate is carried out in the presence of a base, optionally in the presence of triethylamine, N,N-diisopropylethylamine or potassium carbonate.

8. The method according to any one of claims 1 to 3, wherein the compound of formula 5 is obtained by reacting a compound of formula 7 with a compound of formula 2: <Formula 2> <Formula 7> in, X, Y and Z are the same as defined in claim 1.

9. The method according to claim 8, wherein the reaction of the compound of Formula 7 with the compound of Formula 2 is carried out in the presence of a base, optionally in the presence of N,N-diisopropylethylamine or triethylamine.

10. The method according to claim 8 or 9, wherein the compound of formula 7 is obtained by reacting quinuclidinol with bis(4-nitrophenyl) carbonate.

11. The method according to claim 8 or 9, wherein the compound of formula 7 is obtained by reacting quinuclidinol with 4-nitrophenyl chloroformate, optionally in the presence of a base.

12. A compound of formula 5: <Formula 5> in, Z is -CR1R2-; Y is -O- or -CR1R2-; R1 and R2 are independently hydrogen or C1-C6 alkyl; or R1 and R2 together with the carbon atom to which they are attached form a C3-C 10 Cycloalkyl, X is hydrogen; halogen; C1-C6 alkyl; C1-C6 alkyl substituted by 1 to 3 halogen atoms; C1-C6 alkyl having a nitrogen atom, an oxygen atom or a sulfur atom; C1-C6 alkoxy; or C1-C6 alkoxy substituted by 1 to 3 halogen atoms.

13. The compound according to claim 12, wherein Y is -O-, and Z is -CR1R2-.

14. The compound according to claim 12, wherein X is hydrogen, halogen or C1-C6 alkoxy.

Citation Information

Patent Citations

  • Piperidine derivatives as GCS inhibitors

    WO2005068426A1

  • Methods of treating diabetes mellitus

    WO2006053043A2

  • 2-acylaminopropoanol-type glucosylceramide synthase inhibitors

    WO2008150486A2

  • Method of treating lupus with ceramide derivatives

    WO2009117150A2

  • Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease

    WO2010014554A1